



# **British Journal of Rheumatology**

**VOL. XXVI 1987**

Official Journal of  
The British Society  
for Rheumatology  
published by  
Baillière  Tindall-London



# GENERAL INDEX

(A1 and A2 = Abstracts Supplements 1 and 2, E = Editorial, L = Letter to the Editor)

- ABAGHBAND-ZADEH J *see* Bull P  
 ABERNETHY VE *see* Shinebaum R  
 Ability of different articular indices to detect an induced flare of joint inflammation in rheumatoid arthritis, (A1) 64  
 Abnormal mucus glycopeptide in rheumatoid arthritis, (A2) 30  
 Accessory cells in fetal joints, (A2) 123  
 Accurate assessment of function during the treatment of painful shoulders, (A1) 63  
 Acetylation, sulphasalazine and its effects, (L) 229  
 ACKRILL P *see* Chattopadhyay C  
 Acquired haemophilia and rheumatoid arthritis, 381  
 Acupuncture in neck pain, (L) 153  
 Acute pseudogout of the temporomandibular joint: a report of three cases and review of the literature, 51  
 ADAMI S *see* Bhalla AK  
 ADDISON I *see* Turner-Stokes L  
 Adenocarcinoma of the lung presenting with Raynaud's phenomenon, digital gangrene and multiple infarctions in the internal organs, (L) 473  
 Adenosine deaminase in synovial fluid: a new measure for local joint inflammation?, (A1) 2  
 ADU D *see* Beaman M  
 Adult Still's disease presenting as PUO; a not uncommon disorder, (L) 65  
 AEFANE M, CHASSAGNE J, DUBOST JJ, GALTIER B, SAUVEZIE B. Discrepancy between 3H-thymidine uptake and cell cycle studies in stimulated lymphocyte cultures treated with methotrexate, (A2) 57  
 AFOKE NYP, BYERS PD, WEIGHTMAN BO, HUTTON WC. Contact pressures in normal and OA hip joints, (A1) 13  
 AHMED AE, WHALEY K. Characterisation and mechanism of action of a serum inhibitor of complement-mediated prevention of immune precipitation, (A2) 108  
 ATKIN AGF *see* Harris GK  
 AKCASU A *see* Kadir N  
 AKERSSON A *see* Geirsson A  
 AL-ASKA AK *see* Rajapakse CNA  
 AL-HARTHI SS *see* Rajapakse CNA  
 AL-JITAWI S. False positive monospot test in systemic lupus erythematosus, (L) 71  
 AL-KHATEEB N *see* Al-Rawi ZS  
 AL-ORAINY IO *see* Rajapakse CNA  
 AL-RAWI ZS, AL-KHATEEB N, KHALIFA SJ. Brucella arthritis among Iraqi patients, 24  
 ALBERTYN L *see* Hurst NP  
 ALCALAY M *see* Bontoux D  
 ALCOCK M *see* Hurst NP  
 ALDRIDGE S *see* Patrick M  
 Algodystrophy: a common unrecognized cause of chronic knee pain, 270  
 ALGRA PR *see* Collee G  
 ALI SY *see* Brown RA; Rees JA  
 Alkaline phosphatase  
 activity in normal, osteoarthritic, and osteophytic cartilage, (A1) 16  
 substrates and *in vitro* production of the angiogenic factor, ESAF, by calcifying cartilage, (A2) 65  
 ALLARD S *see* Brennan FM  
 ALLARD SA, MUIRDEN KD, HOGG N, MAINI RN. Differential expression of MHC Class II antigens and macrophage sub-populations in rheumatoid pannus, (A2) 124  
 ALLARD SA, MUIRDEN KD, MAINI RN. Correlation of histological features with patterns of damage in different joints in rheumatoid arthritis, (A2) 29  
 ALLARD SA *see also* Horsfall AC; Sethi D; Teo CG  
 ALLEN BR *see* Powell RJ  
 ALLEN R *see* Outhwaite J  
 ALLEN RE, OUTHWAITE J, MORRIS CJ, BLAKE DR. Xanthine oxidoreductase activity in human synovium, (A1) 22  
 ALLINGTON L, CUNNINGTON SJ, MATHEWS M, SPEEDLEY J, TRUSSELL EC, WARD E. The effect of regular physiotherapy on mobility and shape of the spine in patients with ankylosing spondylitis over a two year period, (A1) 70  
 Allopurinol therapy and plasma oxipurinol concentrations, 445  
 Alteration of the interferon system in RA: association of elevated IFN activity with remission status, (A2) 63  
 Alteration of thiol and superoxide dismutase status in rheumatoid arthritis treated with sulphasalazine, 202  
 Amino acids in synovial fluid, (A1) 24  
 AMLOT P *see* Kirkham B  
 AMOR B, CHAOUAT Y, SIMON L. Organization of rheumatology in France, (A2) 98  
 AMOR B *see also* Dougados M; Kahan A  
 AMOS N *see* Love WG; O'Sullivan MM; Pye M; Williamson MER  
 Amos RS, Bax DE. Leucopenia during second line therapy for rheumatoid arthritis with gold or sulphasalazine, (A1) 6  
 AMOS RS *see also* Bax DE  
 Anaemia  
 identification of an inhibitor of *in vitro* erythropoiesis from synovial fluid of rheumatoid patients, (A2) 37  
 iron status, faecal occult blood positivity and prevalence of lesions on upper gastro-intestinal endoscopy in arthritic patients, (A2) 37  
 red cell ferritin as indicator in rheumatoid arthritis, (A2) 36  
 Analgesics in ankylosing spondylitis, 207  
 Analysis of concordance between the diagnosis given to rheumatic diseases by non rheumatologists and those of trained rheumatologists, (A2) 50  
 ANDERSON JAD. Industrial rheumatology and the shoulder, (E) 326  
 ANDERSON JC *see* Austin AK  
 ANDERSON MJ *see* Rowe IF  
 ANDREWS FJ, MORRIS CJ, LEWIS EJ, BLAKE DR. Inflamed joint—an example of iron promoted reperfusion injury?, (A2) 82  
 ANDREWS FJ *see also* Dowling EJ  
 ANDREWS HJ, WRIGHT JK, SAKLATVALA J, CAWSTON TE. Production of plasminogen activator by human rheumatoid synovial cells *in vitro* is stimulated by mononuclear cell conditioned medium, (A2) 61  
 Androgen status of females with rheumatoid arthritis, (L) 316  
 Anglo-US Fellowship Exchange, 1985, 62  
 Animal model of Chikungunya virus-induced chronic destructive polyarthritis, (A2) 80  
 Animal models of arthritis, 227  
 Ankylosing spondylitis  
 antipolynucleotide antibodies, anti-Klebsiella (K30) antibodies and anti-DNA antibody idiotypes, 168

- Ankylosing spondylitis (continued)  
 an approach to measurement of severity and outcome: ankylosing spondylitis assessment questionnaire—a controlled study, (A1) 69  
 B27 negative, (A1) 28  
 computerized axial tomographic study of costovertebral joints, (A2) 16  
 effect of regular physiotherapy on mobility and shape of the spine, (A1) 70  
 genetic versus environmental factors influencing onset and course, (A2) 105  
 homozygous MM in, 65  
 IgA containing immune complexes and hematuria, (A2) 118  
 and IgA nephropathy, (L) 396  
 impairment of cardiac diastolic function, (A1) 71  
 modified costotransversectomy, 66  
 myocardial fibrosis in, (A1) 72  
 a nationwide analytical review: entry variables determining surgical intervention and outcome, (A1) 53  
 natural history, (A2) 114  
 passive stretching in treatment, 40  
 relationship between pelvic, spinal and hip involvement, (A2) 116  
 renal abnormalities in, 341  
 a review of 14% total hip replacements in 86 patients, (A1) 71  
 simple analgesics in, 207  
 sulphasalazine in, (A2) 117  
 synovial membrane in, (A1) 28  
 Ankylosis and serological markers, (A2) 16  
 ANSELL BM *see* Hull RG  
 Antibodies to intermediate filaments in polymyalgia rheumatica/giant cell arteritis: a sequential study, (A1) 61  
 Antibodies to RANA react with a synthetic peptide corresponding to part of the internal repeat sequence of Epstein-Barr nuclear antigen (EBNA-1), (A1) 17  
 Anticardiolipin antibodies  
 Black swan syndrome, (E) 324  
 in an English connective tissue disease population: an association with livedo reticularis and major cerebrovascular disease, (A1) 58  
 ethnic differences in distribution in European and Malay patients with SLE, (A2) 20  
 in infectious mononucleosis, (A1) 59  
 platelet mediated mechanism in thrombosis, (A2) 94  
 raised in primary antiphospholipid syndrome, (A2) 94  
 in rheumatoid arthritis, 346  
 in rheumatoid arthritis and systemic sclerosis, (A2) 20  
 Anticentromere antibody, 17  
 Anti-endothelial antibodies in connective tissue diseases, (A2) 95  
 Antigen-induced chronic inflammation, magnetic resonance imaging, (A2) 82  
 Anti-lipocortin autoantibody responses in severe RA patients treated with pulse intravenous methylprednisolone, (A2) 76  
 Antimalarial drugs prescribed by consultant rheumatologists, 375  
 Antinuclear  
 antibody and detection in connective tissue disease, 188  
 antibody-negative systemic lupus erythematosus in India with anti-ssDNA antibodies, (L) 476  
 antideoxyribonucleoprotein and anti-histone antibodies in juvenile chronic arthritis and transient hip synovitis, (A2) 75  
 Antioxidant status measured by the 'trap' assay in rheumatoid arthritis, (A1) 18  
 Antiphospholipid antibodies, failure to bind human endothelial cells, (A2) 95  
 'Antiphospholipid syndrome', (A2) 19  
 Alpha-1-antitrypsin phenotype and HLA markers in nodal generalised osteoarthritis, (A2) 106  
 Anxiety and depression in primary Sjögren's syndrome: a controlled study using the hospital anxiety and depression scale, (A1) 47  
 ARABI K *see* Rajapakse CNA  
 ARCHER JR. Rheumatoid factors, 225  
 Are age and osteoarthritis modifying factors in presentation and distribution of gout?, (A2) 92  
 Are patients with rheumatoid disease more sensitive to new pain experiences compared to controls?, (A2) 119  
 Are we asking the right questions?, (A1) 51  
 ARIE E, DOHERTY M. Are age and osteoarthritis modifying factors in presentation and distribution of gout?, (A2) 92  
 ARLET J. Contribution of the French rheumatologists to the progress of rheumatology since 40 years, (A2) 97  
 ARMSTRONG RD, HORROCKS A, RICKMAN S, HEINRICH I, KAY A, GIBSON T. Finger flexion function in rheumatoid arthritis: the reliability of eight simple tests, 118  
 ARMSTRONG RD *see also* Gibson T; Luqmani RA  
 Arteritis, temporal, prognosis and management according to initial clinical presentation, (A2) 129  
 Arthritic patients and iron status, faecal occult blood positivity and prevalence of lesions on upper gastrointestinal endoscopy, (A2) 37  
 Arthritis  
 animal models, 227  
 aseptic and bacteria, (A2) 113  
 associated with parvovirus/infection, 13  
 brucella, among Iraqi patients, 24  
 common-sense beliefs, 395  
 how do patients fill in visual analog pain scales?, (A2) 119  
 and human immunodeficiency virus, (A2) 118  
 and IgG (kappa) paraproteinaemia, 142  
 knee and synovial changes, 5  
 measuring progression, (A1) 49  
 measuring the progression, 389  
 production in the guinea-pig by intra-articular reaction between lymphokines and inflammatory leukocytes, (A2) 81  
 reactive, *Chlamydia trachomatis* in, (A1) 53  
 seronegative, and *Chlamydia trachomatis* in women, (A2) 116  
 spinal brucellosis, 28  
 and sport and exercise, 386  
 Arthrocentesis and use of lignocaine-containing solutions, (L) 471  
 Arthropathy  
 dialysis, (A2) 39  
 erosive, induction in guinea-pig, 251  
 pyrophosphate, (A1) 30  
 seronegative and serum biochemistry, 131  
 Arthroplasty, objective and subjective assessment of foot, (A2) 103  
 ARTHUR VM *see* Unsworth J  
 ASHERSON RA, BAGULEY E, HARRIS EN, DERKSEN RHWM, HUGHES GRV. Dementia in SLE, (A2) 17



- ASHERSON RA *see also* Harris EN  
 ASHTON BA *see* Austin AK  
 Assessing the outcome of sulphasalazine therapy in rheumatoid arthritis, (A2) 3  
 Assessment of stiffness in rheumatology: the use of rating scales, 126  
 Association of  
 autoimmune thyroiditis with systemic lupus erythematosus, 359  
 DNA variants near the immunoglobulin heavy chain locus with rheumatoid arthritis, (A2) 104  
 ASTBURY C. Acetylation, sulphasalazine and its effects, (L) 229  
 ASTBURY C *see also* Taggart AJ  
 ASTOR D *see* Dacre J  
 ATASOY S *see* Cakir N  
 Atlanto-axial subluxation in rheumatoid arthritis, 56  
 AUQUITTER L *see* Carter H  
 Auranofin  
 life-table analysis of five-year data, (A2) 6  
 in rheumatoid arthritis, (A2) 6  
 stimulates LTA hydrolase and inhibits 5-lipoxygenase activity in human neutrophils, (A2) 71  
 Austin AK, Hobbs RN, Butler RC, Anderson JC, Ashton BA. Humoral immunity to cartilage matrix components, (A2) 75  
 AUSTIN C *see* Thompson PV  
 Autoantibodies  
 identification of, 161  
 to cytoplasmic filaments in rheumatoid arthritis: a common complex pattern of autoimmunity, (A1) 62  
 to recombinant lipocortin in rheumatoid arthritis and systemic lupus erythematosus, (A1) 54  
 Autoantigens, identification of, 161  
 Autologous mixed lymphocyte reaction and dendritic cells, (E) 85  
 AWADA H *see* Dougados M  
 AXFORD JS, MACKENZIE L, LYDYARD PM, ISENBERG DA, ROITT IM. Decreased B-cell galactosyl transferase activity in rheumatoid arthritis, (A2) 72  
 AYESH R, MITCHELL SC, WARING RH, WITHRINGTON RH, SEIFERT MH, SMITH RL. Sodium aurothiomalate toxicity and sulphoxidation capacity in rheumatoid arthritic patients, 197  
 AZAUS I *see* Bontoux D  
  
 B cell stimulating factors in rheumatoid joints, (A2) 64  
 Back pain, post laminectomy, (A2) 15  
 Back pain and sciatica: controlled trials of manipulation, traction, sclerosant and epidural injections, 416  
 BACKIMER R *see* Isenberg D  
 BACON P *see* Silman A  
 BACON PA *see* Beaman M; Dawes PT; Farr M; Gaston JSH; Kitas GD; Life P; Mageed RA; Robinson MW; Salmon M; Scott DGI; Symmons D; Young SP  
 Bacteria in aseptic arthritis, (A2) 113  
 BADAKERE SS. Antinuclear antibody-negative systemic lupus erythematosus in India with anti-ssDNA antibodies, (L) 476  
 BADAL PAL, MANGION P, WALLACE AS, DIFFEY BL. A controlled trial of diuretics in idiopathic carpal tunnel syndrome, (A1) 29  
 BADLEY EM, PAPAGEORGIOU A. How do patients fill in visual analog pain scales—a study of overall pain in arthritis and pain in individual joints, (A2) 119  
 Badley EM. New methods in the epidemiology of rheumatoid arthritis: initial experience with a postal screening questionnaire for case ascertainment, (A2) 90  
 BAGULEY E, BROWN KA, HASKARD D, HARRIS EN, HUGHES GRV. Anti-endothelial antibodies in connective tissue diseases, (A2) 95  
 BAGULEY E, HARRIS EN, BROWN KA, HASKARD D, HUGHES GRV. Failure of antiphospholipid antibodies to bind human endothelial cells, (A2) 95  
 BAGULEY E *see also* Asherson RA; Harris EN; Khamashta MA  
 BAHLER RC *see* Sun J-P  
 BAKER B *see* Carr S  
 Baker's cyst rupture, 229  
 BALINT GP, WATSON BUCHANAN W, HARDEN R MCG, NORMAN GR, DOMJAN L, BOZSOKY S. Punched-card aid in rheumatological diagnosis, 46  
 BAMJI A, DIEPPE PA, HASLOCK I, SHIPLEY M. What do rheumatologists do?, (A1) 56  
 BARAGAR F *see* Bercezi I  
 BARBER WE *see* Bloxham DP  
 BARDIN T *see* Zingraff J  
 BAREFOOT J *see* Bulstrode SJ  
 BARNES CB *see* Kirwan JR  
 BARNES CG *see* Thompson PW  
 BARNES NC *see* Zakrzewski J  
 BARRY C *see* Foley-Nolan D; Keane A  
 BARTON MAJ *see* Bossingham DH  
 BATAILLE R *see* Soubrier M  
 BATCHELOR JR *see* So AKL  
 BAUER-VINASSAC D, FOURNIER C, MENKES CJ. Effects of chloroquine in adherent synovial cells functions in primary cultures, (A2) 56  
 BAX DE, GREAVES MS, AMOS RS. Do serum sulphasalazine and metabolite concentrations relate to treatment outcome in rheumatoid arthritis?, (A2) 5  
 BAX DE, GREAVES M, SENIOR S, SHERIFF SB, CARLISLE LJ, AMOS RS. Does sulphasalazine impair folic acid absorption in patients with rheumatoid arthritis, (A1) 7  
 BAX DE *see also* Amos RS  
 BEAMAN M, ADU D, HOWIE AJ, MCCONKEY B, MICHAEL J, POPERT AJ. Rheumatoid arthritis and IgA nephropathy, 299  
 BEAMAN M, SCOTT DGI, ADU J, HOWIE A, MICHAEL J, BACON PA. Clinical features and prognosis of Wegener's granulomatosis, (A2) 42  
 BEDI S, CROOK PR, DICK WC, GRIFFITHS ID, PLATT PN. Costs of providing a rheumatological service, 454  
 BEDWELL AE *see* O'Sullivan MM; Pye M  
 BEENEY N *see* Dacre JE  
 Behçet's disease, epididymo-orchitis in, (L) 468  
 Behçet's syndrome  
 acyclovir for oral and genital ulceration, (A1) 31  
 response to monosodium urate crystals, (A2) 44  
 Behçet's uveitis, cyclosporin A in treatment, 285  
 BELCH JFF, MACKENZIE JF, LAND DV, STURROCK RD. Cold challenge and vascular reactivity of the oesophagus in systemic sclerosis complicated by Raynaud's phenomenon, (A1) 38  
 BELCH JFF, ZOMA A, McLAUGHLIN K, CURRAN L, CAPELL HA, FORBES CD, STURROCK RD. Fibrinolysis in systemic lupus erythematosus: effect of desamino D-arginine vasopressin infusion, 262  
 BELCH JFF, ZOMA A, RICHARDS IM, FORBES CD, STURROCK RD. Vascular damage and factor VIII related antigen in the rheumatic diseases, (A1) 32  
 BELCH JFF *see also* Richards IM  
 BENHAMOU CL *see* Kahn M-F

- BERANECK L *see* Kahn M-F
- BERCZI I, COSBY H, HUNTER T, BARAGAR F, McNEILLY AS, FRIESEN HG. Decreased bioactivity of circulating prolactin in patients with rheumatoid arthritis, 433
- BERNARD O *see* Emery P
- BERRY H, BLOOM B, SHAYEGAN-SALEK MS, LUSCOMBE DK, WALKER SR. Quality of life—does it matter?, (A2) 123
- BERRY H *see also* Jawad ASM; Pitt P; Zakrzewski J
- BESWICK T *see* Fonseca A
- BETTS RP *see* Stockley I
- BETTS WH, MCCOLL SR, HURST NP, CLELAND LG. Auranofin stimulates LTA hydrolase and inhibits 5-lipoxygenase activity in human neutrophils, (A2) 71
- BETTS WH *see also* French JK
- BHALLA AK, ADAMI S, CAPELLI R, DI GIOVINE F, DUFF G. Biphosphonates and monocyte function, (A1) 34
- Bicipital swelling in adult-onset Still's disease, 216
- BIENENSTOCK J *see* Jenkins RT
- BILLINGHAM M. Animal models of arthritis, 227
- BINDER AI, GRAHAM EM, SANDERS MD, DINNING W, JAMES DG, DENMAN AM. Cyclosporin A in the treatment of severe Behçet's uveitis, 285
- BINDER AI, SNAITH ML, ISENBERG DA. Sjögren's syndrome: a study of its neurological complications, (A1) 17
- Biphosphonates and monocyte function, (A1) 34
- BIRD H *see* Pullar T
- BIRD HA, DIXON JS, HILL J, SUSSMAN H, TRAFICANTE A, WRIGHT V. Clinical and biochemical evaluation of the potential second-line activity of pronomide in the treatment of rheumatoid arthritis, (A2) 2
- BIRD HA, WALKER A, NEWTON J. Study of hyperlaxity in Olympic gymnasts, (A2) 111
- BIRD HA. Handling data from long-term studies, (A1) 51
- BIRD HA. Whither metrology?, (E) 165
- BIRD HA *see also* Dixon JS; le Gallez P; Leigh TJ; Sittion NG; Taggart AJ; Thornton JH
- BJARNASON I. The gut and RA, (L) 67
- BJELLE A, HAGBERG M, MICHAELSON G. Work-related shoulder-neck complaints in industry: a pilot study, 365
- BLACK C *see* Mahmud T; Senaldi G; Silman A
- BLACK CM *see* Byron M; Harrison NK
- BLACK D *see* Marabani M
- BLACKWELL CC *see* Shinebaum R
- BLAKE DR *see* Allen RE; Andrews FJ; Fonseca A; Griffiths HR; Hewitt SD; Marjanovic M; Outhwaite J; Unsworth J; Winyard PG
- BLANN A *see* Symmonds D
- BLOM-BULOW B *see* Geirsson A
- BLOOM B *see* Berry H
- BLOUNT S, GRIFFITHS HR, LUNEC J. Hydrogen peroxide mediated damage to DNA: implications for SLE, (A2) 69
- BLOXHAM DP, BRADSHAW D, CASHIN CH, DODGE BB, LEWIS EJ, WESTMACOTT D, BARBER WE, MACHIN PJ, OSBOND JM, SELF CR, SMITHEN CE, TONG BP. Ro 31-3948, a potential disease modifying anti-rheumatoid drug, (A2) 2
- BOERS M, VAN RUTHOVEN AWAM, GOEI THE HS, DIKMANS BAC, CATS A. Serum creatinine levels two years later: follow up of a placebo-controlled trial of cyclosporin in rheumatoid arthritis, (A2) 3
- BOIFFARD O *see* Bontoux D
- BOJAR R *see* le Gallez P
- BOUMAR F *see* Ruiz MT
- Bone mineral content and osteocalcin measurements in rheumatoid arthritis: relationship to steroid therapy, (A2) 88
- Bone resorption in patients with early rheumatoid disease treated only with nonsteroidal anti-inflammatory drugs, (A2) 87
- BONNER B *see* Prouse PJ
- BONTOUX D, VANDERMARCO P, BOIFFARD O, AZAIS I, ALCALAY M. Computed tomography and prediction of the chemonucleolysis outcome, (A2) 17
- BOSCO JJ *see* Williamson MER
- BOSSINGHAM D. Seat-belts again, (L) 394
- BOSSINGHAM DH, BARTON MAJ, WALLACE AW. Accurate assessment of function during the treatment of painful shoulders, (A1) 63
- BOYLSTON A *see* Brennan FM
- BOZSOKY S *see* Balint GP
- BRADSHAW D *see* Bloxham DP
- BRAILSFORD S *see* Unsworth J; Winyard PG
- BREEDVELD FC *see* Collee G
- BRÉGEON C, ROLLAND D, MASSON CH, CANONNE F, RENIER JC. Evaluation of the incidence and the prevalence of rheumatoid arthritis in Angers, France, (A2) 91
- BRENCLEY PEC *see* Collins I
- BRENNAN FM, ALLARD S, LONDEI M, BOYLSTON A, CAREL S, MAINI T, FELDMANN M. Expression of T cell receptor idiotypes on peripheral blood lymphocytes and rheumatoid synovial cells, (A2) 125
- BRESNIHAN B *see* Hassan J; McNicholl J; Soden M
- BREWERTON DA. Homozygous MM in ankylosing spondylitis, (L) 65
- BREWERTON DA *see also* Dixey JJ; Pease CT; Rees RG; Revell PA; Rowe IF
- BRIGHTON S, WALKER D, GOODACRE JA, MALCOLM AJ, DICK WC. Animal model of Chikungunya virus-induced chronic destructive polyarthritis, (A2) 80
- BROOKS PM *see* March LM
- BROWN C *see* Venables PJW
- BROWN DH *see* Pullar T
- BROWN EA *see* Sethi D
- BROWN G *see* Spector TD
- BROWN KA *see* Baguley E; Limb GA; Simmons KM
- BROWN N *see* Reid DM
- BROWN RA, MCFARLAND CD, ALI SY, McLAUGHLIN B, TAYLOR CM, WEISS JB. Alkaline phosphatase substrates and *in vitro* production of the angiogenic factor, ESAF, by calcifying cartilage, (A2) 65
- BROWN RA *see also* Rees JA
- Brucella arthritis among Iraqi patients, 24
- Brucellosis in Saudi Arabia, 22
- Brucellosis, spinal, 28
- BRYANS R *see* Greenwood A
- BUCHAN G, TURNER M, FELDMANN M, HIRANO T, KISHIMOTO T, MAINI RN. B cell stimulating factors in rheumatoid joints, (A2) 64
- BUCKLAND-WRIGHT JC, MACFARLANE DG, CHARMICHAEL I, CLARK B. Relationship between soft and hard tissue changes in nodal GOA: a clinical and microfoal radiographic study, (A1) 13
- BUCKLAND-WRIGHT JC, MACFARLANE DG, CLARK B. Quantitative microfoal radiography of disease progression in generalised nodal osteoarthritis of the hand, (A2) 46
- BUCKLEY B *see* Farr M
- BUCKNELL R *see* Nurcombe HL

- BULL P, ARAGHBAND-ZADEH J, CARTER GD, SCOTT JT. Plasma luteinizing hormone, follicle stimulating hormone, prolactin and sex hormones in patients with gout, (A2) 45
- BULSTRODE SJ, BAREFOOT J, HARRISON RA, CLARKE AK. Role of passive stretching in the treatment of ankylosing spondylitis, 40
- BURNS GF *see* Emery P
- BURNS HJ, KLIMIUK PS, HILTON RC, HAENEY M. Gold-induced hypogammaglobulinaemia, 53
- BURRY HC. Sport, exercise and arthritis, 386
- BUTLER MG, D'ARDENNE J, SCOTT DL. P-component in the inflamed synovium, (A1) 23
- BUTLER RC, DAVIE MWJ, WORSFOLD M. Bone mineral content and osteocalcin measurements in rheumatoid arthritis: relationship to steroid therapy, (A2) 88
- BUTLER RC *see also* Austin AK
- BYERS PD *see* Afoke NYP
- BYRON M, FAUX JA, CEDERHOLM-WILLIAMS SA. Vascular damage: role of endothelial and cardiolipin antibodies, (A2) 96
- C4 alleles, measurement of serum levels, (A2) 51
- C4 null phenotypes, frequency in patients with rheumatoid arthritis, (A2) 51
- C4 polymorphisms, in systemic lupus erythematosus, (A2) 52
- C4B null alleles in Felt's syndrome, (A2) 50
- C-reactive protein  
in anticardiolipin antibody positive rheumatoid arthritis patients, 346  
and ESR in polymyalgia rheumatica/giant cell arteritis, (A1) 65  
in rheumatoid arthritis, 351
- Cakir N, Yazici H, Yurdakal S, Akcasu A, Atasoy S. Response to monosodium urate crystals in Behçet's syndrome, (A2) 44
- Calcaneal spurs—a survey of their prevalence and relevance, (A1) 68
- Calcinosis and anticomplement antibody, 17
- Calcium  
intracellular, (A2) 84  
signal for T cell mitogenesis stimulated by interleukin 1 and concanavalin A, (A1) 25
- CALIN A, ELSWOOD J, KLOUDA P. HLA status of 'seronegative rheumatoid arthritis' and seropositive rheumatoid disease—matched for disease severity, (A2) 104
- CALIN A, ELSWOOD J.  
Ankylosing spondylitis—a nationwide analytical review: entry variables determining surgical intervention and outcome, (A1) 53  
Ankylosing spondylitis: a review of 149 total hip replacements in 86 patients, (A1) 71  
Genetic versus environmental factors influencing onset and course of ankylosing spondylitis in 42 sib pairs concordant for disease, (A2) 105  
Natural history of juvenile onset ankylosing spondylitis: a controlled study, (A2) 114  
Relationship between pelvic, spinal and hip involvement in ankylosing spondylitis—one disease process or several?, (A2) 116
- CALIN A *see also* Nemeth R
- CALVIN J *see* Chard MD
- CAMBRIDGE G, FAITH A, SNAITH ML, SAUNDERS C, DUBOWITZ V. Comparative study of *in vitro* lymphocyte function in inflammatory muscle disease, (A2) 53
- CAMBRIDGE G *see also* Turner-Stokes L
- CAMP R. Recent advances in the pathogenesis of psoriasis, (A1) 52
- CAMPBELL AK. Intracellular calcium, (A2) 84
- CANONNE F *see* Brégeon C
- CANTAGREL A *see* Soubrier M
- CAPELL HA *see* Belch JF; Madhok R; Marabani M; Pullar T; Richards IM
- CAPELLI R *see* Bhalla AK
- Cardiac  
involvement in systemic sclerosis, (A1) 41  
surgery, locomotor symptoms following, (A1) 31
- Cardiolipin antibodies, role in vascular damage, (A2) 96
- CARDOE N *see* Kirk AP
- CARLISLE LJ *see* Bax DE
- Carpal tunnel syndrome  
Controlled trial of diuretics, (A1) 29  
diagnosis, 233  
in haemodialysis patients, 181
- CARR S, FARRER M, WALKER DJ, BAKER B. Red cell ferritin as an indicator of iron responsive anaemia in rheumatoid arthritis, (A2) 36
- CARREL S *see* Brennan FM
- CARROLL G. Quantitation of proteoglycans and sulphated glycosaminoglycans in arthritic synovial fluid, (A1) 66
- CARTER GD *see* Bull P
- CARTER H, CHEVALLIER J, AUQUIER L. Recent data on rheumatological disorders in France: observations in private and in hospital practice, (A2) 97
- CARTER-EDWARDS T *see* Nuki G
- Cartilage  
breakdown by a granulomatous reaction, (A1) 25  
matrix components, humoral immunity to, (A2) 75
- CARY NR B *see* Sethi D
- CASHIN CH. The induction of an erosive arthropathy in the guinea-pig with copper II bisglycinate and its treatment with antirheumatic drugs, 251
- CASHIN CH *see also* Bloxham DP
- CASTELLANO JA *see* Pascual E
- CATS A *see* Boers M; Hazes M; Heurkens THM; Peeters A
- CAVENDER DE *see* Haskard DO
- CAWLEY MID *see* Cooper C; Hargreaves C; Howell WM; Kidd BL; Moore K
- CAWSTON T *see* Chard MD
- CAWSTON TE, McLAUGHLIN P, HAZLEMAN BL. Paired serum and synovial fluid values of  $\alpha_2$ -macroglobulin and TIMP in rheumatoid arthritis, 354
- CAWSTON TE. Milwaukee shoulder—synovial fluid contains no active collagenase, (L) 311
- CAWSTON TE *see also* Andrews HJ; Kyle V
- CEDERHOLM-WILLIAMS SA *see* Byton M
- CELINSKA E *see* Panayi GS
- Cervical  
myelopathy complicating multiple joint replacement in rheumatoid disease, 275  
spine disease and frozen shoulder, (A2) 40
- CHAMOT AM *see* Kahn M-F
- Chanhy D, Winnearls C, Maini RN, Feldmann M. Induction of interleukin 1 mRNA and protein by immune complexes: synergy with gamma IFN, (A2) 59
- CHAOUAT Y *see* Amor B
- CHAPMAN K *see* Gowen M
- Characterisation and mechanism of action of a serum inhibitor of complement-mediated prevention of immune precipitation, (A2) 108

- CHARD MD, CALVIN J, CAWSTON T, HAZLEMAN BL. Serum alpha-1-antichymotrypsin concentration as a marker of disease activity in rheumatoid arthritis, (A1) 2
- CHARD MD, SATELLE L, HAZLEMAN BL. The long-term outcome of rotator cuff tendinitis, (A1) 30
- CHARLES P *see* Field M
- CHARMICHAEL I *see* Buckland-Wright JC
- CHASSAGNE J *see* Afane M
- CHATTOPADHYAY C, ACKRILL P, CLAGUE RB. Shoulder pain syndrome and soft-tissue abnormalities in patients on long-term haemodialysis, 181
- CHATTOPADHYAY C, ACKRILL P, MCCLURE JC, CLAGUE RB. Cystic translucencies in bones and beta-2 microglobulin associated amyloid in patients on long-term haemodialysis, (A1) 46
- CHEETHAM BF *see* Emery P
- CHEVALLIER J *see* Carter H
- CHIKANZA I *see* Kirkham B
- Chikungunya virus animal model, (A2) 80
- CHIRICO S *see* Situnayake RD
- Chlamydia trachomatis*  
does enter the joint in 'reactive' arthritis, (A1) 53  
and seronegative arthritis in women, (A2) 116
- Chloroquine  
in adherent synovial cells, (A2) 56  
combined with D-penicillamine in treatment of rheumatoid arthritis, 279  
prescribing by consultant rheumatologists in the UK, 375
- Cholesterol crystals in shoulder synovial fluid, 430
- Chondrocalcinosis, 51
- Chondrodysplasias, segregation analysis of the type II collagen structural gene, (A1) 27
- Chronic knee effusion and aspiration: the effect on quadriceps inhibition, 370
- CHUCK A, WILSON R, PATTRICK M, DOHERTY M. Spectrum of crystal deposition in hypophosphatasia, (A2) 45.
- CHUCK AJ, MURPHY J, WEISS JB, JAYSON MIV. Urinary glycosaminoglycan excretion in systemic sclerosis subsets compared with normal controls, 259
- CHUCK AJ. Fenbufen-associated pneumonitis, (L) 475
- CLAGUE RB *see* Chattopadhyay C; Collins I
- CLAMP JR *see* Hutton CW
- CLARK B *see* Buckland-Wright JC; Coughlan RJ; Grahame R
- CLARKE AK *see* Bulstrode SJ
- CLARKE S *see* Dawes PT
- CLELAND LG *see* Betts WH
- Clinical  
and biochemical evaluation of the potential second-line activity of prinomide in the treatment of rheumatoid arthritis, (A2) 2  
and echocardiographic assessment in juvenile-onset spondylarthropathy, (L) 155  
epidemiological and immunogenetic studies of familial and non-familial rheumatoid arthritis, (A1) 43  
features and prognosis of Wegener's granulomatosis, (A2) 42  
measurements in rheumatology, (E) 81  
and radiological features of Paget's disease in the knee, (A2) 89  
and serological features of the 'anti-phospholipid syndrome', (A2) 19  
significance of the anticitromere antibody, 17
- Clostridium perfringens* in rheumatoid arthritis patients, 329
- COCHRANE P *see* Hajiroussou V
- COHEN B *see* McCormick JN
- COHEN DE LARA A *see* Delecoeuillerie G
- COHEN N. Adult Still's disease presenting as PUO; a not uncommon disorder, (L) 65
- Cold challenge and vascular reactivity of the oesophagus in systemic sclerosis complicated by Raynaud's phenomenon, (A1) 38
- Collagen structural gene  
type II, (A1) 27  
in type II Ehlers Danlos syndrome, (A1) 27
- COLLEE G, BREEDVELD FC, ALGRA PR, PADBERG GW. Rheumatoid arthritis with vertical atlanto-axial subluxation complicated by hydrocephalus, 56
- COLLINS AJ, DU TOIT JA. Upper gastrointestinal findings and faecal occult blood in patients with rheumatic disease taking nonsteroidal anti-inflammatory drugs, 295
- COLLINS AJ *see also* Doube A
- COLLINS I, MORGAN K, CLAGUE RB, BRENCHELY PEC, HOLT PJL. IgG subclasses of anti-type II collagen antibodies in rheumatoid arthritis, (A2) 79
- COLLINS I *see also* Holt PJ
- COLLINS M *see* Dawes PT; Sheeran T
- COLSTON MJ *see* Palacios-Boix AA
- Combination chemotherapy in rheumatoid arthritis, (E) 243
- Combination therapy in rheumatoid arthritis—study design, (L) 314
- Combined D-penicillamine and chloroquine treatment of rheumatoid arthritis—a comparative study, 279
- Combined gold and hydroxychloroquine in rheumatoid arthritis, (A1) 395
- Comparative analysis of disease-associated changes in N-glycosylation, (A2) 112
- Comparative study of *in vitro* lymphocyte function in inflammatory muscle disease, (A2) 53
- Comparison of  
erect and supine radiographs of the hip, (L) 393  
faecal flora in patients with rheumatoid arthritis and controls, 329  
immunofluorescence and immunoperoxidase for demonstration of antinuclear antibodies on HEp-2 substrate, 188  
pain description, mood, and perceived ill-health between patients with diffuse non-articular rheumatism, rheumatoid arthritis and normal controls, (A2) 120  
serial synovial fluid cytology in RA; delineation of subgroups, (A2) 30  
sleep in osteoarthritic patients and normals and its modification by a hypnotic, (A1) 14
- Complement  
activation in progressive systemic sclerosis, (A2) 80  
activation in rheumatoid arthritis occurs through the classical pathway and is related to disease activity, (A1) 18  
—friend or foe?, 409  
—mediated prevention of immune precipitation, (A2) 108
- Computed tomography  
and prediction of the chemonucleolysis outcome, (A2) 17  
to assess the role of popliteal cysts in 90Y therapy for persistent synovitis of the knee, (A2) 8
- Computer-assisted feedback can reduce variation in the clinical assessment of rheumatoid arthritis, (A2) 35

- Computerized axial tomographic study of costovertebral joints in ankylosing spondylitis patients with posterior thoracic pain, (A2) 16
- Computers in rheumatology, 43
- CONNELLY A *see* Young SP
- CONSTABLE TJ *see* Wallis PJW
- Contact pressures in normal and OA hip joints, (A1) 13
- Contribution of the  
clinical metrologists, (A1) 50  
French rheumatologists to the progress of rheumatology since 40 years, (A2) 97
- Controlled  
assessment of the prevalence of Raynaud's phenomenon in Sjögren's syndrome, (A2) 22  
studies of stanozolol in primary Raynaud's phenomenon and in systemic sclerosis, (A2) 24  
study of two psychotropic agents for the relief of pain in osteoarthritis, (A2) 10  
trial of diuretics in idiopathic carpal tunnel syndrome, (A1) 29
- Controversies in the treatment of polymyalgia rheumatica and giant cell arteritis, (A2) 86
- COOK P *see* Cooper C
- COOK PL *see* Kidd BL
- COOKE EM *see* Neumann VC; Shinebaum R
- COOKE J *see* Dixey JJ
- COOPER C, FISHER L, OSMOND C, COOK P, CAWLEY MID. Osteoarthritis of the hip and osteoporosis of the proximal femur: an epidemiological study, (A2) 90
- COOPER C *see* Hargreaves C; Luqmani RA
- Copper II bisglycinate, induction of erosive arthropathy in guinea pigs, 251
- COPPOCK JS, GRIFFITHS A, WILLIAMS A, HERBERT K, SCOTT DL. Serum and synovial fluid proteins and complexes in rheumatoid arthritis and osteoarthritis: quantitative or qualitative differences?, (A1) 23
- COPPOCK JS *see also* Greenwood A; Robinson MW; Williams A
- CORBETT M *see* Winska-Wiloch H
- CORCORAN T *see* Turner-Stokes L
- Correlation of histological features with patterns of damage in different joints in rheumatoid arthritis, (A2) 29
- CORRIN B *see* Harrison NK
- CORRY DG *see* De Brito F
- COSBY H *see* Berdzi I
- COSH JA *see* Reilly PA
- COSTELLO JF *see* Zakrzewski J
- Costs of providing a rheumatological service, 454
- COUGHLAN RJ, GORDON Y, CLARK B, PANAYI GS. 7S IgM in the sera of patients with arthritis, 108
- COUGHLAN RJ, HAZLEMAN BL, PAGE THOMAS DP, SATTELLE L, CRISP AJ, JENNER JR, DANDY DJ. Algodystrophy: a common unrecognized cause of chronic knee pain, 270
- COUGHLAN RJ *see also* Foley-Nolan D
- COULTON LA *see* Gray RES
- COX N *see* Ebringer A
- CRANSTON WI *see* di Giovine F
- CRAWLEY JCW *see* Shawe DJ
- Creatine kinase, effect of sex and race on serum level, (A2) 48
- CREST, 17  
low platelet serotonin levels in patients normalised with ketanserin, (A2) 24  
syndrome and severe subcutaneous calcification, 89
- CRISP AJ *see* Coughlan RJ; Gibson T
- CROOK PR *see* Bedi S
- CROSS M *see* Emmerson BT
- CROSS SJ *see* Holme ER
- CT scanning of the thorax in progressive systemic sclerosis: detection of early fibrosing alveolitis and its morphological features, (A2) 25
- Cultured synovial cells serve as targets for lymphokine-activated killer cells, (A2) 54
- CUNNINGTON SJ *see* Allington L
- CURRAN L *see* Belch JF
- CURREY HLF *see* Kirwan JR; Thompson PW
- Cyclosporin  
A in the treatment of severe Behçet's uveitis, 285  
placebo-controlled trial in rheumatoid arthritis, (A2) 3  
in rheumatoid arthritis: a double blind placebo controlled trial in 52 patients, (A2) 98
- Cystic translucencies in bones and beta-2 microglobulin associated amyloid in patients on long-term haemodialysis, (A1) 46
- Cytokine  
induction, immunoblot analysis, (A1) 24  
mRNA accumulation stimulated by urate crystals, (A2) 60  
Cytoskeletal changes following free radical attack, (A2) 69
- DACRE J, PERRETT D, HERBERT KE, ASTOR D, SCOTT DL. Amino acids in synovial fluid, (A1) 24
- DACRE J *see also* Greenwood A
- DACRE JE, BEENEY N, SCOTT DL. Physiotherapy or steroids for the painful stiff shoulder?, (A2) 13
- DAHA MR *see* Heurkens THM; Peeters A
- DALGEISH R *see* Wordsworth BP
- DANDY DJ *see* Coughlan RJ
- DANG H *see* Isenberg D
- DANN N *see* Stewart HD
- DAR O, SALAMAN MR, SEIFERT MH, ISENBERG DA. Role of polyclonal activation in the development of SLE, (A2) 74
- DARBY A *see* Pitt P
- D'ARZENNE J *see* Butler MG
- DARLINGTON LG, RAMSEY NW. Olive oil for rheumatoid patients?, (A2) 129
- DASGUPTA B, DUKE O, PANAYI GS. Antibodies to intermediate filaments in polymyalgia rheumatica/giant cell arteritis, (A1) 61
- DASGUPTA B, DUKE O, TIMMS AM, MYLES AB, FERNANDEZ L, LATHAM BA, PANAYI GS. Selective depletion and activation of CD8 positive T lymphocytes from peripheral blood in polymyalgia rheumatica and giant cell arteritis, (A2) 55
- DASGUPTA B *see also* Panayi GS
- DAUNT S O'N *see* Fisher L
- DAVID J *see* Mackworth-Young CG
- DAVIDSON A *see* Miller MH
- DAVIE MWJ *see* Butler RC
- DAVIES PG *see* Kirwan JR
- DAVIES R *see* Watts RA
- DAVIES UM, PALMER RG, DENMAN AM. A randomised, double-blind, cross-over trial of acyclovir v. placebo for oral and genital ulceration in Behçet's syndrome, (A1) 31
- DAVIS M *see* Situnayake RD; Thomson W
- DAVIS MJ, DENTON J, FREEMONT AJ, HOLT PJL. Comparison of serial synovial fluid cytology in RA; delineation of subgroups, (A2) 31



- DAVIS P, STEIN M, LATTI A, EMMANUEL J. Sero-negative polyarthritis in Zimbabwean black patients: possible relationship to human immunodeficiency virus infection, (A2) 113
- DAWES P *see* Sheeran T
- DAWES PT, ILCHYSHYN A, GOULDING NJ, ILDERTON E, SHADFORTH MF, YARDLEY H, HALL ND. Elevated epidermal phospholipase A2 activity in rheumatoid arthritis: evidence against a circulating lipocortin antibody, (A1) 62
- DAWES PT, JACKSON R, SHADFORTH MF, LEWIN IV, STANWORTH DR. The relationship between the complex of IgA and alpha-1-antitrypsin, its constituent components and the acute-phase response as measured by C-reactive protein in rheumatoid arthritis treated with gold or D-penicillamine, 351
- DAWES PT, TUNN E, FOWLER PD, SHADFORTH MF, FISHER J, CLARKE S, COLLINS M, BACON PA, POPERT AJ, JONES P, SCOTT DL. Combined gold and hydroxy-chloroquine in rheumatoid arthritis, (A1) 11
- DAWES PT. Senior registrar UK/Eire travelling fellowship, (L) 230
- DAWES PT *see also* Sheeran TP
- DAYMOND TJ, ROWELL FJ. Reduction of prostaglandin E<sub>2</sub> levels in synovial fluid of patients suffering from rheumatoid arthritis following treatment with indomethacin or tiaprofenic acid, (A1) 5
- DE BRITO F, CORRY DG, WILLOUGHBY DA. Polyarthritis—mechanisms exposed in studies with the air pouch, (A1) 26
- DE BRITO F, HOLMES MJG, MOORE AR, WILLOUGHBY DA. The influence of inflammation in the breakdown of cartilage by a granulomatous reaction, (A1) 25
- DE CLERK L *see* Grillet B
- DE VRIES RRP *see* Hazes M
- DEANS AC *see* Rowe IF
- Decreased B-cell galactosyl transferase activity in rheumatoid arthritis, (A2) 72
- Decreased bioactivity of circulating prolactin in patients with rheumatoid arthritis 433
- Deficient interleukin-2 production in rheumatoid arthritis, (A2) 131
- Deflazacort, double-blind acute study, (A1) 54
- DEGEORGES M *see* Kahan A
- DEGNER FL *see* Wittenborg A
- DELAMERE JP *see* Kalra L
- DELARGY M *see* Taggart AJ
- DELCAMBRE B *see* Duquesnoy B
- DELECOEUILLE G, JOLY P, COHEN DE LARA A, PAOLAGGI JB. Polymyalgia rheumatica and temporal arteritis: prognosis and management according to initial clinical presentation, (A2) 129
- DEMAINE AG *see* Sakkas LI
- Dementia in SLE, (A2) 17
- Dendritic cells
- in autologous mixed lymphocyte reaction, 85
  - from inflammatory synovial fluid and rheumatoid synovial membrane augment con A-induced and autologous peripheral blood mononuclear cell proliferation, (A2) 124
- DENMAN AM *see* Bindet AI; Davies UM
- DENTON J *see* Davis MJ
- DEQUEKER J *see* Grillet B
- DERKSEN RHW *see* Asherson RA
- Detection of Epstein-Barr virus DNA in salivary gland biopsies from patients with Sjögren's syndrome, (A1) 16
- Determination of the raised level of keratan sulphate in the synovial fluids of patients with reactive arthritis, (A1) 66
- DEVAUX JY *see* Kahan A
- DHIR H *see* Papasavvas GK
- DI GIOVINE F, NUKI G, DUFF GW. Release of tumour necrosis factor activity from mononuclear cells stimulated with crystals, (A1) 33
- DI GIOVINE F, SITUNAYAKE D, DUFF GW. Radio-immunoassay of interleukin 1 beta in acute and chronic rheumatic disease, (A1) 34
- DI GIOVINE F, TOWNSEND Y, CRANSTON WI, DUFF GW. Inhibition of tumour necrosis factor by alpha MSH, (A2) 62
- DI GIOVINE F *see also* Bhalla AK; Manson J
- DI GIOVINE FS, NUKI G, MANSON J, DUFF G. Urate crystals stimulate cytokine mRNA accumulation in human monocytes, (A2) 60
- DI GIOVINE FS *see also* Symons JA
- Diagnosis
- analysis of concordance between the diagnosis given to rheumatic diseases by non rheumatologists and those of trained rheumatologists, (A2) 50
  - of carpal tunnel syndrome, (L) 233
  - of pseudogout and septic arthritis, 379
  - of rheumatic disease, (L) 73
- Diastolic abnormalities of the left ventricle in rheumatoid and psoriatic arthritis, (A2) 43
- DICK WC *see* Bedi S; Brighton S; Pal B
- DICKENS E *see* Leaver HA; Manson J
- DIEPPE P *see* McCrae F; Patrick M; Veerapen K
- DIEPPE PA *see* Bamji A; Hutton CW; Paine TF; Riordan JW
- Differential
- diagnosis in a patient with secondary Sjögren's syndrome and neuromuscular complications, (L) 470
  - expression of MHC Class II antigens and macrophage subpopulations in rheumatoid pannus, (A2) 124
- DIFFEY BL *see* Badal PAL
- DUKMANS BAC *see* Boers M; Hazes M
- DIMECH WJ *see* Tipping PG
- DINARELLO C *see* Manson J
- DINNING W *see* Binder, AI
- Discordant segregation of the major fibrillar collagen structural genes in type II Ehlers Danlos syndrome, (A1) 27
- Discrepancy between 3H-thymidine uptake and cell cycle studies in stimulated lymphocyte cultures treated with methotrexate, (A2) 57
- DISNEY A *see* Hurst NP
- Distribution of
- immunoregulatory idiotypes on anti-La (SS-B) antibodies in patients with Sjögren's syndrome, (A1) 60
  - radiological joint damage in the hand and relevance of hand dominance in patients with psoriatic arthritis, (A2) 115
- Diuretics and patients with rheumatoid arthritis, (L) 72
- DIXEY J, THOMAS B, TAYLOR-ROBINSON D, OSBORN M, KEAT A. *Chlamydia trachomatis* and seronegative arthritis in women, (A2) 116
- DIXEY JJ *see also* Keat A
- DIXEY JJ, NOORMOHAMED FH, PAWA JS, LANT AF, BREWERTON DA. Influence of nonsteroidal anti-inflammatory drugs and probenecid on the renal response to, and kinetics of piretanide in man, (A2) 9

- DIXEY JJ, TODD CEC, COOKE J, VALENTINE A, KEAT ACS.  
Vertebral angiography in rheumatoid arthritis patients with and without atlanto-axial subluxation, (A1) 45
- DIXEY JJ *see also* Rees RG
- DIXON JS, HILL J, BIRD HA.  
Measurement of proximal interphalangeal joint circumference in rheumatoid arthritis: one joint or ten?, 123
- Serial measurement of proximal interphalangeal joint circumference in rheumatoid arthritis: one joint or ten?, (A1) 63
- DIXON JS. Measuring progression of arthritis—the long-term view, 389
- DIXON JS *see also* Bird HA; le Gallez P; Sittion NG; Taggart AJ. DNA antibody idiomotype in ankylosing spondylitis, 168
- Do anticardiolipin antibodies cause thrombosis through a platelet mediated mechanism?, (A2) 94
- Do conventional assays measure immune complexes?, (A2) 76
- Do serum sulphasalazine and metabolite concentrations relate to treatment outcome in rheumatoid arthritis, (A2) 5
- DOIDGE BB *see* Bloxham DP
- Does D-penicillamine help in chronic adhesive spinal arachnoiditis?, (A2) 15
- Does the negative association between rheumatoid arthritis and schizophrenia provide clues to the aetiology of rheumatoid arthritis?, 307
- Does rheumatoid factor protect lupus patients from nephritis?, (A2) 18
- Does the self administration of drugs by rheumatology in-patients increase subsequent patient knowledge?, (A2) 10
- Does sulphasalazine impair folic acid absorption in patients with rheumatoid arthritis, (A1) 7
- DOHERTY M *see* Arie E; Chuck A; Hutton CW; Patrick M; Ratcliffe A; Smith NJ
- DOHERTY SM *see* Gray RES
- DOMJAN L *see* Balint GP
- DOUBE A, COLLINS AJ. Similarity of haematological parameters of iron status, faecal occult blood positivity and prevalence of lesions on upper gastro-intestinal endoscopy in arthritic patients with microcytic and normocytic anaemia, (A2) 37
- DOUBE A, GOW PJ. Bicipital swelling in adult-onset Still's disease, 216
- DOUBE A. Gas in the calf and possible Baker's cyst rupture, (L) 229
- Double-blind  
acute study of deflazacort and prednisolone in patients requiring corticosteroid therapy, (A1) 54
- placebo-controlled trial of intravenous methylprednisolone in SLE, (A2) 19
- DOUGADOS M, AWADA H, AMOR B. Cyclosporin in rheumatoid arthritis: a double blind placebo controlled trial in 52 patients, (A2) 98
- DOWLING V *see* Keane A
- DOWLING EJ, SYMONS AM, ANDREWS FJ, BLAKE DR.  
Reactive oxygen species, inflammation and drug evaluation, (A1) 19
- DOYLE DV *see* Foster OJF
- DQ $\alpha$  associated restriction fragment length polymorphisms in HLA-DR4 positive rheumatoid arthritis, (A1) 33
- DR4 frequency in female rheumatoid arthritis patients in relation with the age of disease onset, (A1) 26
- DRUEKE T *see* Zingraff J
- Du Tort JA *see* Collins AJ
- DUBOST JJ *see* Afane M; Soubrier M
- DUBOWITZ V *see* Cambridge G
- DUCKWORTH T *see* Stockley I
- DUDENEY C *see* Isenberg DA
- DUFF G *see* Bhalla AK; di Giovine FS; Leaver HA
- DUFF GW. Pathogenesis of inflammation, 390
- DUFF GW *see also* di Giovine F; Symons JA
- DUKE O, POULTER LW, SORG C, PANAYI GS. Accessory cells in foetal joints, (A2) 123
- DUKE O *see also* Dasgupta B
- DUMONDE DC *see* Limb GA; Simmons KM
- DUQUESNOY B, PEREZ T, WALLAERT B, FARRE JM, TONNEL A-B, VOISIN C, DELCAMPRE B. Evidence for activated alveolar macrophage as a component of subclinical inflammatory alveolitis in rheumatoid arthritis, (A2) 99
- DWEK RA *see* Parekh R
- DYER PA *see* Thomson W
- DYKES J *see* Young SP
- Early rheumatoid arthritis in the foot, (A2) 103
- EBONG WW. Septic arthritis in patients with sickle-cell disease, 99
- EBRINGER A, COX N, KHALAFOUR S, PTASZYNSKA T, SHODJAI-MORADI F, WILSON C. Rheumatoid arthritis may be the sequel to proteus reactive arthritis, (A2) 26
- EBRINGER A *see also* Isenberg DA
- EDMOND E *see* McCormick JN
- EDWARDS J. Diagnosis of rheumatic disease, (L) 73
- EDWARDS JCW *see* Mead JC; Sharif M
- EDWARDS NL *see* Yonker RA
- EDWARDS SW *see* Hughes V; Nurcombe HL
- Effect of  
joint movement on an index of free radical damage, (A2) 70
- naproxen on renal haemodynamics in elderly patients, (A2) 9
- regular physiotherapy on mobility and shape of the spine in patients with ankylosing spondylitis over a two year period, (A1) 70
- sex and race on serum creatinine kinase level, (A2) 48
- Effects of  
chloroquine in adherent synovial cells functions in primary cultures, (A2) 56
- pregnancy on the rheumatic diseases, (E) 403
- sulphasalazine on faecal flora in patients with rheumatoid arthritis: a comparison with penicillamine, 334
- Ehlers-Danlos syndrome, 9, (A1) 27
- ELBORN S *see* Taggart AJ
- Elbow, radial head excision, 59
- Elevated  
epidermal phospholipase A2 activity in rheumatoid arthritis: evidence against a circulating lipocortin antibody, (A1) 62
- von Willebrand factor antigen in systemic sclerosis; relationship to visceral disease, (A2) 96
- Elisa increases sensitivity of detection of SLE-specific anti-Sm antibodies, (A1) 59
- ELLIS R *see* Hargreaves C
- ELLIS SA *see* Pease CT
- ELSWOOD J *see* Calin A; Nemeth R

- EMERY P, HERTZOG PJ, CHEETHAM BF. Alteration of the interferon system in RA. Association of elevated IFN activity with remission status, (A2) 63
- EMERY P, LOPEZ AF, BURNS GF, VADAS MA. Synovial fluid neutrophils in RA have membrane antigen changes that reflect activation, (A2) 67
- EMERY P, WOOD N, MACKEY IR, BERNARD O. Loss of high affinity IL-2 receptors in active RA, (A2) 63
- EMERY P. Sulphoxidation ability and thiol status in rheumatoid arthritis patients, (E) 163
- EMERY P *see also* Gibson T; Panayi GS
- EMMANUEL J *see* Davis P
- EMMERSON BT, GORDON RB, CROSS M, THOMSON DB. Plasma oxipurinol concentrations during allopurinol therapy, 445
- Endothelial antibodies, role in vascular damage, (A2) 96
- Enhanced  
chemotaxis of monocytes in rheumatoid arthritis, 245  
oxidative metabolism of neutrophils from patients with systemic sclerosis, 113
- ENSOR M *see* Foster OJF
- Eosinophilic polymyositis presenting as a pseudotumour in the hyper eosinophilic syndrome, 384
- Epidemiological  
aspects of polymyalgia rheumatica/giant cell arteritis, (A2) 85  
study of systemic sclerosis in the West Midlands, (A1) 38
- Epididymo-orchitis in Behçet's disease, (L) 468
- Epidurography in the management of sciatica, 424
- Epstein-Barr  
nuclear antigen, (A1) 17  
virus, antibodies to, in rheumatoid arthritic families, 193  
virus DNA, (A1) 16
- ERHARDT CC, MUMFORD P, VENABLES PJW, MAINI RN. Factors predicting a poor life prognosis in rheumatoid arthritis: an eight year prospective follow-up study, (A1) 44
- ERHARDT CC *see also* Sethi D
- Erythrocyte sedimentation rate, plasma and serum viscosity as measures of disease activity in rheumatoid arthritis, 136
- ESAF production by calcifying cartilage, (A2) 65
- ESPLUGUES J *see* Hutton CW
- Estimation of urinary PGE2 before and after nonsteroidal anti-inflammatory drug administration, (A2) 8
- ESTRADA-G I *see* Palacios-Boix AA
- Ethnic differences in the distribution of anticardiolipin antibodies in European and Malay patients with SLE, (A2) 20
- Evaluation of the  
disability index of the Stanford health assessment questionnaire over time, (A2) 122  
dynamic qualities of grip strength, (A2) 48  
incidence and the prevalence of rheumatoid arthritis in Angers, France, (A2) 91
- EVANS PR *see* Howell WM
- Evidence  
for activated alveolar macrophage as a component of subclinical inflammatory alveolitis in rheumatoid arthritis, (A2) 99  
that phosphatidyl choline synthesised by methylation of phosphatidyl ethanolamine is not an important source of arachidonic acid in stimulated human leucocytes, (A2) 68
- EVISON G. Comparison of erect and supine radiographs of the hip, (L) 393
- Exercise increases serum levels of cytidine deaminase in rheumatoid arthritis, (A2) 28
- Expression of  
an interspecies anti-Sm antibody idiomorph in the sera of SLE patients and their relatives, (A1) 60  
T cell receptor idiotypes on peripheral blood lymphocytes and rheumatoid synovial cells, (A2) 125
- Facial flushing following intra-articular injection of steroid, (A1) 10
- Factor VIII related antigen in rheumatic diseases, (A1) 32
- Factors  
precipitating depressed mood in rheumatoid arthritis, (A2) 121  
predicting a poor life prognosis in rheumatoid arthritis: an eight year prospective follow-up study, (A1) 44
- FAHRER H, SAUVAN MJ, VAN DER LINDEN S, GERBER N. Lyme borreliosis—how useful is the serology? Preliminary report from a Swiss prospective study, (A2) 114
- FAIL B *see* McClelland J
- Failure of antiphospholipid antibodies to bind human endothelial cells, (A2) 95
- FAITH A *see* Cambridge G
- False positive monospot test in systemic lupus erythematosus, (L) 71
- Familial Mediterranean fever and polyarteritis nodosa, 139
- FARID KHAN M *see* Pullar T
- FARR M, BUCKLEY B, SMEDLEY S, BACON PA. Adenosine deaminase in synovial fluid: a new measure for local joint inflammation?, (A1) 2
- FARR M, KITAS G, BACON PA. Assessing the outcome of sulphasalazine therapy in rheumatoid arthritis, (A2) 3
- FARR M *see also* Kitas GD; Symmons D
- FARRE JM *see* Duquesnoy B
- FARRER M *see* Carr S
- FAST A. Diagnosis of carpal tunnel syndrome, (L) 233
- FAUX JA *see* Byron M
- FEELY M *see* Pullar T
- FEIGHERY C *see* Hassan J; Soden M
- FELDMAN R *see* Isenberg DA
- FELDMANN M *see* Brennan FM; Buchan G; Chantry D
- Felty's syndrome and C4B null alleles, (A2) 50
- Fenbafen-associated pneumonitis, (L) 475
- FERNANDEZ L *see* Dasgupta B
- Fibrinolysis in systemic lupus erythematosus: effect of desamino D-arginine vasopressin infusion, 262
- Fibrinolytic activity  
and ibuprofen, (L) 393  
in symptomatic and asymptomatic lumbar spondylosis, (A2) 13
- Fibromyalgia syndrome, sleeping electroencephalograms in patients, (A2) 43
- Fibronectin in human normal and osteoarthritic cartilage, (A1) 15
- FIELD M, CHARLES P, WILLIAMS D, MISRA R, MAINI RN. Elisa increases sensitivity of detection of SLE-specific anti-Sm antibodies, (A1) 59
- FIELDER AHL *see* So AKL
- Finger  
flexion function in rheumatoid arthritis: the reliability of eight simple tests, 118  
joint swelling in rheumatoid arthritis, 123  
First seconds of neutrophil activation: phosphoinositides, protein kinase C, and calcium movements, (A1) 49



- FISHER J *see* Dawes PT  
 FISHER L, DAUNT S O'N. Distribution of radiological joint damage in the hand and relevance of hand dominance in patients with psoriatic arthritis. (A2) 115  
 FISHER L *see also* Cooper C  
 FITZPATRICK R, NEWMAN S, LAMB R, SHIPLEY M. Social relationships in patients with rheumatoid arthritis. (A2) 121  
 FITZPATRICK R *see also* Newman S  
 Flexor tendon function, tests for, 118  
 FLOWER RJ *see* Podgorski MR  
 FOLEY-NOLAN D, BARRY C, COUGHLAN RJ, O'CONNOR P, RODEN D. Low energy high frequency pulsed electromagnetic therapy treatment for persistent neck pain: a double blind placebo controlled trial. (A2) 101  
 Folic acid absorption in rheumatoid arthritis. (A1) 7  
 FONSECA A, BESWICK T, KELSEY S, HAYLLAR J, UNSWORTH J, MURRAY J, BLAKE DR. Low-dose iron absorption test and the anaemia of rheumatoid disease. (A2) 110  
 Foot, early rheumatoid arthritis in. (A2) 103  
 FORBES CD *see* Belch JF; Belch JF  
 FORBES IJ *see* French JK  
 FORBES J *see* Taggart AJ  
 FORSTER SM *see* Rowe IF  
 FOSTER OJF, DOYLE DV, ENSOR M, HUSKISSON EC. Maintenance of remission in rheumatoid arthritis with intermittent penicillamine therapy. (A2) 7  
 FOURNIER C *see* Bauer-Vinassac D  
 FOWLER P *see* Sheeran T  
 FOWLER PD. Combination therapy in rheumatoid arthritis—study design. (L) 314  
 FOWLER PD *see also* Dawes PT  
 FRASER S, LAND D, STURROCK RD. Microwave Thermography—an index of inflammatory joint disease. 37  
 FRASER SM, STURROCK RD. Interventional study of sulphasalazine in ankylosing spondylitis with peripheral joint involvement. (A2) 11  
 FRASER SM *see also* Richards IM  
 FREEMONT AJ, HODSON N, MITCHELL W, JAYSON MIV. Microvascular injury precedes dermal fibrosis in systemic sclerosis. (A2) 25  
 FREEMONT AJ *see also* Davis MJ  
 FRENCH AP *see* O'Sullivan MM  
 FRENCH JK, HURST NP, BETTS WH. Evidence that phosphatidyl choline synthesised by methylation of phosphatidyl ethanolamine is not an important source of arachidonic acid in stimulated human leucocytes. (A2) 68  
 FRENCH JK, HURST NP, WOSNIAK A, ZALEWSKI PD, FORBES IJ. Role of Ca<sup>++</sup> and protein kinase C in neutrophil superoxide release. (A2) 68  
 Frequency of C4 null phenotypes in patients with rheumatoid arthritis who develop proteinuria after gold and penicillamine treatment. (A2) 51  
 FRIESEN HG *see* Bercei I  
 FROCHT A, LEEK JC, ROBBINS DL. Gout and hyperuricaemia in systemic lupus erythematosus. 303  
 Frozen shoulder and cervical spine disease: a case-control study. (A2) 40  
 Gait analysis—its usefulness or otherwise. (A2) 86  
 GALTIER B *see* Afane M  
 GARNER C *see* Symmonds D  
 GARVEY EM *see* Moore K  
 Gas in the calf and possible Baker's cyst rupture. (L) 229  
 GASTON JSH, BACON PA. Possibilities for immunoregulation in the rheumatic diseases—seeing in a glass darkly. 463  
 GASTON JSH *see also* Life P  
 Gastroduodenal ulceration and non-aspirin nonsteroidal anti-inflammatory drugs. 158  
 Gastrointestinal bleeding, indomethacin-induced. (A2) 12  
 GAUCHER A *see* Kahn M-F  
 GEBOES K *see* Grillet B  
 GEE C *see* Griffiths HR  
 GEIRSSON A, BLOM-BULOW B, PAHLM O, AKESSON A. Cardiac involvement in systemic sclerosis. (A1) 41  
 Generalized osteoporosis in rheumatoid arthritis. (A2) 26  
 Genetic heterogeneity in Sjögren's syndrome: the evidence of genetic markers. (A2) 106  
 versus environmental factors influencing onset and course of ankylosing spondylitis in 42 sib pairs concordant for disease. (A2) 105  
 GERBER N *see* Fahrner H  
 GERSTER JC. Clinical and echocardiographic assessment in juvenile-onset spondylarthropathy. (L) 155  
 GETTY CJM *see* Stockley I  
 GHARAVI AE *see* Khamashta MA  
 Giant cell arteritis. (A2) 85  
 antibodies to intermediate filaments. (A1) 61  
 C-reactive protein and ESR. (A1) 65  
 controversies in the treatment. (A2) 86  
 epidemiological aspects. (A2) 85  
 liver involvement. (A2) 38  
 selective depletion and activation of CD8 positive T lymphocytes from peripheral blood. (A2) 55  
 synovitis in. (A2) 38  
 GIBSON C *see* Pal B  
 GIBSON DG *see* Rowe IF  
 GIBSON T, EMERY P, ARMSTRONG RD, CRISP AJ, PANAYI GS. Combined D-penicillamine and chloroquine treatment of rheumatoid arthritis—a comparative study. 279  
 GIBSON T *see also* Armstrong RD; Jenkinson ML; Jobanputra P; Kirkham B; Panayi GS; Price R  
 GIDDINGS J *see* Williamson MER  
 GIL A *see* Khamashta MA  
 GILES LGF, HARVEY AR. Immunohistochemical demonstration of nociceptors in the capsule and synovial folds of human zygapophyseal joints. 362  
 GILES LGF, TAYLOR JR. Human zygapophyseal joint capsule and synovial fold innervation. 93  
 GLYNN D *see* McNicholl J  
 GODDARD DH, NEVILLE M, MOORE ME. Cultured synovial cells serve as targets for lymphokine-activated killer cells. (A2) 54  
 GODDEN DJ *see* Harris GK  
 GOEI THE HS *see* Boers M  
 Gold comparison study of oral and intramuscular in rheumatoid arthritis. (A2) 6  
 -induced hypogammaglobulinaemia. 53  
 therapy combined with hydroxychloroquine. (A1) 11  
 therapy and leucopenia. (A1) 6  
 therapy in rheumatoid arthritis. (A1) 9  
 treatment for rheumatoid arthritis and C-reactive protein. 351  
 GOODACRE JA *see* Brighton S  
 GOODACRE RL *see* Jenkins RT  
 GOODFIELD M *see* Greaves M  
 GORDON RB *see* Emmerson BT

- GORDON Y *see* Coughlan RJ  
 GOSNEY AR *see* Howell WM  
 GOULDING NJ *see* Dawes PT; Podgorski MR  
 Gout  
   age and osteoarthritis as modifying factors in presentation and distribution, (A2) 92  
   and hyperuricaemia in systemic lupus erythematosus, 303  
   hypoxanthine-guanine phosphoribosyl transferase deficiency in three brothers, (A2) 44  
   plasma luteinizing hormone, follicle stimulating hormone, prolactin and sex hormones, (A2) 45  
   plasma oxipurinol concentrations in allopurinol therapy, 445  
 GOW PJ *see* Doube A  
 GOWEN M, CHAPMAN K, RUSSELL RGG. Tumour necrosis factor: its production by and actions on human osteoblasts *in vitro*, (A2) 62  
 GOWER PE *see* Sethi D  
 GRAHAM EM *see* Binder AI  
 GRAHAME R, CLARK B, WATSON M, POLKEY C. Does D-penicillamine help in chronic adhesive spinal arachnoiditis? (A2) 15  
 GRAHAME R *see also* Kirkham B; Panayi GS  
 GRAY RES, DOHERTY SM, COULTON LA, KANIS JA. A double-blind acute study of deflazacort and prednisolone in patients requiring corticosteroid therapy, (A1) 54  
 GREAVES M, MILFORD WARD A, MOULT J, HOLT CM, LINDSEY N, HUGHES P, GOODFIELD M, ROWELL NR. Elevated von Willebrand factor antigen in systemic sclerosis; relationship to visceral disease, (A2) 96  
 GREAVES M *see* Bax DE  
 GREAVES MS *see* Bax DE  
 GREEN M *see* Hurst NP  
 GREENWOOD A, BRYANS R, COPPOCK JS, DACRE J, SCOTT DL, HUSKISSON EC. Measurement of joint damage in osteoarthritis: the development of a standardised assessment technique, (A1) 67  
 GREENWOOD A. The contribution of the clinical metrologist, (A1) 50  
 GREENWOOD A *see also* Williams A  
 GRENNAN A *see* Klimiuk PS  
 GRENNAN D *see* Weiss JB  
 GRENNAN DM *see also* Sidebottom D; Thomson W  
 GRIFFIN BE *see* Teo CG  
 GRIFFIN J *see* Panayi GS  
 GRIFFITHS A *see* Coppock JS  
 GRIFFITHS HR, BLAKE DR, LUNEC J. Increased binding of polyclonal rheumatoid factors to oxygen radical denatured IgG, (A2) 70  
 GRIFFITHS HR, LUNEC J, JEFFERIS R, BLAKE DR, GEE C, WILLSON R. The effect of free radicals on human immunoglobulin G3, (A1) 20  
 GRIFFITHS HR *see also* Blount S  
 GRIFFITHS ID *see* Bedi WS; Pal B  
 GRIFFITHS M *see* Walker DJ  
 GRILLET B, DE CLERK L, DEQUEKER J, RUTGEERTS P, GEBOES K. Systematic ileocolonoscopy and bowel biopsy study in spondylarthropathy, 338  
 GRIMES SM *see* Mathews JA  
 GRINDULIS KA, ROY S. Renal and pancreatic calcification in rheumatoid arthritis with Sjögren's syndrome, 212  
 Grip strength, dynamic qualities, (A2) 48  
 GUERADO-PARRA E *see* Soriano RMG  
 GUÉRIN F *see* Kahan A  
 GUMPEL JM *see* Prouse PJ; Shawe DJ  
 Gut and RA, (L) 67  
 Haemodialysis patients  
   B2 microglobulin derived amyloid and iron, (A2) 39  
   beta2 microglobulin amyloid in sternoclavicular joints, (A2) 39  
   beta2 microglobulin-related amyloidosis, (A2) 40  
   cystic translucencies in bones and beta-2 microglobulin associated amyloid, (A1) 46  
   shoulder pain syndrome, 181  
 Haemoglobin SC disease, and patients with septic arthritis, 99  
 Haemophilia, acquired, and rheumatoid arthritis, 381  
 Haemophilus influenzae in juvenile arthritis, 73  
 HAENY M *see* Burns HJ  
 HAGBERG M *see* Bjelle A  
 HAJIROUSSOU V, COCHRANE P, TUDWAY A, WEBLEY M. A prospective endoscopic study comparing the ulcerogenic effects of piroxicam and sulindac in patients with osteoarthritis, (A1) 12  
 HALIM K *see* Rajapakse CNA  
 HALL MA *see* Hull RG  
 HALL ND *see* Dawes PT; Maslen CL; Podgorski MR  
 HALLIDAY LDC *see* Littler TR  
 HAMBLEY H *see* Zoma A  
 Hand function in established nodal generalised osteoarthritis and erosive osteoarthritis—a controlled study, (A2) 47  
 Handling data from long-term studies, (A1) 51  
 HARDEN R MCG *see* Balint GP  
 HARDINGHAM T *see* Ratcliffe A  
 HARGREAVES C, COOPER C, KIDD BL, ELLIS R, CAWLEY MID. Frozen shoulder and cervical spine disease: a case-control study, (A2) 40  
 HARRIS EN, BAGULEY E, ASHERSON RA, HUGHES GRV. Clinical and serological features of the 'anti-phospholipid syndrome', (A2) 19  
 HARRIS EN. Syndrome of the Black Swan, (E) 324  
 HARRIS EN *see also* Asherson RA; Baguley E; Khamashta MA  
 HARRIS GK, AITKEN AGF, GODDEN DJ, STEVEN MM. Popliteal cyst—diagnosis by real-time ultrasound, (A1) 1  
 HARRIS JRW *see* Rowe IF  
 HARRISON NK, STRICKLAND B, CORRIN B, BLACK CM, TURNER-WARWICK M. CT scanning of the thorax in progressive systemic sclerosis: detection of early fibrosing alveolitis and its morphological features, (A2) 25  
 HARRISON RA *see* Bulstrode SJ  
 HART H *see* McCormick JN  
 HARVEY AR, WRIGHT V. Comparison of pain description, mood, and perceived ill-health between patients with diffuse non-articular rheumatism, rheumatoid arthritis and normal controls, (A2) 120  
 HARVEY AR *see also* Giles LGF  
 HASKARD D *see* Baguley E  
 HASKARD DO, CAVENDER DE, MALIAKKAI D, ZIFF M. T cell adhesion to endothelial cells in patients with systemic lupus erythematosus, (A2) 58  
 HASKARD DO *see also* Pitzalis C  
 HASLOCK I *see* Bamji A; Rhind VM  
 HASSAN J, FEIGHERY C, BRESNihan B, WHELAN A. Immunoregulatory defects in patients with active rheumatoid arthritis, (A1) 36  
 HAY F *see* Winska-Willich H  
 HAYLLAR J *see* Fonseca A  
 HAZELTON RA, SCULLEY TB, POPE JH. The prevalence of antibodies to an Epstein-Barr virus-induced polypeptide (EBNA-2) in the sera of rheumatoid arthritic families, 193

- HAZES M, DIJKMANS BAC, DE VRIES RRP, CATS A, VANDENBROUCKE JP. DR4 frequency in female rheumatoid arthritis patients in relation with the age of disease onset. (A1) 26
- HAZES M, DIJKMANS BAC, VANDENBROUCKE JP, CATS A. Oral contraception and rheumatoid arthritis: a protective effect independent of duration of pill use. (A2) 93
- HAZLEMAN B. Controversies in the treatment of polymyalgia rheumatica and giant cell arteritis. (A2) 86
- HAZLEMAN BL *see* Cawston TE; Chard MD; Coughlan RJ; Kyle V
- Health assessment questionnaire and its ability to assess antirheumatic drug therapy. (A2) 122
- Heat sensitive serum factor influencing spontaneous cellular cytotoxicity which is not demonstrable in patients with rheumatoid arthritis. (A1) 20
- $\mu$ -Heavy chain and monoclonal IgG K paraproteinaemia in systemic lupus erythematosus. 460
- Heel pain in sarcoidosis—is sarcoid a cause of spondylarthropathy? (L) 468
- HEINRICH I *see* Armstrong RD
- HELLIWELL P, HOWE A, WRIGHT V  
Evaluation of the dynamic qualities of grip strength. (A2) 48  
Lack of evidence of objective stiffness in rheumatoid arthritis. (A2) 34
- Helper-inducer T lymphocytes show preferential adhesion to endothelial cells. (A2) 127
- HENDERSON DR *see* Hurst NP
- Henoch-Schönlein purpura associated with co-dydramol. (L) 65
- HENRY JONES J *see* Pye M
- HERBERT K *see* Coppock JS
- HERBERT KE. Are we asking the right questions? (A1) 51
- HERBERT KE *see also* Dacre J
- HERTZOG PJ *see* Emery P
- Heterogeneity of osteoarthritis of the knee. (A1) 45
- HEURKENS THM, WESTEDT ML, JONGES E, CATS A, DAHA MR. Uptake and degradation of soluble complexes of IgG by monocytes from patients with rheumatoid arthritis and rheumatoid vasculitis. (A2) 109
- HEWITT SD, HIDER RC, BLAKE DR, MORRIS CJ. Iron chelators as anti inflammatory therapy. (A2) 83
- HEWITT SD *see also* Marjanovic M
- HIDER RC *see* Hewitt SD
- High prevalence of unrecognised osteomalacia in hospital patients with rheumatoid arthritis. (A2) 87
- HILL J *see* Bird HA; Dixon JS; Taggart AJ; Thornton JH
- HILTON R *see* Noble J
- HILTON RC *see* Burns HJ
- Hind foot disease in rheumatoid arthritis. (A2) 33
- HINTON C *see* Hutton CW
- Hip joint  
osteoarthritis. (A1) 13  
passive stretching in ankylosing spondylitis. 40  
Hip radiographs, comparison of erect and supine. (L) 393
- HIRANO T *see* Buchan G
- Histological abnormalities in the normal joints of patients with rheumatoid arthritis. (A2) 29
- HLA status of 'seronegative rheumatoid arthritis' and seropositive rheumatoid disease—matched for disease severity. (A2) 104
- HLA-B27 related arthritis, sulphasalazine and rheumatoid arthritis. (E) 321
- HLA-DR4 is a restriction determinant for defined mycobacterial antigens in rheumatoid arthritis and healthy subjects. (A2) 130
- HOBBS RN *see* Austin AK
- HOCHBERG MC. Mortality from systemic lupus erythematosus in England and Wales, 1974–1983. 437
- HODGKINSON JP *see* Noble J
- HODSON N *see* Freemont AJ
- HOGG N *see* Allard SA
- HOLDSWORTH SR *see* Tipping PG
- HOLLAND CD *see* Jayson MIV
- HOLLYWELL CA, MORRIS CJ, SCOTT DL. Autoantibodies to cytoplasmic filaments in rheumatoid arthritis: a common complex pattern of autoimmunity. (A1) 62
- HOLME ER, CROSS SJ, VEITCH J, O'NEILL JG, WHALEY K. Measurement of serum levels of C4A and C4B by ELISA. (A2) 51
- HOLMES MJG *see* De Brito F
- HOLT CM *see* Greaves M
- HOLT LPJ, COLLINS I, MORGAN K, KEEN J. Juvenile arthritis: serum autoantibodies to types I, II, IX and XI collagens. (A2) 132
- HOLT PJL *see* Collins I; Davis MJ; Walton K
- Homozygous MM in ankylosing spondylitis. (L) 65
- HOOPER J *see* Worrall J
- HOPKINS SJ, HUMPHREYS M, PRICE J, JAYSON MIV. Synovial fluid contains only picogram levels of biologically active IL-1. (A2) 58
- HORROCKS A *see* Armstrong RD
- HORSFALL AC, VENABLES PJW, MUMFORD PA, ALLARD SA, MAINI RN. Distribution of immunoregulatory idiotypes on anti-La (SS-B) antibodies in patients with Sjögren's syndrome. (A1) 60
- Hospital formulary survey. (L) 313
- How do patients fill in visual analog pain scales—a study of overall pain in arthritis and pain in individual joints. (A2) 119
- HOWARD RJ *see* Unsworth J
- HOWE A *see* Helliwell P
- HOWELL WM, EVANS PR, GOSNEY AR, SMITH JL, WILSON PJ, WALTERS M, CAWLEY MID. DG $\alpha$  associated restriction fragment length polymorphisms in HLA-DR4 positive rheumatoid arthritis. (A1) 33
- HOWIE AJ *see* Beaman M
- HUGHES GRV *see* Baguley E; Harris EN; Mackworth-Young CG
- HUGHES J *see* Shawe DJ
- HUGHES P *see* Greaves M
- HUGHES V, HUMPHREYS JM, EDWARDS SW. Protein synthesis in neutrophils is activated during inflammation. (A2) 67
- HULL RG, HALL MA, ANSELL BM. Referrals of in-patients to rheumatologists: an important source of referral? (A2) 49
- Human immunodeficiency virus infection and arthritis. (A2) 118  
and sero-negative polyarthritis in Zimbabwean black patients. (A2) 113
- Human immunoglobulin G3, effect of free radicals. (A1) 20
- Human zygapophyseal joint capsule and synovial fold innervation. 93
- HUMM G *see* Kyle V
- Humoral immunity to cartilage matrix components. (A2) 75
- HUMPHREYS JM *see* Hughes V
- HUMPHREYS M *see* Hopkins SJ
- HUNTER JA *see* Richards IM
- HUNTER T *see* Berczi I
- HURST NP, SMITH W, HENDERSON DR. IgG (kappa) paraproteinaemia and arthritis. 142

- HURST NP, VAN DEN BERG R, DISNEY A, ALBERTYN L, ALCOCK M, GREEN M, PASCOE V. Prevalence, clinical features and risk factors for beta2 microglobulin-related amyloidosis in patients receiving chronic haemodialysis, (A2) 40
- HURST NP *see also* Betts WH; French JK
- HUSKISSON EC. Combination chemotherapy in rheumatoid arthritis, (E) 243
- HUSKISSON EC *see also* Foster OJF; Greenwood A; Specator T; Williams A
- HUSTON G. Diuretics and patients with rheumatoid arthritis, (L) 72
- HUTCHINSON M *see* McNicholl J
- HUTTON CW, DOHERTY M, DIEPPE PA. Acute pseudogout of the temporomandibular joint: a report of three cases and review of the literature, 51
- HUTTON CW, ESPLUGUES J, DIEPPE PA, CLAMP JR. Abnormal mucus glycopeptide in rheumatoid arthritis, (A2) 30
- HUTTON CW, HINTON C, DIEPPE PA. Intra-articular variation of synovial changes in knee arthritis: biopsy study comparing changes in patellofemoral synovium and the medial tibiofemoral synovium, 5
- HUTTON CW, WATT I. Primary osteoarthritis of the hip—the influence of bone response on its natural history, (A1) 15
- HUTTON WC *see* Afoke NYP
- Hydrocephalus complicating rheumatoid arthritis, 56
- Hydrocortisone, triamcinolone and lignocaine injections for tennis elbow—a controlled study, (A2) 100
- Hydrogen peroxide mediated damage to DNA: implications for SLE, (A2) 69
- Hydroxychloroquine prescribing by consultant rheumatologists in the UK, 375
- Hyper eosinophilic syndrome and eosinophilic polymyositis presenting as a pseudotumour, 384
- Hyperlaxity in Olympic gymnasts, (A2) 111
- Hypermobility, 9
- Hyperuricaemia in systemic lupus erythematosus, 303
- Hypogammaglobulinaemia, gold-induced, 53
- Hypophosphatasia, spectrum of crystal deposition, (A2) 45
- Hypoxanthine-guanine phosphoribosyl transferase deficiency in three brothers with gout: characterisation of a variant enzyme with altered isoelectric point, minor changes in Michaelis constants and normal levels of HPRT messenger RNA, (A2) 44
- Ibuprofen does not affect fibrinolytic activity, (L) 393
- Identification of  
  autoantigens, autoantibodies and their idiotypes, (E) 161  
  an inhibitor of *in vitro* erythropoiesis from synovial fluid of rheumatoid patients and its relationship to anaemia of chronic disease, (A2) 37
- DQw3 polymorphism using an allele specific oligonucleotide probe and association with rheumatoid arthritis, (A2) 111
- IgA  
  containing immune complexes and haematuria in patients with ankylosing spondylitis, (A2) 118  
  and IgM rheumatoid factors as markers of later erosive changes in rheumatoid arthritis, (A1) 4  
  nephropathy in rheumatoid arthritis, 299  
  nephropathy in a young female with ankylosing spondylitis, (L) 396  
  (kappa) paraproteinaemia and arthritis, 142  
  oxygen radical denatured and increased binding of polyclonal rheumatoid factors, (A2) 70  
  subclasses of anti-type II collagen antibodies in rheumatoid arthritis, (A2) 79
- IgM rheumatoid factor, 108
- 7S IgM in the sera of patients with arthritis, 108
- IL-2 receptor in serum and synovial fluid samples from patients with rheumatic diseases, (A2) 64
- IL-2 *see also* Interleukin-2
- ILCHYSHYN A *see* Dawes PT
- ILDERTON E *see* Dawes PT
- Ileitis in spondylarthropathy, 338
- Ileocolonoscopy in spondylarthropathy, 338
- ILLINGWORTH K *see* Klimiuk PS
- Immune complex  
  kinetics of interactions with erythrocyte receptor type 1, (A2) 107  
  and measurement by conventional assay, (A2) 76  
  role of complement and erythrocyte CR1 in the clearance of 125I-tetanus toxoid/anti-tetanus toxoid, (A2) 107
- Immune function of rheumatoid synovial fluid T lymphocytes is of the helper-inducer type, (A1) 37
- Immune response to challenge with exogenous antigen (flu vaccination) in patients with systemic lupus erythematosus and other auto-immune disorders, (A2) 79
- Immunoblot analysis of cytokine induction in human monocytes, (A1) 24
- Immunoglobulin  
  class and IgG subclass of autoantibodies in progressive systemic sclerosis, (A2) 77  
  lambda light chain genes in rheumatoid arthritis, (A2) 52
- Immunoglobulins in rheumatoid arthritis: do they help in assessing activity? (A1) 3
- Immunohistochemical demonstration of nociceptors in the capsule and synovial folds of human zygapophyseal joints, 362
- Immunopathology of chronic synovitis and other chronic inflammation results from the preferential accumulation of helper-inducer T cells, (A2) 126
- Immunoreactive N-acetylglucosamine in chronic synovitis, (A2) 73
- Immunoregulation in the rheumatic diseases, 463
- Immunoregulatory  
  defects in patients with active rheumatoid arthritis, (A1) 36  
  subsets of CD4+ lymphocytes present within rheumatoid synovial membranes and the effect of therapy with disease modifying drugs, (A1) 55
- Impairment of cardiac diastolic function in patients with ankylosing spondylitis, as evaluated by Doppler echocardiography, (A1) 71
- Increased  
  binding of polyclonal rheumatoid factors to oxygen radical denatured IgG, (A2) 70  
  hysterectomy rate before symptom onset in osteoarthritis, (A2) 91  
  intestinal permeability in patients with rheumatoid arthritis: a side-effect of oral nonsteroidal anti-inflammatory drug therapy? 103
- Indomethacin  
  -induced gastro-intestinal ulceration in rats, (A2) 81  
  prostaglandin E<sub>2</sub> levels in rheumatoid arthritis, (A1) 5

- Induction of**  
 an erosive arthropathy in the guinea-pig with copper II bisglycinate and its treatment with antirheumatic drugs, 251  
 interleukin 1 mRNA and protein by immune complexes: synergy with gamma IFN, (A2) 59
- Industrial rheumatology and the shoulder, (E) 326**
- Infection and immunity in the rheumatic diseases, 223**
- Infectious mononucleosis, anticardiolipin antibodies in, (A1) 59**
- Inflamed joint—an example of iron promoted reperfusion injury? (A2) 82**
- Inflammation**  
 in the breakdown of cartilage by a granulomatous reaction, (A1) 25  
 pathogenesis of, 390
- Inflammatory muscle disease, technetium pyrophosphate muscle scans in, 267**
- Influence of**  
 age on clinical and serological manifestations in unselected patients with systemic lupus erythematosus, (A1) 46  
 nonsteroidal anti-inflammatory drugs and probenecid on the renal response to, and kinetics of pirtanide, in man, (A2) 9
- Inhibition of**  
 indomethacin-induced gastrointestinal bleeding, both immediate and persistent, in man by citrate-glucose formulations, (A2) 12  
 tumour necrosis factor by alpha MSH, (A2) 62
- Inositol phosphates as second messengers, (A2) 84**
- Interleukin 1**  
 induction of mRNA, and protein by immune complexes, (A2) 59  
 mediator of lymphocyte emigration in rheumatoid synovitis, (A2) 59, (A2) 128  
 synovial fluid levels, (A2) 58
- Interleukin-2 biology of suppressor-inducer cells in rheumatoid arthritis, (A1) 36**
- International Rimexolone Study Group see van Vliet-Daskalopoulou E**
- Interventional study of sulphasalazine in ankylosing spondylitis with peripheral joint involvement, (A2) 117**
- Intra-articular**  
 rimexolone in the rheumatoid knee: a placebo-controlled, double-blind, multicentre trial of three doses, 450  
 variation of synovial changes in knee arthritis: biopsy study comparing changes in patellofemoral synovium and the medial tibiofemoral synovium, 5
- Intracellular calcium, (A2) 84**
- Iron**  
 chelators as anti-inflammatory therapy, (A2) 83  
 prediction of marrow stores, (A2) 36  
 promoted reperfusion injury, (A2) 82
- IRVINE RF. Inositol phosphates as second messengers, (A2) 84**
- ISENBERG D, DANG H, TAKEI M, SHOENFELD Y, BACKIMER R, TALAL N. Expression of an interspecies anti-Sm antibody idiotype in the sera of SLE patients and their relatives, (A1) 60**
- ISENBERG DA, DUDENEY C, WILLIAMS W, TODD POKROPECK A, STOLLAR BD. Serial studies of antibodies to seven polynucleotides in SLE, (A2) 78**
- ISENBERG DA, FELDMAN R, DUDENEY C, KONIKOFF F, JONES D, EBRINGER A, SHOENFELD Y. A study of antipolynucleotide antibodies, anti-Klebsiella (K30) antibodies and anti-DNA antibody idiotypes in ankylosing spondylitis, 168**
- ISENBERG DA, WILLIAMS W, JONES M, SWANA G, LE PAGE S, ZUMLA A, McADAM KPWJ. Studies of common DNA antibody idiotypes and autoantibodies in SLE spouses, (A2) 73**
- ISENBERG DA see Axford JS; Binder AI; Dar O; Jones DW; Parekh R; Turner-Stokes L**
- JACKSON R see Dawes PT; Sheeran TP**
- JAHANSHAHI M see Pitt P**
- JAMES DG see Binder AI**
- JAMES P see Walker DJ**
- JAMES V see Patrick M**
- JANNINI S see Silman A**
- JANOSSY G see Kirkham B**
- JAWAD ASM, MAKINDE V, SENALDI G, BERRY H, VERGANI D. Complement activation in rheumatoid arthritis occurs through the classical pathway and is related to disease activity, (A1) 18**
- JAYSON MIV, HOLLAND CD, KEEGAN A, MORRIS K, TAYLOR L. Controlled studies of stanozolol in primary Raynaud's phenomenon and in systemic sclerosis, (A2) 24**
- JAYSON MIV see also Chuck AJ; Freemont AJ; Hopkins SJ; Kay EA; Klimiuk PS; Mitchell WS**
- JEFFERIS R see Griffiths HR**
- JEFFERIS R see Mageed RA**
- JENKINS JS see Leach IH; Powell RJ**
- JENKINS RT, ROONEY PJ, JONES DB, BIENENSTOCK J, GOODACRE RL. Increased intestinal permeability in patients with rheumatoid arthritis: a side-effect of oral nonsteroidal anti-inflammatory drug therapy? 103**
- JENKINS VM see Mathews JA**
- JENKINSON ML, GIBSON T, SLACK R. Does the self administration of drugs by rheumatology inpatients increase subsequent patient knowledge? (A2) 10**
- JENKINSON ML. Reason to use lignocaine-containing solutions with circumcision in arthrocentesis, (L) 471**
- JENNER JR see Coughlan RJ**
- JENTIENS T see van Vliet-Daskalopoulou E**
- JESSOP JD see O'Sullivan MM**
- JOBANPUTRA P, GIBSON T. Diagnosis of pseudogout and septic arthritis, 379**
- JOB-DESLANDRE C, WEILL BJ, MENKES CJ. Antinuclear, antideoxyribonucleoprotein and anti-histone antibodies in juvenile chronic arthritis and transient hip synovitis, (A2) 75**
- Joint**  
 damage, radiological assessments, (A1) 50  
 hyperlaxity, benign familial and obstetric complications, (A2) 41  
 inflammation and laboratory markers, 83  
 mobility and Beighton score, (L) 394  
 mobility and mitral valve prolapse in an Arab population, 442  
 mobility with particular reference to racial variation and inherited connective tissue disorders, 9  
 size influences the leukocyte count of inflammatory synovial fluids, (A2) 32
- JOLY P see Delecoeuillier G**
- JONES AKP. Progress in techniques to measure *in vivo* changes in the central opioid system in man, (A2) 47**
- JONES B see Miller MH**
- JONES D see Isenberg DA**
- JONES DA see Jones DW**
- JONES DB see Jenkins RT**



- JONES DW, JONES DA, NEWHAM DJ. Chronic knee effusion and aspiration: the effect on quadriceps inhibition, 370
- JONES DW, MANSELL MA, SAMUELL CT, ISENBERG DA. Renal abnormalities in ankylosing spondylitis, 341
- JONES JM *see* Walker FS
- JONES M *see* Isenberg DA; Turner-Stokes L
- JONES P *see* Dawes PT
- JONES TJ *see* Revell PA
- JONGES E *see* Heurkens THM
- JONSSON H, NIVED O, STURFELT G. The influence of age on clinical and serological manifestations in unselected patients with systemic lupus erythematosus, (A1) 46
- JOSHI R *see* Nuki G
- JOYCE JE *see* Nuki G
- Juvenile arthritis  
antinuclear, antideoxyribonucleoprotein and anti-histone antibodies, (A2) 75  
intra-articular steroid injections, 73  
serum autoantibodies to types I, II, IX and XI col-lagens, (A2) 132
- KAHANA, AMOR B, MENKES CJ, DEVAUX JY, WEBER S, GUÉRIN F, DEGEORGES M. Nicardipine and thallium-201 myocardial perfusion in patients with systemic sclerosis, (A2) 130
- KAHN M-F, CHAMOT AM, BENHAMOU CL, BERANECK L, PROST A, KAPLAN G, GAUCHER A, LE LOËT X, LE GOFF P. The osteoarticular syndrome acne pustulosis hyperostosis osteitis, (A2) 99
- KALRA L, DELAMERE JP. Lymphoreticular malignancy and monoclonal gammopathy presenting as polymyalgia rheumatica, 458
- KANIS JA *see* Gray RES
- KANTEREWICZ E. IgA nephropathy in a young female with ankylosing spondylitis, (L) 396
- KANTHARIA BK. Raised alkaline phosphatase in rheumatoid arthritis: primary biliary cirrhosis, (L) 313
- KAPLAN G *see* Kahn M-F
- KARDAMAKIS D. Low-dose total body irradiation in rheumatoid arthritis, (L) 234
- KATZ P *see* Yonker RA
- KAY A *see* Armstrong RD
- KAY EA, REES JA, JAYSON MIV. Prescribing of chloroquine and hydroxychloroquine by consultant rheumatologists in the UK, 375
- KAY EA *see also* Klimiuk PS
- KEANE A, WOODS R, DOWDING V, RODEN D, BARRY C. Anticardiolipin antibodies in rheumatoid arthritis, 346
- KEAT A, THOMAS B, DIXEY J, OSBORN M, SONNEX C, TAYLOR-ROBINSON D. *Chlamydia trachomatis* does enter the joint in 'reactive' arthritis, (A1) 53
- KEAT A. Bacteria in aseptic arthritis, (A2) 113
- KEAT ACS *see* Dixey JJ; Rowe IF
- KEEGAN A *see* Jayson MIV
- KEEN J *see* Holt LPJ
- KELLAWAY IW *see* Love WG
- KELLY CA, MCCLELLAND J, FAIL B, WALKER D. Erythrocyte sedimentation rate, plasma and serum viscosity as measures of disease activity in rheumatoid arthritis, 136
- KELSEY S *see* Fonseca A
- KESTER RC *see* Wilkinson D
- KHALAPOUR S *see* Ebringer A
- KHALIFA SJ *see* Al-Rawi ZS
- KHAMASHTA MA, HARRIS EN, GHARAVI AE, BAGULEY E, GIL A, VAZQUEZ JJ, HUGHES GRV. Do anti-cardiolipin antibodies cause thrombosis through a platelet mediated mechanism? (A2) 94
- KHAN MA, WOLFE F, KLEINHEKSEL SM, KHAN MK. Clinical, epidemiological and immunogenetic studies of familial and non-familial rheumatoid arthritis, (A1) 43
- KHAN MA *see also* Sun J-P
- KHAN MK *see* Khan MA
- KIDD BL, COOK PL, CAWLEY MID. Spondylitis without radiological sacroiliitis—a clinical study, (A1) 68
- KIDD BL, WALTERS MT, MOORE K, SMITH JL, CAWLEY MID. The synovial membrane in ankylosing spondylitis—an immunohistological comparison with rheumatoid arthritis, (A1) 28
- KIDD BL *see also* Hargreaves C
- Killer cells, lymphokine-activated, (A2) 54
- Kinetics of interactions between immune complexes and erythrocyte complement receptor type 1, (A2) 107
- KINGSLEY G, PITZALIS C, MURPHY J, PANAYI GS. The immune function of rheumatoid arthritis synovial fluid T lymphocytes is of the helper-inducer type, (A1) 37
- KINGSLEY GH, PITZALIS C, WAUGH AP, PANAYI GS. Reduction in immunoregulatory T cell subset and function in rheumatoid arthritis: correlation with disease status, (A2) 55
- KINGSLEY GH *see also* Kirkham B; Pitzalis C
- KIRK AP, PATEL U, PHILLIPS H, CARDOE N. Cervical myelopathy complicating multiple joint replacement in rheumatoid disease, 275
- KIRK AP *see also* Simmons KM
- KIRKHAM B, CHIKANZA I, PITZALIS C, KINGSLEY GH, GRAHAME R, GIBSON T, AMLOT P, JANOSSY G, PANAYI GS. Monoclonal antibody therapy in rheumatoid arthritis: a clinical and immunological study, (A2) 1
- KIRKHAM B, GIBSON T. Hind foot disease in rheumatoid arthritis, (A2) 33
- KIRWAN JR, BARNES CB, DAVIES PG, CURREY HLF. Computer-assisted feedback can reduce variation in the clinical assessment of rheumatoid arthritis, (A2) 35
- KIRWAN JR.  
Measuring progression of arthritis—the long term view, (A1) 49  
The potential of computer applications in rheumatology, (E) 3
- KIRWAN JR *see also* Thompson PW
- KISHIMOTO T *see* Buchan G
- KITAS G *see* Farr M
- KITAS GD, SALMON M, FARR M, BACON PA. Deficient interleukin-2 production in rheumatoid arthritis, (A2) 131
- KITAS GD *see also* Salmon M
- Kiebsiella antibody in ankylosing spondylitis, 168
- KLEINHEKSEL SM *see* Khan MA
- KLENERMAN L *see* Shawe DJ
- KLIMIUK P. Ibuprofen does not affect fibrinolytic activity, (L) 393
- KLIMIUK PS, GRENNAN A, WEINKOVE C, JAYSON MIV. Platelet and plasma serotonin metabolism in systemic sclerosis and primary Raynaud's phenomenon, (A1) 39
- KLIMIUK PS, ILLINGWORTH K, POUNTAIN GD, JAYSON MIV. Fibrinolytic activity in symptomatic and asymptomatic lumbar spondylosis, (A2) 13
- KLIMIUK PS, KAY EA, GRENNAN A, WEINKOVE C, JAYSON MIV. Low platelet serotonin levels in CREST patients normalised with ketanserin: a possible therapeutic effect, (A2) 24

- KLIIMUK PS *see also* Burns HJ  
 KLOUDA P *see* Calin A  
 Knee  
   effusion and aspiration: effect on quadriceps inhibition, 370  
   pain, algodystrophy as cause, 270  
   replacement in rheumatoid arthritis, (A1) 12  
 KNIGHT RK, PIETRUSKO R, ROWLEY-JONES D, McNALLY C. Life-table analysis of five-year data on auranofin, (A2) 6  
 KNIGHT SC. The autologous mixed lymphocyte reaction and dendritic cells, 85  
 KONIKOFF F *see* Isenberg DA  
 KOOTATHAP S *see* Situnayake RD  
 KUNTZ D *see* Zingraff J  
 KYLE V, HUMM G, CAWSTON TE, HAZLEMAN BL. C-reactive protein and ESR in polymyalgia rheumatica/giant cell arteritis, (A1) 65  
 KYLE V, TUDOR J, HAZLEMAN BL. Synovitis is uncommon in polymyalgia rheumatica/giant cell arteritis, (A2) 38  
 KYLE V, WRAIGHT EP, HAZLEMAN BL. Liver involvement in polymyalgia rheumatica/giant cell arteritis, (A2) 38  
 KYRIAZIS N *see* Pitzalis C
- Laboratory markers of joint inflammation and damage, (E) 83  
 LACHMANN PJ. Complement—friend or foe? 409  
 Lack of evidence  
   for gene conversion in B27 negative ankylosing spondylitis, (A1) 28  
   for an increased incidence of osteonecrosis of the hip or adverse medical events in rheumatoid patients treated with pulse methylprednisolone during a ten year period, (A2) 89  
   of objective stiffness in rheumatoid arthritis, (A2) 34  
 LAMB R *see* Fitzpatrick R; Newman S  
 LANCHBURY JSS *see* Palacios-Boix AA  
 LAND D *see* Fraser JF  
 LAND DV *see* Belch JJF  
 LANGEVITZ P *see* Sachs D  
 LANT AF *see* Dixey JJ  
 LATHAM BA *see* Dasgupta B  
 LATIF A *see* Davis P  
 LATIF AB *see* Wilkinson D  
 Law and rheumatologists, 147, 218  
 LE GALLEZ P, BIRD HA, BOJAR R, DIXON JS. Controlled study of two psychotropic agents for the relief of pain in osteoarthritis, (A2) 10  
 LE GOFF P *see* Kahn M-F  
 LE LOËT X *see* Khan M-F  
 LE PAGE S *see* Isenberg DA  
 LEACH IH, JENKINS JS, MURRAY-LESLIE CF, POWELL RJ.  $\mu$ -Heavy chain and monoclonal IgG K paraproteinemia in systemic lupus erythematosus, 460  
 LEAVER HA, DICKENS E, DUFF G. Calcium signal for T cell mitogenesis stimulated by interleukin 1 and concanavalin, (A1) 25  
 LEEK JC *see* Frocht A  
 Legal aspects of rheumatology, 147  
   medical practitioner in the witness box, 218  
   personal injury cases, 218  
 LEIGH TJ, BIRD HA, WRIGHT V. Comparison of sleep in osteoarthritic patients and normals and its modification by a hypnotic, (A1) 14  
 Leprosy presenting as nodular vasculitis, (L) 398  
 Leu 7 dependent cellular cytotoxicity in rheumatoid arthritis, (A2) 54
- Leucopenia during  
   second line therapy for rheumatoid arthritis with gold or sulphasalazine, (A1) 6  
   sulphasalazine therapy for rheumatoid arthritis, (A2) 4  
 Leukotriene B4  
   levels in psoriatic arthropathy, (A2) 71  
   quantitation in synovial fluid of rheumatoid arthritis patients, (A2) 72  
 LEWIN IV *see* Dawes PT  
 LEWIS EJ *see* Andrews FJ; Bloxham DP  
 LEWIS PA *see* O'Sullivan MM  
 Life, the universe and everything—a report based on the Anglo-US Fellowship Exchange, 1985, 62  
 LIFE P, GASTON JSH, BACON PA. T cell lines from synovium, synovial fluid and peripheral blood of a patient with early rheumatoid arthritis, (A2) 125  
 Life-table analysis of five-year data on auranofin, (A2) 6  
 LIGHTMAN SL *see* Rees RG  
 LIMB GA, DUMONDE DC, WOLSTENCROFT RA, BROWN KA. Production of arthritis in the guinea-pig by intra-articular reaction between lymphokines and inflammatory leukocytes, (A2) 81  
 Limited joint mobility in diabetes, 153  
 LINDSEY N *see* Greaves M  
 Liposomes, technetium labelled, and specific uptake in the rat adjuvant-induced arthritic model, (A2) 83  
 LITTLEJOHN GO *see* Miller MH; Tipping PG  
 LITTLER TR, HALLIDAY LDC, MUKHERJEE SK, ORME MCL'E. Open comparison study of oral gold (auranofin) and intramuscular gold (sodium aurothiomalate) in the treatment of rheumatoid arthritis, (A2) 6  
 Liver  
   involvement in polymyalgia rheumatica/giant cell arteritis, (A2) 38  
   secretion of caeruloplasmin, (A1) 21  
 Lo SS. Surgical aid for intractable rheumatoid ulcers, 235  
 Locomotor symptoms following cardiac surgery, (A1) 31  
 LODWICK R *see* Wallis PJW  
 LOIZOU S *see* Mackworth-Young CG  
 LOMAN J *see* Young SP  
 LONDEI M *see* Brennan FM  
 Long-term outcome of rotator cuff tendinitis, (A1) 30  
 LONGLEY S *see* Yonker RA  
 LOPEZ AF *see* Emery P  
 LOPEZ E *see* Pascual E  
 Loss of high affinity IL-2 receptors in active RA, (A2) 63  
 LOTE CJ *see* Unsworth J  
 LOVE WG, AMOS N, WILLIAMS BD, KELLAWAY IW. Stability of 99m technetium labelled liposomes and their specific uptake in the rat adjuvant-induced arthritic model, (A2) 83  
 Low back pain treatment: is a 'yank' in King Arthur's court or elsewhere as effective as traction, epidural injections or what else? (E) 401  
 Low energy high frequency pulsed electromagnetic therapy treatment for persistent neck pain: a double blind placebo controlled trial, (A2) 101  
 Low free testosterone levels in rheumatoid arthritis, (A1) 1  
 Low platelet serotonin levels in CREST patients normalised with ketanserin: a possible therapeutic effect, (A2) 24  
 Low-dose  
   iron absorption test and the anaemia of rheumatoid disease, (A2) 110  
   total body irradiation in rheumatoid arthritis, (L) 234

- LUNEC J *see* Blount S; Griffiths HR; Marjanovic M; Outhwaite J; Situnayake RD; Winyard PG
- LUQMANI RA, COOPER C, ARMSTRONG RD. Evaluation of the disability index of the Stanford health assessment questionnaire over time, (A2) 122
- LUSCOMBE DK *see* Berry H
- LYDYARD PM *see* Axford JS
- Lyme borreliosis—how useful is the serology? Preliminary report from a Swiss prospective study, (A2) 114
- Lymphocyte function in sulphasalazine therapy in rheumatoid arthritis, (A1) 9
- CD4<sup>+</sup> Lymphocytes, immunoregulatory subsets present within rheumatoid synovial membranes, (A1) 55
- Lymphoreticular malignancy and monoclonal gammopathy presenting as polymyalgia rheumatica, 458
- LYNES T *see* Williamson MER
- McADAM KPWJ *see* Isenberg DA
- McCLELLAND J *see* Kelly CA
- McCLURE JC *see* Chattopadhyay C
- McCOLL SR *see* Betts WH
- McCONKEY B *see* Bepman M; Situnayake RD
- McCORMICK JN, WOJTAHA D, EDMOND E, COHEN B, HART H. Do polyclonal rheumatoid factors have an 'internal image' of exogenous and nuclear antigens? (A2) 131
- McCRAE F, SHOULS J, DIEPPE P, WATT I. The heterogeneity of osteoarthritis of the knee, (A1) 45
- McDERMOTT B *see* Taggart AJ
- McFARLAND CD *see* Brown RA
- McFARLANE DG *see* Buckland-Wright JC
- MACHIN PJ *see* Bloxham DP
- McHUGH NJ, MAYMO J, SKINNER RP, MADDISON PJ. Anticardiolipin antibodies in an English connective tissue disease population: an association with livedo reticularis and major cerebrovascular disease, (A1) 58
- McHUGH NJ, REILLY PA, MADDISON PJ. Pregnancy, the menopause and anticardiolipin antibodies in rheumatoid arthritis and systemic sclerosis, (A2) 20
- MacKAY IR *see* Emery P
- McKENNA F, SWINBURNE K, WRIGHT V. Calcaneal spurs—a survey of their prevalence and relevance, (A1) 68
- MACKENZIE JF *see* Belch JFF
- MACKENZIE L *see* Axford JS
- MAKWORTH-YOUNG CG, DAVID J, LOIZOU S, WALPORT MJ. Primary antiphospholipid syndrome: features of patients with raised anticardiolipin antibodies and no other disorder, (A2) 94
- MAKWORTH-YOUNG CG, DAVID J, MORGAN SH, HUGHES GRV. Double-blind placebo-controlled trial of intravenous methylprednisolone in SLE, (A2) 19
- McLAUGHLIN B *see* Brown RA; Weiss JB
- McLAUGHLIN K *see* Belch JFF
- McLAUGHLIN P *see* Cawston TE
- McMICHAEL AJ *see* Pease CT
- McNALLY C *see* Knight RK
- McNEILLY AS *see* Bercei I
- McNICHOLL J, GLYNN D, HUTCHINSON M, BRESNIHAN B. Sequential neurophysiological studies in systemic lupus erythematosus, (A2) 18
- Macrocystosis and sulphasalazine treatment of rheumatoid arthritis, (L) 472
- $\alpha_2$ -Macroglobulin serum and synovial fluid values in rheumatoid arthritis, 354
- McWHIRTER A *see* Mahmud T; Senaldi G
- MADDISON PJ *see* McHugh NJ; Maslen CL; Podgorski MR; Reilly PA
- MADHOK R, MARABANI M, CAPELL HA. Leucopenia during sulphasalazine therapy for rheumatoid arthritis, (A2) 4
- MADHOK R, WILSON R, STURROCK RD. Neural mechanisms in the pathogenesis of rheumatoid arthritis—the effect of substance P on immunoglobulin production in rheumatoid arthritis, (A2)
- MADHOK R *see also* Marabani M
- MAGEED RA, TUNN EJ, SHOKI F, BACON PA, JEFFRIS R. Structural analysis of rheumatoid factors in an early synovitis clinic, (A2) 35
- Magnetic resonance imaging in the assessment of inflammation in the rat air pouch model of antigen-induced chronic inflammation, (A2) 82
- MAHMUD T, PEAKMAN M, SENALDI G, McWHIRTER A, BLACK C, VERGANI D. Immunoglobulin class and IgG subclass of autoantibodies in progressive systemic sclerosis, (A2) 77
- MAINARDI CS *see* Solinger AM
- MAINI RN *see* Allard SA; Buchan G; Chantray D; Erhardt CC; Field M; Horsfall AC; Melsom RD; Misra R; Ratcliffe A; Sethi D; Teo CG; Venables PJW; Williams DG
- MAINI T *see* Brennan FM
- Maintenance of remission in rheumatoid arthritis with intermittent penicillamine therapy, (A2) 7
- MAKINDE V *see* Jawad ASM
- MALCOLM AJ *see* Brighton S
- MALIAKKAI D *see* Haskard DO
- MANGION P *see* Badal PAL
- MANHIRE A *see* Patrickk M
- MANSELL M *see* Turner-Stokes L
- MANSELL MA *see* Jones DW
- MANSON J, DICKENS E, DI GIOVINE F, DINARELLO C, POOLE S, NUKI G. Immunoblot analysis of cytokine induction in human monocytes, (A1) 24
- MANSON J *see also* di Giovine FS
- MARABASHI M, BLACK D, ROBINS SP, STURROCK RD. Urinary pyridinoline—a marker of articular cartilage damage in rheumatoid arthritis, (A2) 31
- MARABANI M, MADHOK R, CAPELL HA, WARING R. Sulphasalazine toxicity does not correlate with sulphoxidation capacity, (A2) 4
- MARABANI M *see also* Madhok R
- MARCH LM, BROOKS PM, NELSON DS, TYNDALL AG. Dendritic cells from inflammatory synovial fluid and rheumatoid synovial membrane augment con A-induced and autologous peripheral blood mononuclear cell proliferation, (A2) 124
- MARIANOVIC M, HEWITT SD, MORRIS CJ, LUNEC J, BLAKE DR. Cytoskeletal changes following free radical attack, (A2) 69
- MARTIN M *see* Pullar T
- MARTIN MFR *see* Wilkinson D
- MASLEN CL, HALL ND, WOOLF AD, MADDISON PJ. Enhanced oxidative metabolism of neutrophils from patients with systemic sclerosis, 113
- MASSON CH *see* Brégeon C
- MATHEWS JA, MILLS SB, JENKINS VM, GRIMES SM, MORRIS MJ, MATHEWS W, SCOTT CM, SITTAMPALAM Y. Back pain and sciatica: controlled trials of manipulation, traction, sclerosant and epidural injections, 416
- MATHEWS M *see* Allington L
- MATHEWS W *see* Mathews JA
- MATTHEWS JM *see* Soriano RMC
- MAYMO J *see* McHugh NJ



- MEAD JC, EDWARDS JCW. Synovial fluid microdistribution, (A2) 46
- Measurement  
of joint damage in osteoarthritis: the development of a standardised assessment technique, (A1) 67  
of proximal interphalangeal joint circumference in rheumatoid arthritis: one joint or ten? 123  
in serum from patients with rheumatic diseases of levels of a non-enzymatic activator of latent metalloproteinases which is also angiogenic, (A2) 65  
of serum levels of C4A and C4B by ELISA, (A2) 51  
of substance P in synovial fluid from patients with inflammatory and non-inflammatory arthritides, (A2) 33
- Measuring progression of arthritis—the long-term view, (A1) 49, 389
- MELSON RD, VENABLES PJW, SMITH PR, MAINI RN. Primary and secondary Sjögren's syndrome are associated with circulating immune complexes containing IgA, (A2) 109
- MENKES B *see* Kahan A
- MENKES CJ *see* Bauer-Vinassac D; Job-Deslandre C; Soubrier M
- Methotrexate, discrepancy between 3H-thymidine uptake and cell cycle studies in stimulated lymphocyte cultures, (A2) 57
- Methylprednisolone  
anti-lipocortin autoantibody responses in severe RA patients, (A2) 76  
double-blind placebo-controlled trial in SLE, (A2) 19  
lack of evidence for increased incidence of osteonecrosis in rheumatoid patients, (A2) 89
- Metrologists in rheumatology units, 165
- MHC class II and C4 polymorphisms in SLE, (A2) 52
- MHC-restricted lymphocyte transformation of rheumatoid arthritis and controls to a mycobacterial antigenic extract, (A1) 35
- MICHAEL J *see* Beaman M
- MICHAELSON G *see* Bjelle A
- Beta2Microglobulin  
amyloid in sternoclavicular joints of long term haemodialysis patients, (A2) 39  
amyloidosis in patients receiving chronic haemodialysis, (A2) 40
- B2Microglobulin derived amyloid and iron in dialysis arthropathy, (A2) 39
- Microvascular injury precedes dermal fibrosis in systemic sclerosis, (A2) 25
- Microwave thermography—an index of inflammatory joint disease, 37
- MIDGLEY J *see* Rowe IF
- MILFORD WARD A *see* Greaves M
- MILLER MH, LITTLEJOHN GO, DAVIDSON A, JONES B, TOPLISS DJ. The clinical significance of the anti-centromere antibody, 17
- MILLS SB *see* Mathews JA
- Milwaukee shoulder—synovial fluid contains no active collagenase, (L) 311
- MINANO A *see* Ruiz MT
- MINH H *see* Villiaume J
- MIOSSEC P, SANY J. Interleukin 1, mediator of lymphocyte emigration in rheumatoid synovitis, (A2) 59, (A2) 128
- MISRA A, VENABLES PJW, PAWLOWSKI T, WATKINS RPF, MAINI RN. Anticardiolipin antibodies in infectious mononucleosis, (A1) 59
- MISRA R *see also* Field M
- MITCHELL SC *see* Ayesch R
- MITCHELL T *see* Pitt P
- MITCHELL W *see* Freemont AJ; Weiss JB
- MITCHELL WS, JAYSON MIV. Post laminectomy low back pain syndrome: clinical features and diagnostic methods, (A2) 15
- MITCHELL WS, TAYLOR LJ, JAYSON MIV. Tissue oxygen and carbon dioxide in systemic sclerosis, (A2) 23
- Mitral valve prolapse and joint mobility in an Arab population, 442
- Modified costotransversectomy in treatment of intractable costovertebral pain in ankylosing spondylitis, (L) 66
- MOLL JMH *see* Wright V
- Monoclonal  
antibody therapy in rheumatoid arthritis: a clinical and immunological study, (A2) 1  
gammopathy, (E) 406  
gammopathy presenting as polymyalgia rheumatica, 458
- MOORE AR *see* De Brito F
- MOORE K, WALTERS MT, GARVEY EM, CAWLEY MID, SMITH JL. Immunoregulatory subsets of CD4<sup>+</sup> lymphocytes present within rheumatoid synovial membranes and the effect of therapy with disease modifying drugs, (A1) 55
- MOORE K *see also* Kidd BL
- MOORE ME *see* Goddard DH
- MORAG B *see* Sachs D
- MORGAN JR *see* O'Sullivan MM
- MORGAN K *see* Collins I; Holt LPJ
- MORGAN R. Non-aspirin nonsteroidal anti-inflammatory drugs and active gastroduodenal ulceration in the elderly, (L) 158
- MORGAN SH *see* David J
- MORKEL MJ *see* Mathews JA
- MORRIS CJ *see* Allen RE; Andrews FJ; Hewitt SD; Hollywell CA; Marjanovic M
- MORRIS K *see* Jayson MIV
- Mortality  
from systemic lupus erythematosus in England and Wales, 1974-1983, 437  
in scleroderma of recent onset, (A1) 42  
and survival in rheumatoid arthritis: a 25 year prospective study of 100 patients, (A2) 128
- MOULT J *see* Greaves M
- MOWAT AG. Role of medical audit in rheumatology, 224
- MURDEN KD. What can be learned from third world rheumatism? (E) 1
- MURDEN KD *see also* Allard SA
- MUKHERJEE SK *see* Littler TR
- MUMFORD P *see* Erhardt CC
- MUMFORD PA *see* Horsfall AC; Venables PJW
- MURPHY J *see* Chuck AJ; Kingsley G; Weiss JB
- MURRAY J *see* Fonseca A
- MURRAY-LESLIE CF *see* Leach IH
- Muscle  
disease, inflammatory and *in vitro* lymphocyte function, (A2) 53  
inhibition with joint effusion and aspiration, 370  
mass in rheumatoid arthritis and asthma, measured by total body potassium, (A2) 27
- MYERS AR. Systemic sclerosis: reasons to be optimistic, (E) 241
- MYLES AB *see* Dasgupta B
- Myocardial fibrosis in ankylosing spondylitis, (A1) 72
- NANSAID use and dyspepsia in a rheumatology clinic, (A2) 11

- Naproxen  
effect on renal haemodynamics in elderly patients, (A2) 9  
-induced pseudoporphyria, 210  
side effects, 70
- Natural history of juvenile onset ankylosing spondylitis: a controlled study, (A2) 114
- Neck pain, persistent, low energy high frequency pulsed electromagnetic therapy treatment, (A2) 101
- Neisseria mucosa* septic arthritis, (L) 314
- NELSON DS *see* March LM
- NEMETH R, SMITH F, ELSWOOD J, CALIN A. Ankylosing spondylitis—an approach to measurement of severity and outcome: ankylosing spondylitis assessment questionnaire—a controlled study, (A1) 69
- Nerve entrapment at the wrist in pyrophosphate arthropathy, (A1) 30
- NEUMANN VC, SHINEBAUM R, COOKE EM, WRIGHT V. Effects of sulphasalazine on faecal flora in patients with rheumatoid arthritis: a comparison with penicillamine, 334
- NEUMANN VC *see also* Shinebaum R
- Neural mechanisms in the pathogenesis of rheumatoid arthritis—the effect of substance P on immunoglobulin production in rheumatoid arthritis, (A2) 78
- Neutrophils  
activation, (A1) 49  
auranofin stimulates LTA hydrolase and inhibits 5-lipoxygenase activity, (A2) 71  
oxidant generation activated by synovial fluid, (A2) 66  
protein synthesis activated during inflammation, (A2) 67  
superoxide release and role of Ca<sup>++</sup> and protein kinase C, (A2) 68  
synovial fluid, in rheumatoid arthritis have membrane antigen changes that reflect activation, (A2) 67
- NEVILLE M *see* Goddard DH
- New methods in the epidemiology of rheumatoid arthritis: initial experience with a postal screening questionnaire for case ascertainment, (A2) 90
- NEWCOMBE RG *see* O'Sullivan MM
- NEWHAM DJ *see* Jones DW
- NEWMAN S, FITZPATRICK R, LAMB R, SHIPLEY M. Factors precipitating depressed mood in rheumatoid arthritis, (A2) 121
- NEWMAN S *see also* Fitzpatrick R
- NEWTON J *see* Bird HA
- NG YC, SCHIFFERLI JA, PACCAUD JP, WALPORT MJ. Role of complement and erythrocyte CR1 in the clearance of 125I-tetanus toxoid/anti-tetanus toxoid immune complexes *in vivo* in humans, (A2) 107
- NG YC, SCHIFFERLI JA, WALPORT MJ. Kinetics of interactions between immune complexes and erythrocyte complement receptor type 1, (A2) 107
- Nicardipine and thallium-201 myocardial perfusion in patients with systemic sclerosis, (A2) 130
- NICHOLAS NS. Effects of pregnancy on the rheumatic diseases, (E) 403
- NICKSCH E *see* Wittenborg A
- NICOLL JJ *see* Reid DM; Tothill P
- NIVED O *see* Jonsson H
- NOBLE J, HODGKINSON JP, HILTON R, SANDERS P. The total condylar knee replacement in patients with rheumatoid arthritis, (A1) 12
- Nociceptors in the capsule and synovial folds of human zygapophyseal joints, 362
- NOEL LH *see* Zingraff J
- Non-aspirin nonsteroidal anti-inflammatory drugs and active gastroduodenal ulceration in the elderly, (L) 158
- Non-caeruloplasmin-bound copper ('phenanthroline copper') is not detectable in fresh serum or synovial fluid from patients with rheumatoid arthritis, (A1) 21
- Nonsteroidal anti-inflammatory drugs  
bias in the medical literature, 231  
effect on gut, 67  
estimation of urinary PGE2 before and after administration, (A2) 8  
influence on renal response to, and kinetics of piritanide in man, (A2) 9  
intestinal permeability in rheumatoid arthritis patients, 103
- NOORMOHAMED FH *see* Dixey JJ
- NORMAN GR *see* Balint GP
- NUKI G, SNYDER FF, JOYCE JE, CARTER-EDWARDS T, JOSHI R, RYLAND HL, WALLACE RC. Hypoxanthine-guanine phosphoribosyl transferase deficiency in three brothers with gout, (A2) 44
- NUKI G *see also* di Giovine FS; Reid DM; Shinebaum R; Symons JA; Tothill P
- NURCOMBE HL, BUCKNELL R, EDWARDS SW. Synovial fluid can 'prime' or activate reactive oxidant generation by neutrophils, (A2) 66
- Objective and subjective assessment of forefoot arthroplasty, (A2) 103
- Obstetric complications of benign familial joint hyperlaxity, (A2) 41
- O'CONNOR P *see* Foley-Nolan D
- O'DOWD A *see* Richards IM
- Oesophageal dysmotility and antientromere antibody, 17
- OGLIVIE DJ *see* Wordsworth BP
- Olive oil for rheumatoid patients? (A2) 129
- O'NEILL JG *see* Holme ER
- Open comparison study of oral gold (auranofin) and intramuscular gold (sodium aurothiomalate) in the treatment of rheumatoid arthritis, (A2) 6
- Opioid system in man, progress in techniques to measure *in vivo* changes, (A2) 47
- Oral contraception and rheumatoid arthritis: a protective effect independent of duration of pill use, (A2) 93
- Organization of rheumatology in France, (A2) 98
- ORME MCL'E *see* Littler TR
- OSBOND JM *see* Bloxham DP
- OSBORN M *see* Dixey J; Keat A
- OSMAN A *see* Rajapakse CNA
- OSMOND C *see* Cooper C
- Osteoarthritis, 9  
alpha-1-antitrypsin phenotype and HLA markers, (A2) 106  
contact pressures in hip joints, (A1) 13  
generalised and erosive, and hand function, (A2) 47  
generalised nodal, (A1) 13  
generalised nodal, of the hand, (A2) 46  
increased hysterectomy rate before symptom onset, (A2) 91  
of the knee, (A1) 45  
measurement of joint damage, (A1) 67  
as modifying factor in presentation and distribution of gout, (A2) 92  
in Saudi Arabia, 22

- serum biochemistry, 131  
 serum and synovial fluid proteins, (A1) 23  
 sleep in, (A1) 14  
 ulcerative effects of piroxicam and sulindac, (A1) 12  
 Osteoarthritis of the hip and osteoporosis of the proximal femur: an epidemiological study, (A2) 90  
 Osteoarticular syndrome: acne pustulosis hyperostosis osteitis, (A2) 99  
 Osteocalcin measurement in rheumatoid arthritis, (A2) 88  
 Osteogenesis imperfecta, 9  
 Osteomalacia  
   in patients with early rheumatoid disease treated only with nonsteroidal anti-inflammatory drugs, (A2) 87  
   prevalence in hospital patients with rheumatoid arthritis, (A2) 87  
 Osteonecrosis and lack of evidence for increased incidence in rheumatoid patients treated with methylprednisolone, (A2) 89  
 Osteoporosis of the proximal femur, an epidemiological study, (A2) 90  
 O'SULLIVAN MM, BEDWELL AE, AMOS N, WILLIAMS BD. Possible mode of action of rheumatoid factor on complement mediated inhibition of immune precipitation, (A2) 108  
 O'SULLIVAN MM, LEWIS PA, NEWCOMBE RG, JESSOP JD. A re-assessment of the Ritchie articular index, (A1) 64  
 O'SULLIVAN MM, POWELL N, FRENCH AP, WILLIAMS KE, MORGAN JR, WILLIAMS BD. Technetium labelled liposome scanning in inflammatory polyarthropathies, (A2) 30  
 O'SULLIVAN MM. Yttrium 90 synovectomy—a new treatment for pigmented villonodular synovitis, (L) 71  
 OTT H. Heel pain in sarcoidosis—is sarcoid a cause of spondarthopathy? (L) 468  
 OUTHWAITE J, UNSWORTH J, ROBINSON RH, ALLEN R, LUNEC J, BLAKE DR. Effect of joint movement on an index of free radical damage, (A2) 70  
 OUTHWAITE J *see also* Allen RE  
 OWEN GM *see* Walker FS  
 OXFORD J *see* Turner-Stokes L
- P-component in the inflamed synovium, (A1) 23  
 P.O.E.M.S. syndrome: an analysis of eight cases, (A2) 42  
 PACCAUD JP *see* Ng YC  
 PADBERG GW *see* Collee G  
 PAGE THOMAS DP *see* Coughlan RJ  
 Paget's disease, clinical and radiological features, (A2) 89  
 PAHLM A *see* Geirsson A  
 PAICE E *see* Watts RA
- Pain  
   low back, 93  
   spinal, 93  
   and stiffness in rheumatoid arthritis, 126  
 PAINE TF, DIEPPE PA. A study of rheumatology referrals from general practice, (A1) 32  
 Painful, swollen calf in a patient with systemic lupus erythematosus, (L) 319  
 Paired serum and synovial fluid values of  $\alpha_2$ -macroglobulin and TIMP in rheumatoid arthritis, 354  
 PAL B, DICK WC, GRIFFITHS ID. Anxiety and depression in primary Sjögren's syndrome: a controlled study using the hospital anxiety and depression scale, (A1) 47  
 PAL B, GIBSON C, PASSMORE J, GRIFFITHS ID, DICK WC. Study of migraine in primary Sjögren's syndrome and other rheumatic disorders, (A2) 21
- PAL B, GRIFFITHS ID, DICK WC. Controlled assessment of the prevalence of Raynaud's phenomenon in Sjögren's syndrome, (A2) 22  
 PAL B, PAPIHA SS. Genetic heterogeneity in Sjögren's syndrome: the evidence of genetic markers, (A2) 106  
 PAL B. Skin-fold thickness and nail-fold capillaries in diabetics: relationship to limited joint mobility and retinopathy, (L) 153  
 PAL B. Use of simple analgesics in the treatment of ankylosing spondylitis, 207  
 PALACIOS-BOIX A, LANCHBURY JSS, PANAYI GS. MHC-restricted lymphocyte transformation of rheumatoid arthritis and controls to a mycobacterial antigenic extract, (A1) 35  
 PALACIOS-BOIX AA, ESTRADA-G I, LANCHBURY JSS, COLSTON MJ, PANAYI GS. HLA-DR4 is a restriction determinant for defined mycobacterial antigens in rheumatoid arthritis and healthy subjects, (A2) 130  
 PALL H *see* Winyard PG  
 PALMER RG *see* Davies UM  
 PANAYI GS, CELINSKA E, EMERY P, GRIFFIN J, WELSH KI, GRAHAME R, GIBSON T. Seronegative and seropositive rheumatoid arthritis: similar diseases, 172  
 PANAYI GS, DASGUPTA B. Polymyalgia rheumatica and giant cell arteritis, (A2) 85  
 PANAYI GS *see also* Coughlan RJ; Dasgupta B; Duke O; Gibson T; Kingsley GH; Kirkham B; Palacios-Box AA; Pitzalis C; Sakkas LI  
 Pancreatic calcification in rheumatoid arthritis with Sjögren's syndrome, 212  
 PANUSH RS *see* Yonker RA  
 PAOLAGGI JB *see* Delecoeuilliere G  
 PAPAGEORGIOU A *see* Badley EM  
 PAPASAVVAS GK, DHIR H, WILLIAMS PL, SHIPLEY ME. Tennis elbow: a comparison of different treatments, (A2) 100  
 PAPIHA SS *see* Pal B  
 PAREKH R, ISENBERG DA, DWEK RA, ROITT IM, ROOK GAW, RADEMACHER TW. Comparative analysis of disease-associated changes in N-glycosylation, (A2) 112  
 PARSONS V *see* Pitt P  
 Parvovirus infection in hospital practice, 13  
 PASCOE V *see* Hurst NP  
 PASCUAL E, CASTELLANO JA, LOPEZ E. Computerized axial tomographic study of costovertebral joints in ankylosing spondylitis patients with posterior thoracic pain, (A2) 16  
 PASCUAL E. Joint size influences the leukocyte count of inflammatory synovial fluids, (A2) 32  
 PASCUAL E *see also* Ruiz MT  
 PASSMORE J *see* Pal B  
 PATEL U *see* Kirk AP  
 Pathogenesis of inflammation, 390  
 Patients with early rheumatoid disease treated only with nonsteroidal anti-inflammatory drugs have evidence of increased bone resorption and focal osteomalacia in iliac crest biopsies, (A2) 87  
 PATRICK M, ALDRIDGE S, MANHIRE A, DOHERTY M. Hand function in established nodal generalised osteoarthritis and erosive osteoarthritis—a controlled study, (A2) 47  
 PATRICK M, DIEPPE P, DOHERTY M. Nerve entrapment at the wrist in pyrophosphate arthropathy, (A1) 30  
 PATRICK M, DOHERTY M. Facial flushing following intra-articular injection of steroid, (A1) 10  
 PATRICK M, JAMES V, WARD AM, DOHERTY M. Alpha-1-antitrypsin phenotype and HLA markers in nodal generalised osteoarthritis, (A2) 106

- PATRICK M *see also* Chuck A; Smith NJ  
 PAWA JS *see* Dixey JJ  
 PAWLOWSKI T *see* Misra R; Venables PJW  
 PEAKER S *see* Pullar T  
 PEAKMAN M *see* Mahmud T  
 PEASE CT, ELLIS SA, McMICHAEL AJ, BREWERTON DA.  
 Lack of evidence for gene conversion in B27 negative  
 ankylosing spondylitis, (A1) 28  
 PEETERS A, VAN DEN WALL BAKE AWL, VAN ALBADA  
 KUIPERS GA, WESTEDT ML, DAHA MR, CATS A. IgA-  
 containing immune complexes and haematuria in  
 patients with ankylosing spondylitis, (A2) 118  
 Penicillamine  
 comparison with sulphasalazine of effects on faecal  
 flora of rheumatoid arthritis patients, 334  
 maintenance of remission in rheumatoid arthritis,  
 (A2) 7  
 D-Penicillamine  
 in chronic adhesive spinal arachnoiditis, (A2) 15  
 combined with chloroquine in treatment of rheu-  
 matoid arthritis, 279  
 and sulphasalazine in rheumatoid arthritis, 32  
 treatment for rheumatoid arthritis and C-reactive  
 protein, 351  
 use of a pharmacological marker to measure com-  
 pliance in rheumatoid arthritis, (A2) 7  
 PENNEKAMP C *see* Wittenborg A  
 PEPINSKY RB *see* Podgorski MR  
 Peptic ulcer in rheumatoid arthritis, (L) 312  
 PEREZ T *see* Duquesnoy B  
 Peripheral neuropathy in thalidomide treated patients,  
 (A2) 12  
 PERRETT D *see* Dacre J  
 PERRY JD *see* Simmons KM  
 PERRY LA *see* Spector T  
 PETRIE JP. Acupuncture in neck pain, (L) 153  
 PETERSEN H *see* Yonker RA  
 Phenytoin is less effective than gold as a second line agent  
 in the treatment of rheumatoid arthritis, (A1) 9  
 PHILLIPS H *see* Kirk AP  
 PHONGSATHORN V *see* Worrall J  
 Phosphatidyl choline synthesised by methylation of phos-  
 phatidyl ethanolamine is not an important source of  
 arachidonic acid in stimulated human leucocytes,  
 (A2) 68  
 Physiotherapy or steroids for the painful stiff shoulder?  
 (A2) 13  
 PIETRUSKO R *see* Knight RK  
 Pill  
 duration of use and protective effect on rheumatoid  
 arthritis, (A2) 93  
 and rheumatoid arthritis: further evidence for protec-  
 tion, (A2) 93  
 PINCHING AJ *see* Rowe IF  
 PIPER PJ *see* Zakrzewski J  
 Piretanide, influence of nonsteroidal anti-inflammatory  
 drugs and probenecid on renal response and kinetics  
 in man, (A2) 9  
 Piroxicam in osteoarthritis, (A1) 12  
 PITKEATHLY DA *see* Ralston SH  
 PITT P, DARBY A, BERRY H, PARSONS V. Patients with early  
 rheumatoid disease treated only with nonsteroidal  
 anti-inflammatory drugs have evidence of increased  
 bone resorption and focal osteomalacia in iliac crest  
 biopsies, (A2) 87  
 PITT P, JAHANSHAH M, WILLIAMS I. Are patients with  
 rheumatoid disease more sensitive to new pain  
 experiences compared to controls? (A2) 119  
 PITT P, MITCHELL T, WILLIAMS I. Lack of evidence for an  
 increased incidence of osteonecrosis of the hip or  
 adverse medical events in rheumatoid patients  
 treated with pulse methylprednisolone during a ten  
 year period, (A2) 89  
 PITZALIS C, KINGSLEY GH, KYRIAZIS N, PANAYI GS.  
 Immunopathology of chronic synovitis and other  
 chronic inflammation results from the preferential  
 accumulation of helper-inducer T cells, (A2) 126  
 PITZALIS C, KINGSLEY GH, PANAYI GS, HASKARD DO.  
 Helper-inducer T lymphocytes show preferential  
 adhesion to endothelial cells, (A2) 127  
 PITZALIS C *see also* Kingsley GH; Kirkham B  
 Plasma  
 luteinizing hormone, follicle stimulating hormone,  
 prolactin and sex hormones in patients with  
 gout, (A2) 45  
 oxipurinol concentrations during allopurinol therapy,  
 445  
 prostanoid levels in patients with Raynaud's syn-  
 drome, (A1) 40  
 Platelet and plasma serotonin metabolism in systemic scler-  
 osis and primary Raynaud's phenomenon, (A1) 39  
 PLATT PN *see* Bedi WS  
 PODGORSKI MR, GOULDING NJ, HALL ND, FLOWER RJ,  
 MADDISON PJ, PEPINSKY RB. Autoantibodies to  
 recombinant lipocortin in rheumatoid arthritis and  
 systemic lupus erythematosus, (A1) 54  
 PODGORSKI MR, GOULDING NJ, HALL ND, MADDISON PJ,  
 FLOWER RJ. Anti-lipocortin autoantibody responses  
 in severe RA patients treated with pulse intravenous  
 methylprednisolone, (A2) 76  
 POLKEY C *see* Grahame R  
 Polyarteritis nodosa and familial Mediterranean fever,  
 139  
 Polyarthritis  
 animal model of Chikungunya virus, (A2) 80  
 and IgG (kappa) paraproteinaemia, 142  
 —mechanisms exposed in studies with the air pouch,  
 (A1) 26  
 Polyarthropathy, inflammatory, technetium labelled lipo-  
 some scanning, (A2) 30  
 Polymyalgia rheumatica  
 antibodies to intermediate filaments, (A1) 61  
 with bilateral subclavian artery occlusion, (L) 469  
 C-reactive protein and ESR, (A1), 65  
 controversies in the treatment, (A2) 86  
 epidemiological aspects, (A2) 85  
 and giant cell arteritis, (A2) 85  
 liver involvement, (A2) 38  
 lymphoreticular malignancy and monoclonal gam-  
 mopathy presenting as, 458  
 selective depletion and activation of CD8 positive T  
 lymphocytes from peripheral blood, (A2) 55  
 synovitis in, (A2) 28  
 and temporal arteritis: prognosis and management  
 according to initial clinical presentation, (A2)  
 129  
 nRNP Polypeptides, solid-phase assays for the quantita-  
 tion of human autoantibodies to, (A2) 77  
 Sm Polypeptides, solid-phase assays for the quantitation  
 of human autoantibodies to, (A2) 77  
 POOLE S *see* Manson J  
 POPE JH *see* Hazelton RA  
 POPE R *see* Pye M  
 POPERT AJ *see* Beaman M; Dawes PT  
 Popliteal cyst  
 diagnosis by real-time ultrasound, (A1) 1  
 rupture, 229

- Possibilities for immunoregulation in the rheumatic diseases—seeing in a glass darkly, 463
- Possible
- danger of intra-articular steroid injection in children with respiratory tract infections, (L) 73
  - mode of action of rheumatoid factor on complement mediated inhibition of immune precipitation, (A2) 108
- Post-laminectomy low back pain syndrome: clinical features and diagnostic methods, (A2) 15
- Posters, proper presentation, 292
- Potential of computer applications in rheumatology, (E) 3
- POULTER LW *see* Duke O
- POUNTAIN GD *see* Klimiuk PS
- POVEY S *see* Sakkas LJ
- POWELL N *see* O'Sullivan MM
- POWELL RJ, JENKINS JS, SMITH NJ, ALLEN BR. Peripheral neuropathy in thalidomide treated patients, (A2) 12
- POWELL RJ *see also* Leach IH
- PRAS M *see* Sachs D
- Prediction of marrow iron stores and serum ferritin levels, (A2) 36
- Prednisolone, double blind acute study, (A1) 54
- Pregnancy
- effects on the rheumatic diseases, (E) 403
  - the menopause and anticardiolipin antibodies in rheumatoid arthritis and systemic sclerosis, (A2) 20
  - and reproductive history in women with systemic sclerosis, (A1) 41
- Prescribing of chloroquine and hydroxychloroquine by consultant rheumatologists in the UK, 375
- Prevalence
- of antibodies to an Epstein-Barr virus-induced polypeptide (EBNA-2) in the sera of rheumatoid arthritic families, 193
  - clinical features and risk factors for beta2 microglobulin-related amyloidosis in patients receiving chronic haemodialysis in South Australia, (A2) 40
- Prevention of indomethacin-induced gastrointestinal ulceration in rats by glucose-citrate formulations: role of ATP in mucosal defects, (A2) 81
- PRICE EJ *see* Williamson MER
- PRICE J *see* Hopkins SJ
- PRICE R, SINCLAIR H, GIBSON T. Hydrocortisone, triamcinolone and lignocaine injections for tennis elbow—a controlled study, (A2) 100
- Primary
- antiphospholipid syndrome: features of patients with raised anticardiolipin antibodies and no other disorder, (A2) 94
  - osteoarthritis of the hip—the influence of bone response on its natural history, (A1) 15
  - and secondary Sjögren's syndrome are associated with circulating immune complexes containing IgA, (A2) 109
- Prinomide in the treatment of rheumatoid arthritis, (A2) 2
- PRITCHARD MH. Peptic ulcer in rheumatoid arthritis, (L) 312
- PRITCHARD MH *see also* Walker FS
- Probenecid, influence on renal response to, and kinetics of pirtanide in man, (A2) 9
- Production of
- arthritis in the guinea-pig by intra-articular reaction between lymphokines and inflammatory leukocytes, (A2) 81
  - plasminogen activator by human rheumatoid synovial cells *in vitro* is stimulated by mononuclear cell conditioned medium but not by purified porcine IL-1 $\alpha$  or recombinant human IL-1 $\beta$ , (A2) 61
- Progress in techniques to measure *in vivo* changes in the central opioid system in man, (A2) 47
- Prolactin decreased bioactivity in patients with rheumatoid arthritis, 433
- Proper presentation: a visual and verbal ABC, 292
- Prospective endoscopic study comparing the ulcerogenic effects of piroxicam and sulindac in patients with osteoarthritis, (A1) 12
- PROST A *see* Kahn M-F
- Prostaglandin E<sub>2</sub> levels in rheumatoid arthritis patients, (A1) 5
- Protein synthesis in neutrophils is activated during inflammation, (A2) 67
- Proteus mirabilis*, (A2) 26
- PROUSE PJ, BONNER B, REID CDL, GUMPEL JM. Identification of an inhibitor of *in vitro* erythropoiesis from synovial fluid of rheumatoid patients and its relationship to anaemia of chronic disease, (A2) 37
- PRUZANSKI W. Rheumatological disorders and monoclonal gammopathy—a new syndrome? (E) 406
- Pseudogout
- acute of temporomandibular joint, 51
  - diagnosis, 379
- Pseudoporphyria, naproxen-induced, 210
- Pseudotumour in the hypercosinophilic syndrome, 384
- Psoriasis, secretor state of patients, (A2) 105
- Psoriatic arthritis
- diastolic abnormalities of the left ventricle, (A2) 43
  - distribution of radiological joint damage in the hand and relevance of hand dominance, (A2) 115
- Psoriatic arthropathy
- leukotriene B<sub>4</sub> levels, (A2) 71
  - secretor state of patients, (A2) 105
- Psychological parameters in rheumatoid arthritis sufferers and their relatives: correlation with disease severity, (A1) 47
- PRASZYNSKA T *see* Ebringer A
- PULLAR T, PEAKER S, MARTIN M, BIRD H, FEELY M. Use of a pharmacological marker to measure compliance with high-dose D-penicillamine in rheumatoid arthritis, (A2) 7
- PULLAR T, ZOMA A, CAPELL HA, FARID KHAN M, BROWN DH, SMITH WE. Alteration of thiol and superoxide dismutase status in rheumatoid arthritis treated with sulphasalazine, 202
- Pulmonary oedema, jaundice and renal impairment with naproxen, (L) 70
- Punched-card aid in rheumatological diagnosis, 46
- PYE D *see* Tothill P
- PYE M, BEDWELL A, AMOS N, WILLIAMS BD. Frequency of C4 null phenotypes in patients with rheumatoid arthritis who develop proteinuria after gold and penicillamine treatment, (A2) 51
- PYE M, POPE R, HENRY JONES J, WILLIAMS G. Eosinophilic polymyositis presenting as a pseudotumour in the hypercosinophilic syndrome, 384
- PYE RJ *see* Sterling JC
- Quality of life—does it matter? (A2) 123
- Quantitation of
- leukotriene B<sub>4</sub> in synovial fluid of patients with rheumatoid arthritis by specific radio-immunoassay, (A2) 72
  - proteoglycans and sulphated glycosaminoglycans in arthritic synovial fluid, (A1) 66



- Quantitative microfocal radiography of disease progression in generalised nodal osteoarthritis of the hand, (A2) 46
- QUINNELL RC *see* Stewart HD
- RADEMACHER TW *see* Parekh R
- Radial head excision in rheumatoid arthritis, 59
- Radio-immunoassay of interleukin 1 beta in acute and chronic rheumatic diseases, (A1) 34
- Radiological assessments of joint damage, (A1) 50
- RAE S. Acupuncture in neck pain, (L) 153
- RAE SA *see* Zakrzewski J
- RAINSFORD KD. Prevention of indomethacin-induced gastrointestinal ulceration in rats by glucose-citrate formulations: role of ATP in mucosal defects, (A2) 81
- RAINSFORD KD *see also* Walker FS
- Raised alkaline phosphatase in rheumatoid arthritis: primary biliary cirrhosis? (L) 313
- RAJAH SM *see* Wilkinson D
- RAJAPAKSE CNA, AL-ASKA AK, AL-ORAINIY I, HALIM K, ARABI K. Spinal brucellosis, 28
- RAJAPAKSE CNA, AL-ORAINIY IO, AL-HARTHI SS, OSMAN A, SMITH J. Joint mobility and mitral valve prolapse in an Arab population, 442
- RAJAPAKSE CNA. The spectrum of rheumatic diseases in Saudi Arabia, 22
- RAISTON SH, WILLOCKS LJ, SMITH GD, PITKEATHLY DA. High prevalence of unrecognised osteomalacia in hospital patients with rheumatoid arthritis, (A2) 87
- RAISTON SH. Macrocytosis and sulphasalazine treatment of rheumatoid arthritis, (L) 472
- RAMSEY NW *see* Darlington LG
- Randomised, double-blind, cross-over trial of acyclovir v. placebo for oral and genital ulceration in Behçet's syndrome, (A1) 31
- RASKER JJ *see* Reilly PA
- RATCLIFFE A, MAINI RN, DOHERTY M, HARDINGHAM T. The determination of the raised level of keratan sulphate in the synovial fluids of patients with reactive arthritis, (A1) 66
- Raynaud's phenomenon  
and adenocarcinoma of the lung, (L) 473  
anticentromere antibody, 17  
complicating systemic sclerosis, (A1) 38  
controlled studies of stanozolol, (A2) 24  
plasma prostanoid levels, (A1) 40  
platelet and plasma serotonin metabolism, (A1) 39  
in Sjögren's syndrome, (A2) 22
- Re-assessment of the Ritchie articular index, (A1) 64
- Reactive arthritis, determination of keratan sulphate level in synovial fluid, (A1) 66
- Reactive oxygen species, inflammation and drug evaluation, (A1) 19
- Reappraisal of synovectomy and radial head excision in rheumatoid arthritis, 59
- Reason to use lignocaine-containing solutions with circumspexion in arthrocentesis, (L) 471
- Recent advances in the pathogenesis of psoriasis, (A1) 52
- Recent data on rheumatological disorders in France: observations in private and in hospital practice, (A2) 97
- Red cell ferritin as an indicator of iron responsive anaemia in rheumatoid arthritis, (A2) 36
- Reduction  
in immunoregulatory T cell subset and function in rheumatoid arthritis: correlation with disease status, (A2) 55
- of prostaglandin E<sub>2</sub> levels in synovial fluid of patients suffering from rheumatoid arthritis following treatment with indomethacin or tiaprofenic acid, (A1) 5
- REES JA, ALI SY. Ultrastructural localisation of alkaline phosphatase activity in normal, osteoarthritic, and osteophytic cartilage, (A1) 16
- REES JA, BROWN RA, ALI SY. Ultrastructural localisation of fibronectin in normal human and osteoarthritic cartilage, (A1) 15
- REES JA *see also* Kay EA
- REES RG, DIXEY JJ, ROWE IF, LIGHTMAN SL, BREWERTON DA. Measurement of substance P in synovial fluid from patients with inflammatory and non-inflammatory arthritides, (A2) 33
- REEVE PA. Pulmonary oedema, jaundice and renal impairment with naproxen, (L) 70
- Referrals of in-patients to rheumatologists: an important source of referral? (A2) 49
- REID CDM *see* Prouse PJ
- REID DM, TOTHILL P, NICOLL JJ, BROWN N, NUKI G. Muscle mass in rheumatoid arthritis and asthma, measured by total body potassium, (A2) 27
- REID DM *see also* Tothill P
- REILLY PA, COSH JA, RASKER JJ, MADDISON PJ. Mortality and survival in rheumatoid arthritis: a 25 year prospective study of 100 patients, (A2) 128
- REILLY PA.  
Painful, swollen calf in a patient with systemic lupus erythematosus, (L) 319  
Trends in rheumatoid arthritis, (L) 158
- REILLY PA *see also* McHugh NJ
- Reinforcement of bias in the medical literature: nonsteroidal anti-inflammatory drugs and the stomach—a case in point, (L) 231
- Reiter's syndrome and amyloidosis, (L) 156
- Relationship between  
the complex of immunoglobulin A and alpha-1-antitrypsin, its constituent components and the acute-phase response as measured by C-reactive protein in rheumatoid arthritis treated with gold or D-penicillamine, 351  
pelvic, spinal and hip involvement in ankylosing spondylitis—one disease process or several? (A2) 116  
soft and hard tissue changes in nodal GOA: a clinical and microfocal radiographic study, (A1) 13
- Release of tumour necrosis factor activity from mononuclear cells stimulated with crystals, (A1) 33
- Renal abnormalities in ankylosing spondylitis, 341
- Renal and pancreatic calcification in rheumatoid arthritis with Sjögren's syndrome, 212
- RENIER JC *see* Brégeon C
- Response to monosodium urate crystals in Behçet's syndrome, (A2) 44
- REVELL PA, JONES TJ, SWETTENHAM KV, BREWERTON DA. Myocardial fibrosis in ankylosing spondylitis, (A1) 72
- Rheumatic disease  
diagnosis, 73  
infection and immunity in, 223  
punched-card diagnostic system, 46  
radio-immunoassay of interleukin 1 beta, (A1) 34  
vascular damage and factor VIII related antigen, (A1) 32
- Rheumatic diseases, upper gastrointestinal findings and faecal occult blood in patients with, taking nonsteroidal anti-inflammatory drugs, 295

**Rheumatism**

diffuse non-articular, and pain description, mood, and perceived ill-health, (A2) 120

Third World, 1

**Rheumatoid arthritis**

ability of different articular indices to detect an induced flare of joint inflammation, (A1) 64

abnormal mucus glycopeptide, (A2) 30

and acquired haemophilia, 381

alteration of the interferon system, (A2) 63

alteration of thiol and superoxide dismutase status with sulphasalazine treatment, 202

androgen status of females, (L) 316

anti-lipocortin autoantibody responses in patients treated with pulse intravenous methylprednisolone, (A2) 76

antibodies to nuclear antigen, (A1) 17

anticardiolipin antibodies in, 346

antinuclear antibody detection, 188

antioxidant status, (A1) 18

assessing the outcome of sulphasalazine therapy, (A2) 3

assessment of stiffness, 126

association of DNA variants near the immunoglobulin heavy chain locus, (A2) 104

association of DQw3 polymorphism, (A2) 111

autoantibodies to cytoplasmic filaments, (A1) 62

autoantibodies to recombinant lipocortin, (A1) 54

B lymphocytes in, 108

bone mineral content and osteocalcin measurements, (A2) 88

cholesterol crystals in shoulder synovial fluid, 430

clinical, epidemiological and immunogenetic studies, (A1) 43

combination chemotherapy, (E) 243

combination therapy, (L) 314

combined D-penicillamine and chloroquine treatment, 279

comparison of serial synovial fluid cytology, (A2) 31

comparison study of oral gold (auranofin) and intramuscular gold (sodium aurothiomalate), (A2) 6

complement activation, (A1) 18

computer-assisted feedback and clinical assessment, (A2) 35

correlation of histological features with patterns of damage in different joints, (A2) 29

cyclosporin in a double blind placebo controlled trial, (A2) 98

cyclosporin placebo-controlled trial, (A2) 3

decreased B-cell galactosyl transferase activity, (A2) 72

decreased bioactivity of circulating prolactin, 433

deficient interleukin-2 production, (A2) 131

diastolic abnormalities of the left ventricle, (A2) 43

diuretics and, 72

DR4 frequency in female patients, (A1) 26

effect of substance P in immunoglobulin production, (A2) 78

effects of chloroquine in adherent synovial cells, (A2) 56

effects of sulphasalazine on faecal flora of patients, 334

elevated epidermal phospholipase A2 activity, (A1) 62

enhanced chemotaxis of monocytes, 245

erythrocyte sedimentation rate, 136

evaluation of the incidence and prevalence in Angers, France, (A2) 91

evidence for activated alveolar macrophage as a component of subclinical inflammatory alveolitis, (A2) 99

evidence of protective role of the pill, (A2) 93

exercise increases serum levels of cytidine deaminase, (A2) 28

factors precipitating depressed mood, (A2) 121

factors predicting a poor life prognosis, (A1) 44

faecal flora in patients, 329

finger flexion function tests, 118

in the foot, (A2) 103

in Saudi Arabia, 22

frequency of C4 null phenotypes in patients who develop proteinuria after gold and penicillamine treatment, (A2) 51

generalized osteoporosis, (A2) 26

heat sensitive serum factor, (A1) 20

hind foot disease, (A2) 33

histological abnormalities in normal joints, (A2) 29

and HLA-B27 related arthritis, (E) 321

HLA-DR4 is a restriction determinant for defined mycobacterial antigens, (A2) 130

HLA-DR4 positive, (A1) 33

IgA and IgM rheumatoid factors as markers of erosive change, (A1) 4

and IgA nephropathy, 299

IgG subclasses of anti-type II collagen antibodies, (A2) 79

IL-2 biology of suppressor-inducer cells, (A1) 36

immunoglobulin lambda light chain genes, (A2) 52

immunoglobulins in, (A1) 3

immunoregulatory defects in patients, (A1) 36

incidence of unrecognised osteomalacia in hospital patients, (A2) 87

intestinal permeability in patients treated with non-steroidal anti-inflammatory drugs, 103

intra-articular rimexolone in the rheumatoid knee, 450

lack of evidence of objective stiffness, (A2) 34

Leu 7 dependent cellular cytotoxicity, (A2) 54

leucopenia during second line therapy, (A1) 6

leucopenia during sulphasalazine therapy, (A2) 4

loss of high affinity IL-2 receptors, (A2) 63

low-dose total body irradiation, 234

macrocytosis and sulphasalazine treatment, (L) 472

maintenance of remission with intermittent penicillamine therapy, (A2) 7

may be the sequel to Proteus reactive arthritis, (A2) 26

measurement of proximal interphalangeal joint circumference, 123

MHC-restricted lymphocyte transformation to a mycobacterial antigenic extract, (A1) 35

microwave thermography, 37

monoclonal antibody therapy, (A2) 1

mortality and survival, (A2) 128

muscle mass measured by total body potassium, (A2) 27

negative association with schizophrenia, 307

new methods in the epidemiology, (A2) 90

non-caeruloplasmin-bound copper, (A1) 21

and nonsteroidal anti-inflammatory drugs, 67

and pain description, mood, and perceived ill-health, (A2) 120

paired serum and synovial fluid values of  $\alpha_2$ -macroglobulin and TIMP, 354

D-penicillamine/sulphasalazine combination in, 32

peptic ulcer in, (L) 312

## Rheumatoid arthritis (continued)

- phenytoin as a second line agent, (A1) 9
  - plasma and serum viscosity, 136
  - pregnancy, the menopause and anticardiolipin antibodies, (A2) 20
  - prevalence of antibodies to an Epstein-Barr virus-induced polypeptide, 193
  - prinomide in treatment, (A2) 2
  - prostaglandin E<sub>2</sub> levels following treatment with indomethacin or tiaprofenic acid, (A1) 5
  - protective effect independent of duration of pill use, (A2) 93
  - psychological parameters in sufferers and their relatives, (A1) 47
  - quantitation of leukotriene B<sub>4</sub> in synovial fluid, (A2) 72
  - raised alkaline phosphatase levels and primary biliary cirrhosis, (L) 313
  - red cell ferritin as an indicator of iron responsive anaemia, (A2) 36
  - reduction in immunoregulatory T cell subset and function, (A2) 55
  - and relationship between the complex of IgA and alpha-1-trypsin, its constituent components and the acute phase response, 351
  - 7S IgM serum levels, 108
  - secretor state of patients, (A2) 105
  - serial measurement of proximal interphalangeal joint circumference, (A1) 63
  - seronegative and seropositive rheumatoid disease, (A2) 104
  - serum alpha-1-antichymotrypsin concentration, (A1) 2
  - serum biochemistry, 131
  - serum sulphasalazine and metabolite concentrations and treatment outcome, (A2) 5
  - serum and synovial fluid proteins, (A1) 23
  - similarity between seronegative and seropositive diseases, 172
  - with Sjögren's syndrome, 212
  - social relationships of patients, (A2) 121
  - spine bone mineral in, (A2) 27
  - sulphasalazine and folic acid absorption, (A1) 7
  - sulphasalazine in, (A1) 8, 32
  - sulphasalazine and gut-mediated immune effect, (L) 318
  - sulphasalazine and lymphocyte function, (A1) 9
  - sulphoxidation ability and thiol status of patients, 163
  - sulphoxidation capacity and sodium aurothiomalate toxicity, 197
  - synovectomy and radial head excision, 59
  - synovial fluid neutrophils have membrane antigen changes that reflect activation, (A2) 67
  - T cell lines from synovium, synovial fluid and peripheral blood, (A2) 125
  - testosterone levels in, (A1) 1
  - total condylar knee replacement, (A1) 12
  - trends in, 158
  - uptake and degradation of soluble complexes of IgG by monocytes, (A2) 109
  - urinary pyridinoline as marker of articular cartilage damage, (A2) 31
  - use of a pharmacological marker to measure compliance with high dose D-penicillamine, (A2) 7
  - vertebral angiography in patients, (A1) 45
  - with vertical atlanto-axial subluxation complicated by hydrocephalus, 56
- Rheumatoid disease
- anaemia and low-dose iron absorption test, (A2) 110
  - are patients more sensitive to new pain experiences? (A2) 119
  - cervical myelopathy complicating multiple joint replacement in, 275
- Rheumatoid factor, 225
- as marker of erosive change in rheumatoid arthritis, (A1) 4
  - possible mode of action on complement mediated inhibition of immune precipitation, (A2) 108
  - structural analysis, (A2) 35
- Rheumatoid pannus and differential expression of MHC Class II antigens and macrophage sub-populations, (A2) 124
- Rheumatoid synovial
- cells and production of plasminogen activator, (A2) 61
  - fluid T lymphocytes, immune function, (A1) 37
  - membrane and secretion of caeruloplasmin, (A1) 21
- Rheumatoid synovitis and interleukin 1 as mediator of lymphocyte emigration, (A2) 59, (A2) 128
- Rheumatoid ulcers and surgical acid, 235
- Rheumatoid vasculitis and uptake and degradation of soluble complexes of IgG by monocytes, (A2) 109
- Rheumatological disorders
- in France, (A2) 97
  - and monoclonal gammopathy—a new syndrome? (E) 406
- Rheumatology
- assessment of stiffness, 126
  - clinical measurements in, 81
  - computer applications, 3
  - computers in, 43
  - contribution of French rheumatologists, (A2) 97
  - industrial, and the shoulder, (E) 326
  - inpatients and self administration of drugs, (A2) 10
  - legal aspects, 147, 218
  - organization in France, (A2) 98
  - punched-card diagnostic system, 46
  - referrals from general practice, (A1) 32
  - role of medical audit in, 224
- RHIND VM, UNSWORTH A, HASLOCK I. Assessment of stiffness in rheumatology: the use of rating scales, 126
- RICHARDS AJ. Henoch-Schönlein purpura associated with co-dydramol, (L) 65
- RICHARDS IM, BELCH JFF, O'DOWD A, STURROCK RD. Leukotriene B<sub>4</sub> levels in psoriatic arthropathy, (A2) 71
- RICHARDS IM, FRASER SM, CAPELL HA, HUNTER JA. Phenytoin is less effective than gold as a second line agent in the treatment of rheumatoid arthritis, (A1) 9
- RICHARDS IM *see also* Belch JFF
- RICKMAN S *see* Armstrong RD
- RIORDAN JW, DIEPPE PA. Cholesterol crystals in shoulder synovial fluid, 430
- RISTORI JM *see* Soubrier M
- RITCHIE articular index, (A1) 64
- Ro 31-3948, a potential disease modifying antirheumatoid drug, (A2) 2
- ROBBINS DL *see* Frocht A
- ROBERTS SD *see* Taggart AJ
- ROBINS SP *see* Marabani M
- ROBINSON MW, COPPOCK JS, BACON PA, WALTON KW, SCOTT DGI, SCOTT DL. Do conventional assays measure immune complexes? (A2) 76
- ROBINSON RH *see* Outhwaite J
- RODEN D *see* Foley-Nolan D; Keane A
- ROTT IM *see* Axford JS; Parekh R



## Role of

- Ca++ and protein kinase C in neutrophil superoxide release, (A2) 68
- complement and erythrocyte CR1 in the clearance of 125I-tetanus toxoid/anti-tetanus toxoid immune complexes *in vivo* in humans, (A2) 107
- medical audit in rheumatology, 224
- passive stretching in the treatment of ankylosing spondylitis, 40
- polyclonal activation in the development of SLE, (A2) 74
- ROLLAND D *see* Brégeon C
- ROMAN E *see* Spector TD
- ROOK G *see* Sharif M
- ROOK GAW *see* Parckh R
- ROONEY M *see* Soden M
- ROONEY PJ. Reinforcement of bias in the medical literature: nonsteroidal anti-inflammatory drugs and the stomach—a case in point, (L) 231
- ROONEY PJ *see also* Jenkins RT
- ROWE IF, DEANS AC, MIDDLEY J, ANDERSON MJ, KEAT AC. Parvovirus infection in hospital practice, 13
- ROWE IF, FORSTER SM, SEIFERT MH, KEAT AC, THOMAS B, TAYLOR-ROBINSON D, PINCHING AJ, HARRIS JRW. Human immunodeficiency virus infection and arthritis, (A2) 118
- ROWE IF, GIBSON DG, KEAT ACS, BREWERTON DA. Diastolic abnormalities of the left ventricle in rheumatoid and psoriatic arthritis, (A2) 43
- ROWE IF *see also* Rees RG
- ROWELL FJ *see* Daymond TJ
- ROWELL NR *see* Greaves M
- ROWLEY DI *see* Stockley I
- ROWLEY-JONES D *see* Knight RK
- ROY S *see* Grindulis KA
- RUÍZ MT, MIÑANO A, BOLUMAR F, PASCUAL E. Analysis of concordance between the diagnosis given to rheumatic diseases by non rheumatologists and those of trained rheumatologists, (A2) 50
- RUSSELL RGG *see* Gowen M
- RUTGEERTS P *see* Grillet B
- RYLANCE HL *see* Nuki G
- SACHS D, LANGEVITZ P, MORAG B, PRAS M. Polyarteritis nodosa and familial Mediterranean fever, 139
- Sacroiliitis and spinal brucellosis, 28
- SAKKAS LI, DEMAINE AG, POVEY S, PANAYI GS, WELSH KI. Association of DNA variants near the immunoglobulin heavy chain locus with rheumatoid arthritis, (A2) 104
- SAKLATVALA J *see* Andrews HJ
- SALAMAN MR *see* Dar O
- SALMON M, KITAS GD, BACON PA. The IL-2 biology of suppressor-inducer cells in rheumatoid arthritis, (A1) 36
- SALMON M *see also* Kitas GD; Symmons D
- SAMANTA A. Polymyalgia rheumatica with bilateral subclavian artery occlusion, (L) 469
- SAMUELL CT *see* Jones DW
- SANDERS MD *see* Binder AI
- SANDERS P *see* Noble J
- SANDERS PA *see* Sidebottom D; Thomson W
- SANSON D *see* So AKL
- SANY J *see* Miossec P
- Sarcoidosis, heel pain in, (L) 468
- SATELLE L *see* Chard MD; Coughlan RJ
- SAUNDERS C *see* Cambridge G
- SAUVAIN MJ *see* Fahrer H
- SAUVEZIE B *see* Afane M; Soubrier M
- SCHAEFFER RTC *see* van Vliet-Daskalopoulou E
- SCHIFFERLI JA *see* Ng YC
- Sciatica
- controlled trials of manipulation, traction, sclerosant and epidural injections, 416
- epidurography in the management, 424
- Sclerodactyly and anticentromere antibody, 17
- Scleroderma
- anticentromere antibody, 17
- antinuclear antibody detection, 188
- mortality in, (A1) 42
- SCOTT CM *see* Mathews JA
- SCOTT DGI, SYMMONS DPM, BACON PA. Mortality in scleroderma of recent onset, (A1) 42
- SCOTT DGI *see also* Beaman M; Robinson MW
- SCOTT DL. Clinical measurements in rheumatology, (E) 81
- SCOTT DL. Radiological assessments of joint damage, (A1) 50
- SCOTT DL *see also* Butler MG; Coppock JS; Dacre JE; Dawes PT; Greenwood A; Hollywell CA; Robinson MW; Williams A
- SCOTT JS *see* Thornton JH
- SCOTT JT *see* Bull P
- SCULLEY TB *see* Hazelton RA
- Seat-belts again, (L) 394
- Secretion of caeruloplasmin by the rheumatoid synovial membrane and liver, (A1) 21
- Secretor state of patients with psoriasis, psoriatic arthropathy and rheumatoid arthritis, (A2) 105
- Segregation analysis of the type II collagen structural gene (COL2 A1) in the chondrodysplasias, (A1) 27
- SEIFERT MH *see* Ayeshe R; Dar O; Rowe IF
- Selective depletion and activation of CD8 positive T lymphocytes from peripheral blood in polymyalgia rheumatica and giant cell arteritis, (A2) 55
- SELF CR *see* Bloxham DP
- SENALDI G, VERGANI D, McWHIRTER A, BLACK C. Complement activation in progressive systemic sclerosis, (A2) 80
- SENALDI G *see also* Jawad ASM; Mahmud T
- Senior registrar UK/Eire travelling fellowship, (L) 230
- SENIOR S *see* Bax DE
- Septic arthritis
- diagnosis of, 379
- Neisseria mucosa*, (L) 314
- in patients with sickle-cell disease, 99
- Sequential neurophysiological studies in systemic lupus erythematosus, (A2) 18
- Serial measurement of proximal interphalangeal joint circumference in rheumatoid arthritis: one joint or ten? (A1) 63
- Serial studies of antibodies to seven polynucleotides in SLE, (A2) 78
- Serological markers of ankylosis and spondylitis, (A2) 16
- Seronegative
- arthropathy and serum biochemistry, 131
- and seropositive rheumatoid arthritis: similar diseases, 172
- polyarthritides in Zimbabwean black patients: possible relationship to human immunodeficiency virus infection, (A2) 1113
- Serum
- alpha-1-antichymotrypsin concentration as a marker of disease activity in rheumatoid arthritis, (A1) 2
- biochemistry in rheumatoid arthritis, seronegative arthropathies, osteoarthritis, SLE and normal subjects, 131

## Serum (continued)

- creatinine levels two years later: follow up of a placebo-controlled trial of cyclosporin in rheumatoid arthritis, (A2) 3
- and synovial fluid proteins and complexes in rheumatoid arthritis and osteoarthritis: quantitative or qualitative differences? (A1) 23
- SETHI D, WOODROW DF, BROWN EA, CARY NRB, ERHARDT CC, ALLARD SA, MAINI RN, GOWER PE. B2microglobulin derived amyloid and iron in dialysis arthropathy, (A2) 39
- Severe subcutaneous calcification in the 'CREST' syndrome: evidence of high turnover of calcific deposits, 89
- SHADFORTH MF *see* Dawes PT; Sheeran TP
- SHARIF M, ROOK G, EDWARDS JCW. Immunoreactive N-acetylglucosamine in chronic synovitis, (A2) 73
- SHARQUIE KE. Epididymo-orchitis in Behçet's disease, (L) 468
- SHAW DJ, HUGHES J, KLENERMAN L, GUMPEL JM. Early rheumatoid arthritis in the foot, (A2) 103
- SHAW DJ, SMITH T, CRAWLEY JCW, GUMPEL JM. Use of single photon emission computed tomography to assess the role of popliteal cysts in 90Y therapy for persistent synovitis of the knee, (A2) 8
- SHAYEGAN-SALEK MS *see* Betty H
- SHEERAN T, DAWES P, COLLINS M, FOWLER P, SHADFORTH M. Health assessment questionnaire and its ability to assess anti-rheumatic drug therapy, (A2) 122
- SHEERAN T, JACKSON R, DAWES P, SHADFORTH M. Leu 7 dependent cellular cytotoxicity in rheumatoid arthritis, (A2) 54
- SHEERAN TP, JACKSON R, DAWES PT, SHADFORTH MF. A heat sensitive serum factor influencing spontaneous cellular cytotoxicity which is not demonstrable in patients with rheumatoid arthritis, (A1) 20
- SHELDON P, WEBB C. Sulphasalazine suppression of human and murine lymphocyte transformation, (A2) 57
- SHELDON P. HLA-B27 related arthritis, sulphasalazine and rheumatoid arthritis, (E) 321
- SHELDON PJ. Sulphasalazine in rheumatoid arthritis: pointers to a gut-mediated effect, (L) 318
- SHERIFF SB *see* Bax DE
- SHINEBAUM R, BLACKWELL CC, ABERNETHY VE, SITUNAYAKE RD, WEIR DM, NUKI G. Secretor state of patients with psoriasis, psoriatic arthropathy and rheumatoid arthritis, (A2) 105
- SHINEBAUM R, NEUMANN VC, COOKE EM, WRIGHT V. Comparison of faecal flora in patients with rheumatoid arthritis and controls, 329
- SHINEBAUM R *see also* Neumann VC
- SHIPLEY M *see* Banji A; Fitzpatrick R; Newman S; Winska-Wiloch H
- SHIPLEY ME *see* Papisavvas GK
- SHODIAI-MORADI F *see* Ebringer A
- SHOENFELD Y *see* Isenberg DA
- SHOKI F *see* Mageed RA
- SHORE A. Possible danger of intra-articular steroid injection in children with respiratory infections, (L) 73
- Shoulder
- neck complaints in industry, 365
- pain following routine cardiac surgery, (A2) 102
- pain syndrome and soft-tissue abnormalities in patients on long-term haemodialysis, 181
- physiotherapy or steroids in treatment? (A2) 13
- SHOULS J *see* McCrae F
- Sickle-cell anaemia and patients with septic arthritis, 99
- SIDEBOTTOM D, SANDERS PA, GRENNAN DM. Immunoglobulin lambda light chain genes in rheumatoid arthritis, (A2) 52
- SILMAN A, BLACK C. Pregnancy and reproductive history in women with systemic sclerosis, (A1) 41
- SILMAN A, JANNINI S, BACON P. An epidemiological study of systemic sclerosis in the West Midlands, (A1) 38
- SILMAN AJ. Epidemiological aspects of polymyalgia rheumatica/giant cell arteritis, (A2) 85
- SILMAN AJ. Use of Beighton score to compare joint mobility between groups, (L) 394
- SILMAN AJ *see also* Spector TD
- Similarity of haematological parameters of iron status, faecal occult blood positivity and prevalence of lesions on upper gastrointestinal endoscopy in arthritic patients with microcytic and normocytic anaemia, (A2) 37
- SIMMONS KM, BROWN KA, KIRK AP, PERRY JD, DUMONDE DC. Enhanced chemotaxis of monocytes in rheumatoid arthritis, 245
- SIMON L *see* Amor B
- SINCLAIR H *see* Price R
- SINHA SK *see* Wallis PJW
- SITTAMPALAM Y *see* Mathews JA
- SITTON NG, DIXON JS, BIRD HA, WRIGHT V. Serum biochemistry in rheumatoid arthritis, seronegative arthropathies, osteoarthritis, SLE and normal subjects, 131
- SITUNAYAKE D *see* di Giovine F
- SITUNAYAKE RD, KOOTTATHEP S, THURNAM DI, CHIRICO S, SMITH E, LUNEC J, DAVIS M, MCCONKEY B. Antioxidant status measured by the 'trap' assay in rheumatoid arthritis, (A1) 18
- SITUNAYAKE RD *see also* Shinebaum R
- Sjögren's syndrome
- anxiety and depression in, (A1) 47
- associated with circulating immune complexes containing IgA, (A2) 109
- controlled assessment of the prevalence of Raynaud's phenomenon, (A2) 22
- differential diagnosis in a patient with neuromuscular complications, (L) 470
- distribution of immunoregulatory idiotypes on anti-La (SS-B) antibodies, (A1) 60
- Epstein-Barr virus DNA, (A1) 16
- genetic heterogeneity, (A2) 106
- with rheumatoid arthritis, 212
- a study of its neurological complications, (A1) 17
- study of migraine in, (A2) 21
- Skin-fold thickness and nail-fold capillaries in diabetics: relationship to limited joint mobility and retinopathy, (L) 153
- SKINNER RP *see* McHugh NJ
- SLACK R *see* Jenkinson ML
- SLE *see* systemic lupus erythematosus
- Sleep in osteoarthritic patients, (A1) 14
- Sleeping electroencephalograms in patients with primary fibromyalgia syndrome, (A2) 43
- SLEDLEY S *see* Fair M
- SMITH E *see* Situnayake RD
- SMITH F *see* Nemeth R
- SMITH GD *see* Ralston SH
- SMITH J *see* Rajapakse CNA
- SMITH JL *see* Howell WM; Kidd BL; Moore K
- SMITH MA *see* Tothill P
- SMITH NJ, PATTRICK M, DOHERTY M. Sleeping electroencephalograms in patients with primary fibromyalgia syndrome, (A2) 43

- SMITH NJ *see also* Powell RJ  
 SMITH PR *see* Melsom RD  
 SMITH R *see* Wordsworth P  
 SMITH RL *see* Ayeshe R  
 SMITH T *see* Shawe DJ  
 SMITH W *see* Hurst NP  
 SMITH WE *see* Pullar T  
 SMITHEN CE *see* Bloxham DP  
 SNAITH ML *see* Binder AI; Cambridge G; Turner-Stokes L  
 SNYDER FF *see* Nuki G  
 SO AKL, FIELDER AHL, WARNER CA, BATCHELOR JR, WALPORT MJ. MHC class II and C4 polymorphisms in SLE, (A2) 52  
 SO AKL, WARNER C, SANSOM D, WALPORT MJ. Identification of DQw3 polymorphism using an allele specific oligonucleotide probe and association with rheumatoid arthritis, (A2) 111  
 Social relationships in patients with rheumatoid arthritis, (A2) 121  
 SODEN M, ROONEY M, WHELAN A, FEIGHERY C, BRESNIHAN B. Histological abnormalities in the normal joints of patients with rheumatoid arthritis, (A2) 29  
 Sodium aurothiomalate  
   in rheumatoid arthritis, (A2) 6  
   toxicity and sulphoxidation capacity in rheumatoid arthritic patients, 197  
 Solid-phase assays for the quantitation of human autoantibodies to nRNP and Sm polypeptides, (A2) 77  
 SOLINGER AM, SULLIVAN JL, WILDER RL, MAINARDI CS. Life, the universe and everything—a report based on the Anglo-US Fellowship Exchange, 1985, 62  
 Soluble IL-2 receptor in serum and synovial fluid samples from patients with rheumatic diseases, (A2) 64  
 SONNEX C *see* Keat A  
 SORG C *see* Duke O  
 SORIANO RMG, MATTHEWS JM, GUERADO-PARRA E. Acquired haemophilia and rheumatoid arthritis, 381  
 SOUBRIER M, BATAILLE R, TREVES R, RISTORI JM, CANTAGREL A, DUBOST JJ, MENKES CJ, SAUVEZIE B. P.O.E.M.S. syndrome: an analysis of eight cases, (A2) 42  
 SPECTOR T, PERRY LA, TUBB G, HUSKISSON EC. Low free testosterone levels in rheumatoid arthritis, (A1) 1  
 SPECTOR TD, BROWN G, SILMAN AJ. Increased hysterectomy rate before symp.om onset in osteoarthritis, (A2) 91  
 SPECTOR TD, ROMAN E, SILMAN AJ. Pill and rheumatoid arthritis: further evidence for protection, (A2) 93  
 SPECTOR TD, SILMAN AJ. Does the negative association between rheumatoid arthritis and schizophrenia provide clues to the aetiology of rheumatoid arthritis? 307  
 SPECTOR TD. Androgen status of females with rheumatoid arthritis, (L) 316  
 Spectrum of  
   crystal deposition in hypophosphatasia, (A2) 45  
   rheumatic diseases in Saudi Arabia, 22  
 SPEEDLEY J *see* Allington L  
 Spinal brucellosis, 28  
 Spine bone mineral in rheumatoid arthritis and asthma: effects of corticosteroids and comparison with total body calcium, (A2) 27  
 Spondylarthropathy  
   juvenile-onset and clinical and echocardiographic assessment, 155  
   systemic ileocolonoscopy and bowel biopsy in, 338  
 Spondylitis  
   serological markers, (A2) 16  
   without radiological sacroiliitis—a clinical study, (A1) 68  
 Spondylosis, lumbar, fibrinolytic activity in, (A2) 13  
 Sport, exercise and arthritis, 386  
 Stability of 99m technetium labelled liposomes and their specific uptake in the rat adjuvant-induced arthritic model, (A2) 83  
 Stanford health assessment questionnaire, (A2) 122  
 STANWORTH DR *see* Dawes PT  
 STEIN M *see* Davis P  
 STERLING JC, PYE RJ. Naproxen-induced pseudoporphyria, 210  
 Steroid injection and facial flushing, (A1) 10  
 STEVEN MM *see* Harris GK  
 STEWART HD, QUINNELL RC, DANN N. Epidurography in the management of sciatica, 424  
 Still's disease  
   bicipital swelling, 216  
   presenting as PUO, 65  
 STOCKLEY I, BETTS RP, GETTY CJM, ROWLEY DI, DUCKWORTH T. Objective and subjective assessment of forearm arthroplasty, (A2) 103  
 STOLLAR BD *see* Isenberg DA  
 Stretching, passive, in ankylosing spondylitis, 40  
 STRICKLAND B *see* Harrison NK  
 Structural analysis of rheumatoid factors in an early synovitis clinic, (A2) 35  
 Studies of common DNA antibody idiotypes and autoantibodies in SLE spouses, (A2) 73  
 Study of antipolynucleotide antibodies, anti-Klebsiella (K30) antibodies and anti-DNA antibody idiotypes in ankylosing spondylitis, 168  
   hyperlaxity in Olympic gymnasts, (A2) 111  
   migraine in primary Sjögren's syndrome and other rheumatic disorders, (A2) 21  
   rheumatology referrals from general practice, (A1) 32  
 STURFELT G *see* Jonsson H  
 STURROCK RD *see* Belch JFF; Fraser SM; Madhok R; Marabani M; Richards IM; Zoma A  
 Substance P in the capsule and synovial folds of human zygapophyseal joints, 362  
 Sudeck's atrophy *see* algodystrophy  
 Sulindac in osteoarthritis, (A1) 12  
 SULLIVAN JL *see* Solinger AM  
 Sulphasalazine  
   and acetylation, 229  
   alone or in combination with D-penicillamine in rheumatoid arthritis, 32  
   alteration of thiol and superoxide dismutase status in rheumatoid arthritis, 202  
   in ankylosing spondylitis with peripheral joint involvement, (A2) 117  
   assessing the outcome of therapy in rheumatoid arthritis, (A2) 3  
   dementia in, (A2) 17  
   effects on faecal flora in patients with rheumatoid arthritis, 334  
   folic acid absorption in rheumatoid arthritis, (A1) 7  
   and HLA-B27 related arthritis, (E) 321  
   and leucopenia, (A1) 6  
   leucopenia during therapy for rheumatoid arthritis, (A2) 4  
   and lymphocyte function in rheumatoid arthritis, (A1) 9  
   in rheumatoid arthritis: pointers to a gut-mediated immune effect, (L) 318

- Sulphasalazine (continued)  
 serum and metabolite concentrations and treatment outcome in rheumatoid arthritis, (A2) 5  
 suppression of human and murine lymphocyte transformation, (A2) 57  
 toxicity does not correlate with sulphoxidation capacity, (A2) 4  
 in treatment of rheumatoid arthritis and macrocytosis, (L) 472  
 in young and elderly patients with rheumatoid arthritis, (A1) 8
- Sulphoxidation  
 ability and thiol status in rheumatoid arthritis patients, (E) 163  
 capacity and association with sodium aurothiomalate toxicity in rheumatoid arthritic patients, 197
- SUMMERS GD, WEBLEY M, TAYLOR AR. A reappraisal of synovectomy and radial head excision in rheumatoid arthritis, 59
- SUN J-P, KHAN MA, BAHLEH RC. Impairment of cardiac diastolic function in patients with ankylosing spondylitis, as evaluated by Doppler echocardiography, (A1) 71
- Superoxide dismutase status in sulphasalazine treated rheumatoid arthritis, 202
- Surgical aid for intractable rheumatoid ulcers, 235
- SUSSMAN H *see* Bird HA
- SWANA G *see* Isenberg DA
- SWANNELL AJ. Hospital formulary survey, (L) 313
- SWETTENHAM KV *see* Revell PA
- SWEZEY RL. Low back pain treatment: is a 'yank' in King Arthur's court or elsewhere as effective as traction, epidural injections or what else: (E) 401
- SWINBURNE K *see* McKenna F
- SYKES B *see* Wordsworth BP
- SYMMONS AM *see* Dowling EJ
- SYMMONS D, SALMON M, GARNER C, BLANN A, FARR M, BACON PA. Sulphasalazine and lymphocyte function in rheumatoid arthritis, (A1) 9
- SYMMONS DPM *see* Scott DGI
- SYMONS JA, WOOD NC, NUKI G, DI GIOVINE FS, DUFF GW. Soluble IL-2 receptor in serum and synovial fluid samples from patients with rheumatic diseases, (A2) 64
- Syndrome of the Black Swan, (E) 324
- Synovectomy in rheumatoid arthritis, 59
- Synovial fluid  
 active in collagenase content in Milwaukee shoulder, (L) 311  
 amino acids in, (A1) 24  
 arthritic and proteoglycans and sulphated glycosaminoglycans, (A1) 66  
 can 'prime' or activate reactive oxidant generation by neutrophils, (A2) 66  
 contains only picogram levels of biologically active IL-1, (A2) 58  
 joint size influences the leukocyte count, (A2) 32  
 measurement of substance P in patients with inflammatory and non-inflammatory arthritides, (A2) 33  
 microdistribution, (A2) 46  
 neutrophils in RA have membrane antigen changes that reflect activation, (A2) 67  
 proteins in rheumatoid arthritis and osteoarthritis, (A1) 23
- Synovial fold innervation, 93
- Synovial membrane  
 in ankylosing spondylitis—an immunohistological comparison with rheumatoid arthritis, (A1) 28  
 rheumatoid and immunoregulatory subsets of CD4<sup>+</sup> lymphocytes, (A1) 55
- Synovitis  
 chronic and immunoreactive *N*-acetylglucosamine, (A2) 73  
 is uncommon in polymyalgia rheumatica/giant cell arteritis, (A2) 38  
 of the knee, single photon emission computed tomography to assess the role of popliteal cysts in 90Y therapy, (A2) 8  
 pigmented villonodular and yttrium 90 synovectomy, 71  
 transient hip and antinuclear, antideoxyribonucleoprotein and anti-histone antibodies, (A2) 75
- Synovium changes in knee arthritis, 5
- Systematic ileocolonoscopy and bowel biopsy study in spondylarthropathy, 338
- Systemic lupus erythematosus  
 antinuclear antibody detection, 188  
 association of autoimmune thyroiditis with, 359  
 autoantibodies to recombinant lipocortin, (A1) 54  
 does rheumatoid factor protect patients from nephritis? (A2) 18  
 double-blind placebo-controlled trial of intravenous methylprednisolone, (A2) 19  
 ethnic differences in the distribution of anticardiolipin antibodies, (A2) 20  
 expression of an interspecies anti-Sm antibody idio-type, (A1) 60  
 false positive monospot test, 71  
 fibrinolysis in, 262  
 gout and hyperuricaemia in, 303  
 $\mu$ -heavy chain and monoclonal IgG K paraproteinaemia, 460  
 immune response to challenge with exogenous antigen (flu vaccination), (A2) 79  
 implications of hydrogen peroxide mediated damage to DNA, (A2) 69  
 in India with anti-ssDNA antibodies, (L) 476  
 influence of age on clinical and serological manifestations, (A1) 46  
 MHC class II and C4 polymorphisms, (A2) 52  
 mortality from in England and Wales, 1974-1983, 437  
 painful, swollen calf in a patient, (L) 319  
 role of polyclonal activation in the development, (A2) 74  
 sequential neurophysiological studies, (A2) 18  
 serial studies of antibodies to seven polynucleotides, (A2), 78  
 serum biochemistry, 131  
 and SLE-specific anti-Sm antibodies, (A1) 59  
 studies of common DNA antibody idiotypes and autoantibodies in spouses, (A2) 73  
 T cell adhesion to endothelial cells, (A2) 58
- Systemic sclerosis  
 cardiac involvement, (A1) 41  
 cold challenge and vascular reactivity of the oesophagus, (A1) 38  
 complement activation in, (A2) 80  
 controlled studies of stanozolol, (A2) 24  
 CT scanning of the thorax, (A2) 25  
 elevated von Willebrand factor antigen, (A2) 96  
 enhanced oxidative metabolism of neutrophils, 113  
 epidemiological study, (A1) 38  
 immunoglobulin class and IgG subclass of autoantibodies, (A2) 77  
 microvascular injury precedes dermal fibrosis in, (A2) 25

- nicardipine and thallium-201 myocardial perfusion, (A2) 130  
 platelet and plasma serotonin metabolism, (A1) 39  
 pregnancy, the menopause and anticardiolipin antibodies, (A2) 20  
 pregnancy and reproductive history in women patients, (A1) 41  
 reasons to be optimistic, (E) 241  
 tissue oxygen and carbon dioxide, (A2) 23  
 urinary glycosaminoglycan excretion, 259
- T cell**  
 adhesion to endothelial cells in patients with systemic lupus erythematosus, (A2) 58  
 helper-inducer preferential accumulation, (A2) 126  
 helper-inducer, preferential adhesion to endothelial cells, (A2) 127  
 lines from synovium, synovial fluid and peripheral blood of a patient with early rheumatoid arthritis, (A2) 125  
 mitogenesis, calcium signal for, (A1) 25  
 receptor idiotypes and expression on blood lymphocytes and rheumatoid synovial cells, (A2) 125
- TAGGART AJ, HILL J, ASTBURY C, DIXON JS, BIRD HA, WRIGHT V.** Sulphasalazine alone or in combination with D-penicillamine in rheumatoid arthritis, 32
- TAGGART AJ, McDERMOTT B, DELARGY M, ELBORN S, FORBES J, ROBERTS SD.** Sulphasalazine in young and elderly patients with rheumatoid arthritis, (A1) 8
- TAKEI M** *see* Isenberg D
- TAYLOR AR** *see* Summers GD
- TAYLOR CM** *see* Brown RA
- TAYLOR JR** *see* Giles LGF
- TAYLOR L** *see* Jayson MIV
- TAYLOR LJ** *see* Mitchell WS
- TAYLOR-ROBINSON D** *see* Dixey J; Keat A; Rowe IF
- Technetium**  
 labelled liposome scanning in inflammatory polyarthropathies, (A2) 30  
 pyrophosphate muscle scans in inflammatory muscle disease, 267
- Telangiectasia and anticomplement antibody, 17**
- Tendinitis, rotator cuff, (A1) 30**
- Tennis elbow**  
 a comparison of different treatments, (A2) 100  
 hydrocortisone, triamcinolone and lignocaine for, (A2) 100
- Tenosynovitis, tests in, 118**
- TEO CG, VENABLES PJW, GRIFFIN BE, ALLARD SA, MAINI RN.** Detection of Epstein-Barr virus DNA in salivary gland biopsies from patients with Sjögren's syndrome, (A1) 16
- Testosterone levels in rheumatoid arthritis, (A1) 1**
- Thalidomide, peripheral neuropathy in patients, (A2) 12**
- The effect of free radicals on human immunoglobulin G3, (A1) 20**
- The influence of inflammation in the breakdown of cartilage by a granulomatous reaction, (A1) 25**
- Thiol alteration in sulphasalazine treated rheumatoid arthritis, 202**
- THOMAS B** *see* Dixey J; Keat A; Rowe IF
- THOMPSON K** *see* Winska-Wiloch H
- THOMPSON PW, AUSTIN C, KIRWAN JR.** Serological markers of ankylosis and spondylitis, (A2) 16
- THOMPSON PW, KIRWAN JR, CURREY HLF.** The ability of different articular indices to detect an induced flare of joint inflammation in rheumatoid arthritis, (A1) 64
- THOMPSON PW, WHEATCROFT S, BARNES CG.** Exercise increases serum levels of cytidine deaminase in rheumatoid arthritis, (A2) 28
- THOMPSON PW.** Laboratory markers of joint inflammation and damage, (E) 83
- THOMSON DB** *see* Emerson BT
- THOMSON W, SANDERS PA, DAVIS M, DYER PA, GRENNAN DM.** C4B null alleles in Felty's syndrome, (A2) 50
- THORNTON JH, HILL J, BIRD HA, SCOTT JS.** Obstetric complications of benign familial joint hyperlaxity, (A2) 41
- THOULD AK, THOULD JB.** Computers in rheumatology, 43
- THOULD B** *see* Thould AK
- THURNHAM DI** *see* Situnayake RD
- Thyroiditis, autoimmune, and association with systemic lupus erythematosus, 359**
- Tiaprofenic acid, prostaglandin E<sub>2</sub> levels in rheumatoid arthritis, (A1) 5**
- TIMMS AM** *see* Dasgupta B
- TIMP** serum and synovial fluid values in rheumatoid arthritis, 354
- TIPPING PG, DIMECH WJ, LITTLEJOHN GO, HOLDSWORTH SR.** Comparison of immunofluorescence and immunoperoxidase for demonstration of antinuclear antibodies on HEP-2 substrate, 188
- Tissue oxygen and carbon dioxide in systemic sclerosis, (A2) 23**
- TODD CEC** *see* Dixey JJ
- TODD POKROPECK A** *see* Isenberg DA
- TONG BP** *see* Bloxham DP
- TONNEL A-B** *see* Duquesnoy B
- TOPLISS DJ** *see* Miller MH
- Total condylar knee replacement in patients with rheumatoid arthritis, (A1) 12**
- TOTHILL P, PYE D, NICOLL JJ, SMITH MA, REID DM, NUKI G.** Spine bone mineral in rheumatoid arthritis and asthma: effects of corticosteroids and comparison with total body calcium, (A2) 27
- TOTHILL P** *see also* Reid DM
- TOWNSEND Y** *see* di Giovine F
- TRAFICANTE A** *see* Bird HA
- Travelling fellowship, 230**
- TREASURE T** *see* Watts RA
- Trends in rheumatoid arthritis, (L) 158**
- TREVES R** *see* Soubrier M
- Triamcinolone acetate injection and facial flushing, (A1) 10**
- TRUSSELL EC** *see* Allington L
- TSAI HH.** Modified costotransversectomy in treatment of intractable costovertebral pain in ankylosing spondylitis, (L) 66
- TUBB G** *see* Spector T
- TUDOR J** *see* Kyle V
- TUDWAY A** *see* Hajirovossou V
- Tumour necrosis factor**  
 activity from mononuclear cells, (A1) 33  
 inhibition by alpha MSH, (A2) 62  
 its production by and actions on human osteoblasts *in vitro*, (A2) 62
- TUNN E** *see* Dawes PT
- TUNN EJ** *see* Maged RA
- TURNER M** *see* Buchan G
- TURNER-STOKES L, CAMBRIDGE G, CORCORAN T, OXFORD J, SNAITH ML.** Immune response to challenge with exogenous antigen (flu vaccination) in patients with systemic lupus erythematosus and other autoimmune disorders, (A2) 79



- TURNER-STOKES L, JONES M, ADDISON I, MANSELL M, ISENBERG DA. Does rheumatoid factor protect lupus patients from nephritis? (A2) 18
- TURNER-WARWICK M *see* Harrison NK
- TYNDALL AG *see* March LM
- Ultrastructural localisation of**  
alkaline phosphatase activity in normal, osteoarthritic, and osteophytic cartilage, (A1) 16  
fibronectin in human normal and osteoarthritic articular cartilage, (A1) 15
- UNSWORTH A *see* Rhind VM
- UNSWORTH J, BRAILSFORD S, HOWARD RJ, ARTHUR VM, LOTE CJ, BLAKE DR. Estimation of urinary PGE2 before and after nonsteroidal anti-inflammatory drug administration, (A2) 8
- UNSWORTH J *see also* Fonseca A; Outhwaite J
- Upper gastrointestinal findings and faecal occult blood in patients with rheumatic diseases taking nonsteroidal anti-inflammatory drugs, 295
- Uptake and degradation of soluble complexes of IgG by monocytes from patients with rheumatoid arthritis and rheumatoid vasculitis: a longitudinal study of its relation with disease activity, (A2) 109
- Urate crystals stimulate cytokine mRNA accumulation in human monocytes, (A2) 60
- Urinary**  
glycosaminoglycan excretion in systemic sclerosis subsets compared with normal controls, 259  
pyridinoline—a marker of articular cartilage damage in rheumatoid arthritis, (A2) 31
- Use of**  
Beighton score to compare joint mobility between groups, (L) 394  
a pharmacological marker to measure compliance with high-dose D-penicillamine in rheumatoid arthritis, (A2) 7  
single analgesics in the treatment of ankylosing spondylitis, 207  
single photon emission computed tomography to assess the role of popliteal cysts in 90Y therapy for persistent synovitis of the knee, (A2) 8
- Uveitis *see* Behçet's uveitis, 285
- VADAS MA *see* Emery P
- VALENTINE A *see* Dixey JJ
- VAN ALBADA KUIPERS GA *see* Peeters A
- VAN DEN BERG R *see* Hurst NP
- VAN DEN WALL BAKE AWL *see* Peeters A
- VAN DER LINDEN S *see* Fahret H
- VAN LINTHOUDT D. *Neisseria mucosa* septic arthritis, (L) 314
- VAN OFFEL JF. Differential diagnosis in a patient with secondary Sjögren's syndrome and neuromuscular complications, (L) 470
- VAN RUTHOVEN AWAM *see* Boers M
- VAN VLIET-DASKALOPOULOU E, JENTIENS T, SCHEFFER RTC, INTERNATIONAL RIMEXOLONE STUDY GROUP. Intra-articular rimexolone in the rheumatoid knee: a placebo-controlled, double-blind, multicentre trial of three doses, 450
- VANDENBROUCKE JP *see* Hazes M
- VANDERMARCO P *see* Bontoux D
- Vascular damage**  
and factor VIII related antigen in the rheumatic diseases, (A1) 32  
role of endothelial and cardiolipin antibodies, (A2) 96
- Vasculitis**  
nodular, and leprosy, (L) 398  
and paraproteinaemia, 142
- VAZQUEZ JJ *see* Khamashta MA
- VEERAPEN K, WATT I, DIEPPE P. Severe subcutaneous calcification in the 'CREST' syndrome: evidence of high turnover of calcific deposits, 89
- VEITCH J *see* Holme ER
- VENABLES PJW, PAWLOWSKI T, MUMFORD PA, BROWN C, WILLIAMS DG, MAINI RN. Antibodies to RANA react with a synthetic peptide corresponding to part of the internal repeat sequence of Epstein-Barr nuclear antigen, (A1) 17
- VENABLES PJW *see also* Erhardt CC; Horsfall AC; Melsom RD; Misra R; Teo CG
- VERGANI D *see* Jawad ASM; Mahmud T; Senaldi G
- Vertebral angiography in rheumatoid arthritis patients with and without atlanto-axial subluxation, (A1) 45
- VICARY FR *see* Watts RA
- VILLIAUMEY J, MINH N. Clinical and radiological features of Paget's disease in the knee, (A2) 89
- VOISIN C *see* Duquesnoy B
- Von Willebrand factor antigen in systemic disease, (A2) 96
- VOWDEN P *see* Wilkinson D
- WAKEFIELD D. Reiter's syndrome and amyloidosis, (L) 156
- WALKER A *see* Bird HA
- WALKER D *see* Brighton S; Kelly CA
- WALKER DJ, GRIFFITHS M, JAMES P. Psychological parameters in rheumatoid arthritis sufferers and their relatives: correlation with disease severity, (A1) 47
- WALKER DJ *see also* Carr S
- WALKER FS, PRITCHARD MH, JONES JM, OWEN GM, RAINSFORD KD. Inhibition of indomethacin-induced gastrointestinal bleeding, both immediate and persistent, in man by citrate-glucose formulations, (A2) 12
- WALKER SR *see* Berry H
- WALLACE AS *see* Badal PAL
- WALLACE AW *see* Bossingham DH
- WALLACE RC *see* Nuki G
- WALLAERT B *see* Duquesnoy B
- WALLIS PJW, LODGWICK R, SINHA SK, CONSTABLE TJ. Effect of naproxen on renal haemodynamics in elderly patients, (A2) 9
- WALPORT M. The identification of autoantigens, autoantibodies and their idiotypes, (E) 161
- WALPORT MJ *see* Mackworth-Young CG; Ng YC; So AKL; Weetman AP
- WALTERS M *see* Howell WM
- WALTERS MT *see* Kidd BL; Moore K
- WALTON K, HOLT PJL. Locomotor symptoms following cardiac surgery, (A1) 31
- WALTON KW *see* Robinson MW
- WANG F *see* Williamson MER
- WARD AM *see* Patrick M
- WARD E *see* Allington L
- WARING R *see* Marabani M
- WARING RH *see* Ayeshe R
- WARNER CA *see* So AKL
- WATKINS RPF *see* Misra R
- WATSON BUCHANAN W *see* Balint GP
- WATSON M *see* Grahame R
- WATT I *see* Hutton CW; McCrae F; Veerapen K

- WATTS RA, PAICE E, DAVIES R, TREASURE T. Shoulder pain following routine cardiac surgery, (A2) 102
- WATTS RA, PAICE E, WHITE AG, VICARY FE, NANSARD use and dyspepsia in a rheumatology clinic, (A2) 11
- WAUGH AP *see* Kingsley GH
- WEBB C *see* Sheldon P
- WEBER S *see* Kahan A
- WEBLEY M *see* Hajiroussou V; Summers GD
- WEBSTER EM *see* Yonker RA
- WEETMAN AP, WALPORT MJ. The association of autoimmune thyroiditis with systemic lupus erythematosus, 359
- Wegener's granulomatosis, (A2) 42
- WEIGHTMAN BO *see* Afoke NYP
- WEILL BJ *see* Job-Deslandre C
- WEINKOVE C *see* Klimiuk PS
- WEIR DM *see* Shinebaum R
- WEISS JB, MURPHY J, McLAUGHLIN B, MITCHELL W, GRENNAN D. Measurement in serum from patients with rheumatic diseases of levels of a non-enzymatic activator of latent metalloproteinases which is also angiogenic, (A2) 65
- WEISS JB *see also* Brown RA; Chuck AJ
- WEISSMANN G. The first seconds of neutrophil activation: phosphoinositides, protein kinase C, and calcium movements, (A1) 49
- WELSH KI *see* Panayi GS; Sakkas LI
- WESTEDT ML *see* Heurkens THM; Peeters A
- WESTMACOTT D *see* Bloxham DP
- WHALEY K *see* Ahmed AE; Holme ER
- What can be learned from Third World rheumatism: (E) 1
- What do rheumatologists do? (A1) 56
- What a rheumatologist should know about the law: I. Battery, breach of contract and negligence, 147; II. Personal injury cases and the medical practitioner in the witness box, 218
- WHEATCROFT S *see* Thompson PW
- WHELAN A *see* Hassan J; Soden M
- WHITE AG *see* Watts RA
- Whither metrology? (E) 165
- WHITTLE MW. Gait analysis—its usefulness or otherwise, (A2) 86
- WILDER RL *see* Solinger AM
- WILKINSON D, VOWDEN P, LATIF AB, RAJAH SM, MARTIN MFR, KESTER RC. Plasma prostanoid levels in patients with Raynaud's syndrome, (A1) 40
- WILLIAMS A, GREENWOOD A, COPPOCK JS, SCOTT DL, HUSKISSON EC. Immunoglobulins in rheumatoid arthritis: do they help in assessing activity? (A1) 3
- WILLIAMS A *see also* Coppock JS
- WILLIAMS BD *see* Love WG; O'Sullivan MM; Pye M; Williamson MER
- WILLIAMS D *see* Field M
- WILLIAMS DG, MAINI RN. Solid-phase assays for the quantitation of human autoantibodies to nRNP and Sm polypeptides, (A2) 77
- WILLIAMS DG *see also* Venables PJW
- WILLIAMS G *see* Pye M
- WILLIAMS GH. Common-sense beliefs about arthritis, (L) 395
- WILLIAMS I *see* Pitt P
- WILLIAMS KE *see* O'Sullivan MM
- WILLIAMS PL *see* Papavasavas GK
- WILLIAMS W *see* Isenberg DA
- WILLIAMSON MER, PRICE EJ, WANG F, BOSCO JJ, GIDDINGS J, AMOS N, LYNES T, WILLIAMS BD. Ethnic differences in the distribution of anticardiolipin antibodies in European and Malay patients with SLE, (A2) 20
- WILLOCKS LJ *see* Ralston SH
- WILLOUGHBY DA *see* De Brito F
- WILLSON R *see* Griffiths HR
- WILMALARATNA HSK. Adenocarcinoma of the lung presenting with Raynaud's phenomenon, digital gangrene and multiple infarctions in the internal organs, (L) 473
- WILSON C *see* Ebringer A
- WILSON PJ *see* Howell WM
- WILSON R *see* Chuck A; Madhok R
- WINNEARLS C *see* Chantray D
- WINSKA-WILLOCH H, THOMPSON K, YOUNG A, CORBETT M, SHIPLEY M, HAY F. IgA and IgM rheumatoid factors as markers of later erosive changes in rheumatoid arthritis, (A1) 4
- WINYARD PG, BLAKE DR, PALL H, LUNEC J. Non-caeruloplasmin-bound copper is not detectable in fresh serum or synovial fluid from patients with rheumatoid arthritis, (A1) 21
- WINYARD PG, BRAILSFORD S, LUNEC J, BLAKE DR. Secretion of caeruloplasmin by the rheumatoid synovial membrane and liver, (A1) 21
- WITHRINGTON RH *see* Ayeshe R
- WITTENBORG A, NICKSCH E, PENNEKAMP C, DEGNER FL. Generalized osteoporosis in rheumatoid arthritis, (A2) 26
- WOJTAHA D *see* McCormick JN
- WOLFE F *see* Khan MA
- WOLSTENCROFT RA *see* Limb GA
- WONG WS. Leprosy presenting as nodular vasculitis, (L) 398
- WOOD N *see* Emery P
- WOOD NC *see* Symons JA
- WOODROW DF *see* Sethi D
- WOODS R *see* Keane A
- WOOLF AD. Infection and immunity in the rheumatic diseases, 223
- WOOLF AD *see also* Maslen CL
- WORDSWORTH BP, OGILVIE DJ, DALGEISH R, SYKES BC. Discordant segregation of the major fibrillar collagen structural genes in type II Ehlers Danlos syndrome, (A1) 27
- WORDSWORTH BP, OGILVIE DJ, WYNNE DAVIES R, SYKES BC. Segregation analysis of the type II collagen structural gene (COL2A1) in the chondrodysplasias, (A1) 27
- WORDSWORTH P, OGILVIE D, SMITH R, SYKES B. Joint mobility with particular reference to racial variation and inherited connective tissue disorders, 9
- Work-related shoulder-neck complaints in industry: a pilot study, 365
- WORRALL J, PHONGSATHORN V, HOOPER J, PAICE E. Effect of sex and race on serum creatinine kinase level, (A2) 48
- WORSFOLD M *see* Butler RC
- WOSNIAK A *see* French JK
- WRAIGHT EP *see* Kyle V
- WRIGHT JK *see* Andrews HJ
- WRIGHT SJ. What a rheumatologist should know about the law: I. Battery, breach of contract and negligence, 147; II. Personal injury cases and the medical practitioner in the witness box, 218
- WRIGHT V, MOLL JMH. Proper poster presentation: a visual and verbal ABC, 292
- WRIGHT V *see also* Bird HA; Harvey AR; Helliwell P; Leigh TJ; McKenna F; Neumann VC; Shinebaum R; Sitton NG; Taggart AJ
- WYNNE DAVIES R *see* Wordsworth BP

- Xanthine oxido-reductase activity in human synovium, (A1) 22
- YARDLEY H *see* Dawes PT
- YAZICI H *see* Cakir N
- YONKER RA, WEBSTER EM, EDWARDS NL, KATZ P, LONGLEY S, PETTERSEN H, PANUSH RS. Technetium pyrophosphate muscle scans in inflammatory muscle disease, 267
- YOUNG A *see* Winska-Wiloch H
- YOUNG SP, DYKES J, CONNELLY A, LOMAN J, BACON PA. Magnetic resonance imaging in the assessment of inflammation in the rat air pouch model of antigen-induced chronic inflammation, (A2) 82
- Yttrium 90 synovectomy—a new treatment for pigmented villonodular synovitis, (L) 71
- YURKADAL S *see* Cakir N
- ZAKRZEWSKI JT, RAE SA, BARNES NC, BERRY H, PIPER PJ, COSTELLO JF. Quantitation of leukotriene B4 in synovial fluid of patients with rheumatoid arthritis by specific radio-immunoassay, (A2) 72
- ZALEWSKI PD *see* French JK
- ZIFF M *see* Haskard DO
- ZINGRAFF J, BARDIN T, NOEL LH, DRUEKE T, KUNTZ D. Beta 2 microglobulin amyloid in sternoclavicular joints of long term haemodialysis patients, (A2) 39
- ZOMA A, HAMBLEY H, STURROCK RD. Prediction of marrow iron stores and serum ferritin levels, (A2) 36
- ZOMA A *see also* Belch JJJ; Pullar T
- ZUMLA A *see* Isenberg DA
- Zygapophyseal joint capsule and synovial fold innervation, 93







